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CHAPTER I 
INTRODUCTION 
The renin-angiotensin-aldosterone system is involved in the 
regulation of blood volume and pressure (Fujii and Vatner, 1985; Joy 
and Lowe, 1970), and the maintenance of sodium balance (Parfrey et al., 
1981; Davis and Freeman, 1976). Renin is the rate limiting enzyme in 
the formation of the vasopressor substance angiotensin II (ANG II). 
ANG II is the active component of this system and is involved in 
several physiological functions in addition to its vasoconstriction 
effect. The primary source of renin in the blood is the specialized 
juxtaglomerular cells located in the afferent arterioles of the kidney. 
The synthesis, storage and secretion of renin occurs in these 
juxtaglomerular cells (Taugner et al., 1984). 
Renin secretion is regulated in part, by a renal baroreceptor that 
senses changes in renal perfusion pressure (Blaine et al., 1971). The 
release of renin from the kidney is also modulated by the amount of 
sodium that is reabsorbed across the specialized macula densa cells in 
the distal tubule (Fray, 1978; Itoh and Carretero, 1985). In addition, 
the renal nerves and circulating catecholamines increase renin 
secretion by stimulating renal beta-receptors. ANG II and vasopressin 
inhibit renin release (Bunag et al., 1967). Studies by De Vito et al. 
1 
2 
(1971) provided evidence for the presence of a renin-releasing factor 
in the plasma of hypovolemic dogs. However, these results could not be 
replicated by Polomski et al (1974), and no further studies were 
reported. 
Brain serotonergic neurons stimulate renin secretion. 
Administration of the serotonin (5-HT) releasers, PCA (p-
chloroamphetamine) or fenfluramine, or the serotonin agonists MK-212 
and quipazine produced dose-dependent increases in plasma renin 
activity (PRA; Lorens and Van de Kar, 1987; Van de Kar et al., 1985b; 
1981). The effect of fenfluramine could be prevented by pretreatment 
with the 5-HT uptake inhibitors indalpine and fluoxetine or the 5-HT 
synthesis inhibitor PCPA (p-chlorophenylalanine; Van de Kar et al., 
1985b). Injections of the 5-HT neurotoxin 5, 7-dihydroxytryptamine 
(5,7-DHT) into the dorsal raphe nucleus prevented the effect of PCA on 
renin secretion suggesting that brain 5-HT neurons in the dorsal raphe 
nucleus mediate the effect of PCA (Van de Kar et al., 1982). The 
dorsal raphe nucleus sends projections to the arcuate, anterolateral 
and the suprachiasmatic nuclei of the hypothalamus (Van de Kar and 
Lorens, 1979; Azmitia and Segal, 1978). Posterolateral deafferentation 
or mechanical ablation of the hypothalamus prevented the PCA- induced 
increase in PRA (Karteszi et al., 1982), suggesting that the dorsal 
raphe nucleus may send projections to the hypothalamus that are 
involved in the regulation of renin secretion. 
The role of the sympathetic nervous system in mediating the PCA-
induced increase in PRA has also been investigated. The serotonergic 
stimulation of renin secretion was not mediated by either the 
3 
sympathetic nervous system or adrenal catecholamines (Van de Kar and 
Richardson-Morton, 1986). Transection of the spinal cord proximal to 
the exit of the renal nerves did not prevent the effect of PCA on renin 
secretion . These studies suggest that the sympathetic nervous system 
. is not involved in mediating the serotonergic stimulation of renin 
secretion. 
Taken together, these results indicate that a serotonergic pathway 
originating in the dorsal raphe nucleus with nerve terminals in the 
hypothalamus regulate renin secretion. The exact location of the 
terminals has not been identified. It is possible that the 
paraventricular nucleus (PVN) may play a role in mediating the 5-HT-
induced increase in renin secretion since studies by Gotoh et al. 
(1987) have demonstrated that electrolytic lesions of the PVN prevent 
the PCA-induced increase in PRA. Studies by Richardson Morton et al. 
(1986) and Gotoh et al. (1987) have also indicated that the PVN is 
involved in the stress-induced increase in PRA. Since the sympathetic 
nervous system was not shown to play a role in the PCA-induced increase 
in PRA, there should be another way for the brain to communicate with 
the kidneys. One possibility is that the hypothalamus releases a 
hormonal factor into the blood that circulates to the kidneys and 
increase renin secretion. 
In order to test this hypothesis, a group of donor rats were 
treated with PCA or saline. Their plasma was collected and injected in 
a group of recipient rats. The PRA values in the recipient rats were 
increased after injection of the PCA-plasma, but injection of plasma 
from rats that were treated with saline did not alter PRA (Van de Kar 
4 
~ al., 1982a). These data suggested that PCA may stimulate the 
release of a factor (renin-releasing factor; RRF) into the circulation 
that produces an increase in renin secretion in conscious rats. 
Pretreatment of the rats with the 5-HT synthesis inhibitor p-
chlorophenylalanine (PCPA) did not alter the response of PRA to 
administration of the PCA-plasma. Depleting 5-HT stores with PCPA 
prevented any release of 5-HT by residual PCA molecules present in the 
plasma fractions. 
The present studies were designed to investigate RRF in vitro 
using a kidney slice renin release bioassay. Studies were designed to 
determine the molecular weight of RRF and to characterize the nature of 
this substance is a peptide. Plasma from rats that received either 
injections of serotonin agonists or rats that were stressed were tested 
to determine if these stimuli could increase the plasma concentration 
of RRF. Other experiments were developed to study the distribution of 
RRF in the rat brain and attempt to identify where RRF cell bodies are 
located. In addition, hypothalamic explants were superfused in vitro 
with a high potassium solution to test if depolarization of the 
hypothalamus could stimulate the release of RRF. 
Many neuroendocrine systems have a feedback system that regulates 
the synthesis and release of a hormone from the hypothalamus or 
pituitary gland. Once the factor reaches the target organ, the target 
increases the secretion of its hormone which acts as a message to the 
brain to halt the production of the hormone. To test for the 
possibility of a feedback loop in the regulation of the release of the 
RRF from the hypothalamus, the concentration of RRF in the hypothalami 
5 
of nephrectomized rats was compared with the RRF concentration in sham-
operated rats. The results of this experiment suggest that there is a 
negative feedback loop from the kidney to the hypothalamus that 
regulates the release of RRF. 
CHAPTER II 
LITERATURE REVIEW 
A. overview 
1. Renin-angiotensin enzyme cascade 
The regulation of blood pressure in the body relies to a large 
extent on the integrity of the renin-angiotensin-aldosterone system 
(RAAS). Renin is the rate limiting enzyme in the formation of ANG II. 
The enzyme is synthesized, stored and released from the granular 
juxtaglomerular cells located in the afferent arterioles of the kidney 
(Taugner et al., 1986; Cantin et al., 1977). 
The juxtaglomerular cells, afferent and efferent arterioles and 
distal tubule are referred to collectively as the juxtaglomerular 
apparatus (JGA) . The JG cells are in close proximity to the macula 
densa, a specialized portion of the distal tubule that is sensitive to 
changes in sodium reabsorption across the tubular epithelium. 
When released from the kidney, renin circulates in the blood and 
cleaves the leucine-leucine bond (a leucine-valine bond in humans) in 
the renin substrate, angiotensinogen, to liberate the decapeptide, 
angiotensin I (ANG I). Angiotensin converting enzyme (ACE) cleaves two 
amino acids from ANG I to form the octapeptide angiotensin II. 
Degradation of ANG II by the action of aminopeptidase A leads to the 
6 
7 
formation of angiotensin III, while the action of other angiotensinases 
leads to inactive peptide fragments. 
asp-arg-val-tyr-ile-his-pro-phe-his-leu-leu-ile-his-ser-R 
Angiotensinogen l Renin 
asp-arg-val-tyr-ile-his-pro-phe-his-leu + leu-ile-his-ser-R 
angiotensin I l angiotensin converting enzyme 
asp-arg-val-tyr-ile-his-pro-phe + his-leu 
angiotensin II 
~ aminopeptidase 
arg-val-tyr-ile-his-pro-phe 
angiotensin III l angiotensinases 
inactive fragments 
Figure 1. Diagrammatic representation of the renin-angiotensin system 
enzyme cascade. 
2. Role of the angiotensins 
The angiotensins (ANG I, ANG II and ANG III) exert a number of 
pharmacological actions, all of which are involved in maintaining blood 
pressure and plasma volume. ANG II is the most active peptide of the 
renin-angiotensin enzyme cascade and produces profound increases in 
blood pressure (Fujii and Vatner, 1985; Fagard et al., 1985; Ross and 
White, 1966). ANG II is a potent vasoconstrictor and contracts 
vascular smooth muscle directly by stimulating vascular receptors 
(Fujii and Vatner, 1985; Coruzzi et al., 1983). In addition to 
8 
increasing systemic blood pressure, ANG II acts directly on the heart 
to increase myocardial contractility (Koch-Weser, 1965). ANG I 
enhances the release of catecholamines from the adrenal medulla and 
sympathetic nerve terminals (Peach et al., 1971; Ross and White, 1966). 
In addition, ANG II also prevents the reuptake of norepinephrine by the 
sympathetic nerves (Khairallah, 1972), thus prolonging the effect of 
norepinephrine at the synapse. ANG I is equally effective as ANG II in 
stimulating the release of adrenal catecholamines but is less potent in 
producing vasoconstriction (Peach et al., 1971). 
Another principal mechanism of action for ANG II is the 
stimulation of aldosterone synthesis and secretion from the zona 
glomerulosa of the adrenal cortex (Aguilera et al., 1980; Davis and 
Freeman, 1976). Aldosterone produces an increase in sodium and water 
reabsorption from the distal tubule (Biron et al., 1961) thus 
increasing extracellular fluid and volume. The heptapeptide, ANG III 
has been reported to be equally effective in inducing steroid synthesis 
in the adrenal cortex (Braley et al., 1983; Blair-West et al., 1980). 
Circulating levels of ANG II are able to influence the release of 
pituitary hormones. Systemic ANG II facilitates the neuronal firing of 
neurohypophysial neurons of the paraventricular and supraoptic nuclei 
(Ferguson and Renaud, 1986). It has been demonstrated that the release 
of vasopressin and ACTH (adrenocorticotropin hormone) are stimulated by 
increased plasma levels of ANG II (Keller-Wood et al., 1986; Spinedi 
and Negro-Vilar, 1983; Ramsay et al., 1978). LH (luteinizing hormone) 
secretion is also stimulated by ANG II. However, this effect does not 
appear to be mediated by circulating intravenous ANG II but rather by 
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intracerebral injections of ANG II (Steele~ al., 1983). 
The subfornical organ (SFO), median eminence and area postrema are 
circumventricular organs of the brain. These brain regions are not 
located within the blood-brain barrier and therefore may be responsive 
to circulating factors. Immunoreactive staining for ANG II has been 
demonstrated in the SFO and area postrema (Gehlert et al., 1986; Lind 
~al., 1985). Destruction of the subfornical organ (SFO) prevents the 
increased neuronal firing of neurohypophysial neurons (Ferguson and 
Renaud, 1986). This finding suggests that ANG II may influence the 
firing rate and possibly the release of substances from 
neurohypophysial neurons by influencing SFO neuronal firing. The 
pressor response to ANG II and the ANG II-induced drinking response 
were also attenuated by lesions in the SFO (Lind et al., 1983). Joy 
and Lowe (1970) and Fink et l!l., (1987) demonstrated that ablation of 
the area postrema prevents the ANG II-induced pressor response. 
Therefore it appears that ANG II, by stimulating receptors in the 
circumventricular organs, can further influence the regulation of 
plasma volume through central nervous system pathways. 
B. Historical Overview 
Studies in the late 1800's, Tigersteadt and Bergmann (as reviewed 
by Brod, 1986) demonstrated that kidney extracts, when injected into 
bilaterally nephrectomized rabbits, produced a prolonged increase in 
blood pressure. This pressor material was found primarily in the renal 
cortex of the kidney whereas other tissue extracts did not produce an 
increase in blood pressure. This substance was called renin. Later, 
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in 1934, Goldblatt et al produced an increase in blood pressure by 
placing a clamp around, and occluding the renal arteries. The degree 
of hypertension appeared to be dependent on the tightness of the clamp 
around the renal artery. They concluded that the kidney may play a 
.role in the development of hypertension. This increase in blood 
pressure was independent of the sympathetic nervous system or the 
adrenal medulla (Goldblatt et al., 1934). Tying off the renal veins 
prevented the hypertension from developing (Goldblatt et al., 1937). 
This indicated that the kidney releases a substance that is responsible 
for the development of hypertension. 
The attention then turned to renin as a causative substance for 
hypertension. When renin was purified, it increased blood pressure in 
intact animals but had no vasopressor activity when it was infused into 
the isolated dog tail (Friedman et al., 1938). However, when blood was 
used to perfuse the dog tail preparation, the vasoconstrictor effect of 
the kidney extracts returned. This finding led to the theory that 
renin was not the vasoactive substance but it was the interaction of 
renin and renin-activator that led to the formation of the vasoactive 
product. The substrate (renin-activator) is present in the alpha-2 
globulin fraction of plasma. 
Two independent groups, Page and Helmer (1940) in the United 
States and Braun-Menendez (1940) in Argentina, studied the pressor 
effect of renin. They found that plasma (renin-activator) and renin 
when incubated together formed a heat stable and potent vasoconstrictor 
substance that produced an immediate and dose-dependent increase in 
blood pressure. Renin, when administered, had a latent period before 
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the vasopressor effect could be observed. It became evident that renin 
was the enzymatic catalyst in the formation of this peptide. Page and 
Helmer named this peptide angiotonin and Braun-Menendez referred to it 
as hypertensin. It was not until 1958 that the nomenclature was 
standardized when the two groups compromised and called the substance 
angiotensin. The renin-activator became known as angiotensinogen 
(renin-substrate; proangiotensin). 
Studies were begun to isolate and purify angiotensin. However, 
upon purification it was discovered that dialyzing the solution 
containing angiotensin with sodium chloride instead of water, produced 
a pressor material in a different molecular weight range. This led to 
the discovery that there were two forms of angiotensin. The second 
peptide could be formed from angiotensin I by plasma supplemented with 
sodium chloride. However, if renin was incubated with plasma in the 
absence of chloride only angiotensin I was formed. Using isolated 
perfused kidneys, Skeggs et al. (1954) showed that ANG II was a more 
potent vasoconstrictor that ANG I. Therefore rapid conversion of ANG I 
to ANG II results in the pressor activity. These results suggested 
that an additional enzyme was required for the conversion of ANG I to 
ANG II. This newly found enzyme was named angiotensin converting 
enzyme (ACE). ACE circulated in the plasma and required the presence 
of chloride ions for its activity (Skeggs et al., 1956). A later study 
by Ng and Vane (1967) showed that as blood circulated through the lungs 
there was a stronger vasoconstriction produced than blood that 
circulated through other vascular beds. They therefore concluded that 
the highest concentration of this enzyme occurred in the lung. 
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The association of renin with the glomeruli was identified by Cook 
and Pickering (1959). They succeeded in separating the glomeruli from 
the rest of the kidney tissue by first injecting iron oxide into the 
glomerulus. The cortex was dissected and put through a sieve. A 
magnet was then used to separate the glomerular fragments from the 
tubules. Bioassay indicated that the vascular pole of the glomerulus 
contained more renin activity than the tubules. Similar results were 
reported by Bing and Wiberg (1958) who showed that destruction of the 
renal cortex reduces the renin content of the kidney. These data 
support earlier findings of Goormaghtigh (1939) who demonstrated that 
renin was localized in the arterioles of the juxtaglomerular apparatus. 
These were some of the first studies that reported the localization of 
renin at the glomerular area of the renal cortex. 
These studies have indicated that there are two enzymatic steps 
needed to form ANG II from angiotensinogen. Since renin and 
angiotensin have been implicated in the pathogenesis of hypertension, 
many studies have focussed on the inhibition of this enzyme cascade as 
a possible treatment of hypertension. The development of substrate 
analogues (Plattner et al., 1986), converting enzyme inhibitors (Mento 
and Wilkes, 1987), renin antibodies (Dzau et al., 1980) and ANG II 
antagonists (Wilkes, 1984) are pharmacological approaches to the 
possible treatment of hypertension. 
C. Angiotensinogen 
Angiotensinogen is the substrate for renin and thus the precursor 
for ANG I, and ultimately ANG II. There is renin-substrate specificity 
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that allows the interaction of renin only with homologous substrate. 
For example, human renin will only react with human angiotensinogen; 
non-primate angiotensinogen will preferentially react with homologous 
substrate. It has been proposed that the specificity of the enzyme-
substrate interaction may be due to the variation in the amino acid 
sequence between the human and non-primate forms (Tewksbury et al. , 
1981; Bouhnik et al., 1981). 
Angiotensinogen is a glycoprotein that is primarily localized in 
the liver although other organs have been found to contain 
angiotensinogen. Recent studies using immunocytochemistry (Richoux et 
al., 1983) and Northern Blot analysis with complementary mRNA sequences 
for angiotensinogen (Ingelfinger et al., 1986) identified that the 
liver contains and synthesizes angiotensinogen. Clauser et al., (1983) 
demonstrated that angiotensinogen is released from liver slices and its 
productions can be prevented by treatment with cycloheximide, a protein 
synthesis inhibitor. Incubation of liver slices in the absence of 
oxygen also prevents the secretion of angiotensinogen indicating that 
the release is an active process. 
Angiotensinogen circulates in the plasma in two forms which are 
referred to as Aol and Ao2 (Hilgenfeldt and Schott, l987a; 1987b; 
Tewksbury, 1983). The dissimilarity in molecular weight is 
attributable to the difference in the number of carbohydrate residues 
present on Aol and Ao2. Hilgenfelt and Schott (1987) demonstrated that 
the two forms of angiotensinogen do not differ in their affinity for 
endogenous renin. 
There are a variety of factors that can modulate the plasma 
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concentration of angiotensinogen. The levels of renin substrate can be 
decreased by diseases that affect liver function, such as cirrhosis 
(Schroeder et al., 1970; Ayers, 1967). Adrenalectomy (Carretero and 
Gross, 1967; Nasjletti and Masson, 1969; Reid, 1977) and hypophysectomy 
(Goodwin et al., 1970) also reduce the circulating levels of 
angiotensinogen. The decrease in angiotensinogen levels produced by 
adrenalectomy can be prevented by administration glucocorticoids (Reid, 
1977; Nasjletti and Masson, 1969). Nasjletti and Masson, (1969) found 
that mineralocorticoids and sodium replacement also inhibited the 
effect of adrenalectomy. From these reports it appears that the 
pituitary adrenal-axis is necessary for maintaining plasma substrate 
levels. In addition to the pituitary-adrenal axis, the pituitary-
thyroid axis may play a role in regulating the synthesis of 
angiotensinogen. Rats that have been thyroidectomized have a decreased 
plasma angiotensinogen concentration; this decrease is reversed by 
thyroid hormone replacement therapy (Bouhnik et al., 1981; Dzau and 
Herrmann, 1982). Rats that were made hyperthyroid by administration of 
1-thyroxine also had elevated levels of renin substrate (Dzau and 
Herrmann, 1982). Increased levels of angiotensinogen are also achieved 
by administration of ethinyl estradiol (Glauser et al., 1983; Krakoff 
and Eisenfeld, 1977). However, this treatment does not increase 
angiotensinogen levels in hypophysectomized animals. Dexamethasone, a 
glucocorticoid, also increases the production of angiotensinogen by the 
liver. 
The release of angiotensinogen may be subject to a feedback 
control by the renin-angiotensin system. The final product of the 
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pathway, ANG II has been shown to stimulate the release of 
angiotensinogen (Herrmann et al., 1980; Reid, 1977). Captopril, a 
converting enzyme inhibitor, reduces circulating levels of ANG II, and 
also produces a decrease in the circulating levels of angiotensinogen 
(Radziwill et al., 1986; Hermann and Dzau, 1983). 
D. Renin 
1. Renin synthesis 
Renin is a proteolytic enzyme with a molecular weight of 
approximately 36, 000 to 40, 000. Renin is primarily localized in and 
secreted from the granulated cells of the afferent arterioles (Lacasse 
et al., 1985; Taugner et al., 1982a; Taugner et al., 1979). Renin-like 
immunoreactivity has also been demonstrated in the cells of the 
efferent arteriole (Taugner et al., 1981) and along extended lengths of 
the afferent arteriole and interlobular artery (Taugner et al., 1979; 
Taugner et al., 1981). Renin-like immunoreactivity has also been 
described in tissues other than the kidney. Extrarenal sources of 
renin include blood vessels (Re et al., 1982), pituitary (Deschepper 
et al., 1986; Naruse et al., 1985), adrenal gland (Baba et al., 1982), 
testes (Deschepper et al., 1986) and heart (Dzau and Re, 1987). These 
studies were performed by using either immunocytochemical techniques or 
in situ hybridization using renin messenger RNA. These extrarenal 
renin sources are not identified in all species, only kidney renin is 
universally present in all species. Perhaps the richest source of 
renin is the submaxillary gland of the mouse (Menzie et al., 1978; 
Cohen~ al., 1972). Purification and isolation studies for renin have 
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been performed using submaxillary renin. It is important to keep in 
mind that renal and submaxillary renin are not identical in structure; 
renal renin is glycosylated whereas submaxillary gland renin does not 
contain carbohydrate moieties (Kawamura et al., 1986). Studies have 
indicated that renal renin may be the major source of the circulating 
enzyme. Van de Kar and Richardson Morton (1986) have reported that 
after bilateral nephrectomy the plasma levels of renin are below the 
sensitivity limit of the radioimmunoassay (less than 10 pg) suggesting 
that renal renin is the major source of renin in the plasma. 
Renin is synthesized from messenger RNA as a preprozymogen that is 
processed at the endoplasmic reticulum and converted to prorenin. This 
proenzyme (prorenin) is further processed in the rough endoplasmic 
reticulum and is packaged in a crystalline form in the golgi apparatus 
which then forms protogranules. The protogranules mature into dense 
secretory granules (Taugner et al., 1987; Lacasse et al., 1985) which 
secrete renin from the epithelial cells. It has long been believed 
that only the dense granules contain renin. Recently, the presence of 
immunoreactive renin vacuoles in the cytoplasm of these granule cells 
may suggest an alternative pathway for the packaging and release of 
renin (Lacasse et al., 1985; Taugner et sij.., 1984). 
There has been some debate as to whether the dense granules 
contain and release active or inactive (prorenin) renin. The presence 
of prorenin has been identified in both plasma and kidney (Sealey et 
fil., 1983; Morris and Johnston, 1976) and has been immunologically 
identified as inactive renin (Bouhnik et al., 1985). Kawamura et al. 
(1986) showed that isoelectric focusing of stored renin resulted in 
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several peaks of differing isoelectric points with the majority of 
renin activity present in one peak. Renin that was secreted from 
isolated glomeruli also exhibited different isoelectric points. 
However, there was a redistribution of renin activity between the 
different isoelectric points, and there were two peaks that contained a 
considerable amount of renin activity. Kawamura et al. (1986) 
therefore concluded that there may be some processing of renin 
occurring in the cytoplasm. Cathepsin B is an intracellular enzyme 
that has been cited to convert inactive to active renin (Takahashi et 
al., 1982). In other studies, Taugner et al. (1983) have found that 
mature secretory granule cells exhibit both renin-like and cathepsin B-
like immunoreactivity. It is suggested that cathepsin B is involved in 
the activation of prorenin to active renin which probably occurs in the 
dense granules. 
Studies using antisera raised against different determinants of 
the renin prosegment have indicated that prorenin is found 
predominantly in the protogranules of the epithelioid cells while there 
is very little staining in the mature granules (Taugner et al., 1987). 
Therefore it was concluded that this prosegment was cleaved off in the 
golgi complex. In contrast, labelling for immunoreactive renin 
increases from the protogranules to the mature granules (Taugner et 
al. , 198 7; Lacasse et al. , 1985) . It is therefore suggested that 
activation of renin from prorenin occurs in the protogranules. 
Altogether, these results indicate that there may be stores of inactive 
renin that are further processed to active renin and released into the 
circulation. 
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2. Renin release 
Renin is released from the kidney primarily by exocytotic 
mechanisms. The granules have been observed to fuse with the plasma 
membrane of the juxtaglomerular cell and release their contents into 
the extracellular space (Taugner et al., 1986; Taugner, Buhr le and 
Nobiling, 1984). Other groups have reported invaginations of the 
plasma membrane into the interior of the epithelioid cell that come in 
close contact with the dense granules (Ryan et al., 1982; Peter, 1976). 
These invaginations of the plasma membrane contain material that 
appears to be similar to that present in the dense granules which 
suggests that these granules empty their contents into these 
invaginations. 
It has been hypothesized that renin is released from the JG cells 
into the lymphatics and not directly into the blood. Lever and Peart 
(1962) first demonstrated renin activity in renal lymph. The highest 
renin activity was present in the renal venous plasma which correlated 
with increased levels in the lymph (Horky et al., 1971). Since 
injection of renin into the plasma produced an increase in blood 
pressure without altering the renin concentration in the lymphatics, 
Horky et al. (1971) hypothesized that renin was first secreted into the 
lymph and then diffused into the circulation. The relationship between 
renin in the plasma and renal lymph was illustrated by O'Morchoe et al. 
(1981). In response to injection of furosemide, renin concentration 
rose in the renal artery, renal vein and lymph. The increase in renin 
concentration was more immediate and marked in the renal lymph whereas 
a few minutes were required to reach peak renin levels in the plasma. 
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Therefore, renin may be released into the lymph where it then diffuses 
into the blood. 
3. Metabolism of renin 
Renin circulates in the plasma with a half-life of approximately 
7.0 minutes (Kim et al., 1987). Other half-life values for renin have 
been reported to be between 3. 0 and 15. 0 minutes (Fiselier et al. , 
1984; Assaykeen et al., 1968). The clearance of renin from plasma 
follows a two component system with a rapid component (t1;2 - 7. 0 
minutes) and a slow component with a t1;2 of about 65 minutes (Kim et 
al., 1987). 
Plasma renin values are dependent on the relative rates of renin 
release and the clearance from the plasma. A major portion of renin is 
inactivated by the liver (Heacox et al., 1967), however the kidney is 
also involved in eliminating renin from the plasma (Kim et al., 1987; 
Peters-Haefeli et al., 1971). Partial hepatectomy produced a decrease 
in the clearance of renin and increased the half-life of the slow phase 
(from 65 minutes to 94 minutes) while nephrectomy prolonged the half-
life of the rapid phase (6 minutes to 10. 5 minutes). The increased 
half-life suggests that both the kidney and the liver are involved in 
the catabolism of renin. Intravenous infusion of radiolabelled renin 
accumulated preferentially in the liver and kidney. Fifteen minutes 
after injection of renin, radioactive degradation products, with 
molecular weights lower than that for renin, were present in both the 
liver and kidney (Kim et al., 1987). Although the liver accumulated 
about 60% of the radiolabelled renin, the kidney accumulated only 11%. 
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These studies suggest that both the liver and kidney are responsible 
for the clearance of circulating renin with the liver being the more 
predominant. 
A pure antibody against renin is not widely available for use in a 
direct radioimmunoassay (RIA) for renin. Renin is measured in the 
plasma primarily by RIA of generated ANG I. To prevent conversion of 
ANG I to ANG II, ACE inhibitors are added to the samples. Plasma renin 
activity (PRA) is the measure of the ability of plasma to generate ANG 
I, which depends on the amount of renin and renin substrate present in 
the plasma sample. Unless there is saturation of the enzyme with the 
substrate, variations in substrate levels may influence the amount of 
ANG I produced. Plasma renin concentration (PRC) is a measure of the 
ability of renin to generate ANG I in the presence of a saturating 
concentration of renin substrate. The normal plasma concentration of 
angiotensinogen is less than the Km required for renin to generate ANG 
I at maximum velocity. In order to measure renin concentration, the 
samples are saturated with renin substrate so that the reaction 
proceeds at Vmax· Therefore any variation in substrate levels will not 
influence PRC values. PRC is a better indication of the amount of 
renin circulating in the plasma. 
E. Regulation of renin secretion 
1. Role of plasma electrolytes 
la. Macula densa 
The macula densa region of the distal tubule is composed of 
columnar cells that are in contact with the afferent arteriole. The 
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basement membrane of the macula densa cells appears to fuse with the 
membranes of the afferent arteriole that surround the granular cells 
(Barajas and Powers, 1984). In addition, the macula densa cells have 
short extensions of cytoplasm that extend into the mesangial cell area 
of the JGA and the granule cells of the arterioles {Sottiurai and 
Malvin, 1982). These anatomical findings suggest that there may be a 
functional relationship between the cells of the macula densa and the 
renin containing cells of the afferent arteriole. It has been 
hypothesized that the macula densa is the sensor for changes in ionic 
concentrations of the tubular fluid that signals the granular cells to 
alter renin release. 
lb. Sodium 
Sodium has been shown to play a role in hypertension and the 
regulation of blood pressure (Parfrey et al., 1981; Dawson and Oparil, 
1987; McCaa, 1982; Takata et al., 1986). In addition, renin secretion 
appears to be inversely regulated by distal tubular sodium 
concentration. In the study by Parfrey et al. (1981) it was observed 
that as patients were changed from a high to a low sodium diet their 
PRA values increased. In hypertensive patients, reduction of sodium 
led to lowered blood pressure. However, reduction in sodium levels did 
not alter blood pressure in normotensive patients. It appears that in 
hypertensive patients there is a greater sensitivity to changes in 
sodium. Rats that are supplemented with NaCl in their drinking water 
also have decreased PRA values and increased blood pressure (Pyykonen 
.tl. al., 1986). It is conceivable that increased sodium may decrease 
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renin by stimulating the renal baroreceptor as a result of the 
increased blood pressure and extracellular fluid (ECF) volume. To test 
this hypothesis, Anderson et al. (1975) infused dextran solutions of 
different osmolarities or a Ringer's salt solution into sodium depleted 
dogs. PRA was decreased only in the group that received the Ringer's 
salt solution which restored the sodium levels. Replacement of 
extracellular fluid with the dextran solutions did not reduce PRA 
values. The plasma volume and mean arterial pressure were not 
significantly different between the dextran-infused and saline-infused 
groups. This suggests that renin secretion may be inversely 
proportional to plasma sodium concentration. A similar study was 
performed in salt-depleted humans (Tuck et al., 1975). When the 
subjects received saline infusions, PRA decreased, but there were no 
alterations in PRA after dextran infusion. The increase in ECF volume 
was similar in both the saline-infused and dextran-infused groups. If 
the renal baroreceptor contributed to the suppression of renin release, 
then all of the groups would be expected to have a similar decrease in 
PRA after restoration of plasma volume. These data support the 
proposed mechanism of sodium-induced suppression of renin release 
independent of changes in plasma volume. 
One of the first studies that actually measured the amount of 
sodium at the macula dens a area was performed by Churchill et al. , 
(1978). The changes in sodium concentration in the distal tubule were 
correlated with alterations in renin secretion. Micropuncture sampling 
of the distal tubular fluid showed that the tubular sodium load was 
proportional to dietary sodium. In sodium-deprived rats, renin 
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secretion was increased when compared with the control group maintained 
on a standard diet. Renin secretion was decreased in the animals that 
were fed a high sodium diet. This study suggested that there was an 
inverse correlation between plasma renin activity and the sodium load 
in the distal tubule. 
le. High ceiling diuretics, sodium and renin secretion 
The effect of sodium on renin secretion was also tested using the 
high ceiling diuretic ethacrynic acid and a thiazide diuretic, 
chlorothiazide (Cooke et al., 1970). Ethacrynic acid prevents sodium 
and chloride reabsorption by inhibiting the active sodium-chloride co-
transporter in the ascending loop of Henle. The thiazides inhibit 
sodium reabsorption in the distal tubule downstream from the macula 
densa. It was observed that renin secretion was increased after 
administration of ethacrynic acid and persisted when the volume was 
restored. Chlorothiazide failed to produce an increase in renin 
secretion during volume restoration. The effects of these two 
diuretics implies that the effect of chlorothiazide on renin release is 
mediated by changes in plasma volume. The effect of ethacrynic acid 
appears to be mediated by the macula densa. The results of this study 
suggest that changes in sodium sensed by the macula densa cells in the 
early part of the distal tubule serve as a regulator of renin release. 
The finding with ethacrynic acid seems to contradict the results of 
other studies indicating that sodium ions decrease renin release 
(Parfrey et al., 1981; Fray, 1978; Churchill et al., 1978; Tuck~ .al., 
1975; Anderson et al., 1975; Bunag et al., 1966a). However, another 
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study which used furosemide, a diuretic with actions similar to 
ethacrynic acid, to investigate the effect of salt and water loss on 
PRA (Vander and Carlson, 1969) supported the findings by Cooke et al. 
(1970). Small doses of furosemide produced a natriuresis and diuresis 
that was prevented by replacing the volume loss. Larger doses of 
furosemide produced significant increases in PRA in dogs that were not 
reversed by replenishing the salt and water losses. These results 
provided evidence that the loop diuretics may inhibit sodium transport 
at the macula densa cells, resulting in elevated PRA. 
One proposed hypothesis by Meyer et al. (1968) was that furosemide 
might affect renin release by inhibiting sodium transport into the 
macula densa cells. This would account for the inability of the 
increased sodium load to the macula densa after furosemide to decrease 
renin release. Meyer et al. (1968) noticed that furosemide produced a 
large increase in renin release in volume-replete rabbits. They 
concluded that since the loss of volume did not increase renin there 
may be a change in the delivery of sodium to the cells of the macula 
densa. This theory was tested in 1982 by Sottiurai and Malvin. They 
correlated intracellular sodium concentration in the macula densa cells 
with changes in PRA that occurred as a result of altering sodium 
intake. In sodium-depleted states, there was the expected rise in PRA 
but without any changes in the intracellular content of sodium in the 
macula densa cells. Infusion of saline reduced PRA but did not alter 
the intracellular concentration of sodium. The authors concluded that 
intracellular sodium in the macula densa cells is not affected by 
changes in dietary sodium and furthermore, that this is not the 
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mechanism by which the macula densa regulates renin secretion from the 
afferent arteriole. 
Itoh and Carretero (1985) have observed that the macula densa is 
necessary for the regulation of renin release from isolated afferent 
arteriole preparations. They noted that in vitro afferent arteriole 
preparations had a higher rate of renin release than afferent 
arterioles with an intact macula densa. When these arterioles are 
incubated with furosemide, in doses that correspond to those used in 
vivo studies, only the arterioles with the macula densa were stimulated 
to increase renin release. This implies a role for the macula densa in 
the furosemide-induced increase in renin release that is independent of 
the baroreceptor effect. Since this was an in vitro study, it appears 
that furosemide may directly affect the macula densa. 
Upon histological analysis of the macula densa cells Sottiurai and 
Malvin (1982) noted that the intercellular spaces between the cells 
were dilated after perfusion. This finding was also observed by 
Kaissling and Kitz (1982). In addition, they noted that when rats 
received either mannitol infusion (osmotic diuretic) or furosemide, the 
intercellular spaces between the macula densa cells were narrower than 
those of control animals. From a functional perspective, the closing 
of these spaces might prevent sodium from gaining access to the JG 
cells and therefore sodium would not be able to inhibit renin 
secretion. In hypervolemic conditions the intercellular spaces were 
dilated. Kaissling and Kitz (1982) did not attribute these findings as 
artifacts of the tissue processing since the spacing between the 
epithelial cells of the tubules were not altered under the different 
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test conditions. Whether the treatment effects on the macula densa 
cell spaces reflect a true occurrence in vivo remains to be determined. 
However, these findings are interesting and may suggest a mechanism of 
action for the macula densa in transducing the signal from the ionic 
concentration of the tubular lumen to the renin secreting cells. 
ld. Potassium 
In addition to sodium, another cation, potassium, is thought to 
regulate renin secretion. The first study on potassium-regulated renin 
release was done by Vander (1970). In normal dogs, infusion of 
potassium chloride into the renal artery produced a decrease in PRA 
without altering renal plasma flow or blood pressure. Infusion of 
potassium increased the urinary excretion of both sodium and potassium 
from the perfused kidney. The decrease in PRA could have been due to a 
decrease in either sodium or potassium reabsorption that would have 
resulted in an increase of sodium delivery to the distal tubule/macula 
densa. The possibility that potassium exerts its effect on the JGA was 
not ruled out. Shade et al. (1972) demonstrated that potassium 
produces a decrease in renin secretion that is dependent on an intact 
renal system and glomerular filtration rate. In the non-filtering 
kidney, potassium was without effect on renin secretion (Shade et al., 
1972). Kirchner and Mueller (1982) tested the potassium-induced 
inhibition of renin secretion using salts other than chloride. PRA was 
measured after infusion of potassium chloride, bicarbonate, nitrate and 
acetate in sodium deficient rats. After each infusion, PRA levels 
decreased about 50% from the control values. Arterial pressure, plasma 
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volume and sodium balance were similar between the control and 
treatment groups. In conscious rats maintained on a sodium-deficient, 
high potassium diet, the increase in potassium levels blocked the rise 
in PRA after sodium depletion. In 1976, Kotchen ~ al. found similar 
results using a low sodium chloride diet supplemented with potassium 
bicarbonate. If potassium chloride was used instead of potassium 
bicarbonate, not only was there a blockade of the sodium-induced 
increase in PRA but a further suppression of PRA was observed. 
le. Chloride 
Since potassium chloride produced a greater suppression of PRA, 
Kotchen et al. (1976) suggested a role for chloride in addition to 
potassium in regulating renin release. This spurred interest in 
chloride as a new modulator for renin secretion. Not only did 
potassium chloride inhibit renin secretion when compared with potassium 
bicarbonate but sodium chloride inhibited renin release when compared 
with sodium bicarbonate (Kotchen et al., 1976). Furthermore, Kotchen 
et al. (1978) and Kirchner et al. (1978) demonstrated that both sodium 
chloride and sodium bromide decreased PRA while sodium infusion as an 
acetate, nitrate or carbonate salt did not alter renin release. It has 
been postulated that bromide is handled by the kidney in a similar 
manner to chloride, and either of these ions can influence renin 
secretion. Kotchen et al. (1978) tested the role of chloride by 
infusing choline chloride versus the bicarbonate salt. Again, only the 
chloride salt produced a suppression of renin release. These changes 
occurred independently of variations in sodium or potassium balance 
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(Kotchen et al., 1978) or blood pressure or volume (Kirchner et al., 
1978). 
Rostand et al. (1985) measured the quantities of chloride in the 
tubules and correlated the concentration of chloride with changes in 
renin release in the perfused rat kidney. Substituting sodium nitrate 
and thiocyanate salts for chloride reduced the amount of chloride in 
the kidney and also produced an elevation of renin release. Analysis 
of the data revealed a negative correlation between chloride and renin 
activity. Therefore, it is possible that chloride, in addition to the 
cations, may be important in regulating renin release from the 
juxtaglomerular cells. 
lf. Calcium 
Calcium plays an important role in secretory and smooth muscle 
cells. It provides a signal for the release of neurotransmitters and 
for muscle contraction. However, with respect to renin release, there 
may be an inverse relationship between renin secretion and the 
intracellular concentration of calcium. In 1974, Kotchen et al. 
infused calcium chloride into the renal artery of dogs and observed a 
fall in renin release that was accompanied by increased calcium levels 
in the blood. There was no alteration of renal blood flow or of 
arterial pressure. An increase in sodium excretion was observed while 
the plasma concentration of sodium was unaffected by calcium treatment. 
Addition of calcium directly to kidney cortical cells produced a dose-
dependent suppression of renin release whereas sodium did not alter the 
spontaneous release of renin (O' Dea et al., 1984). Kotchen et al. 
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(1974) examined the effect of calcium on the generation of ANG II from 
renin. Infusion of calcium did not interfere with the renin-substrate 
interaction or with angiotensinase activity. It was therefore 
concluded that calcium inhibited renin release by the macula densa or 
by a direct effect on the juxtaglomerular cells. 
Recent studies investigating the role of calcium in regulating 
renin release have used pharmacological agents to alter calcium 
concentrations. BAY K 8644 is a calcium channel agonist that activates 
the slow inward calcium channel. It has been shown that BAY K 8644 
vasoconstricts smooth muscle and reduces renal blood flow, dose-
dependently (Dietz, 1986). Infusion of the agonist into perfused 
kidney (Dietz, 1986) or addition to cortical slices (Matsumura et al., 
1985) does not alter basal levels of renin release. However, when BAY 
K 8644 was added with 15 mM potassium there was a significant decrease 
in renin release from the slices (Matsumura et al., 1985; May and 
Peart, 1986). The dose of potassium was reported to be below the 
threshold level for depolarization of the cells. The effect of BAY K 
8644 was reversed by addition of nifedipine, a calcium channel 
antagonist. Other investigators have indicated that addition of calcium 
channel antagonists elevate renin release from kidney slices by 
decreasing the amount of intracellular calcium (Henrich and Campbell, 
1986; Antonipillai and Horton, 1985). 
The hypothesis that renin secretion is modulated by stores of 
intracellular calcium has not been defined. However, calmodulin, an 
intracellular protein that has multiple binding sites for calcium, has 
been implicated in controlling renin release (Park et al., 1986; Fray 
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and Park, 1986; Fray et al., 1983). Addition of calmodulin antagonists 
such as trifluoperazine (Fray et al., 1983), calmidazolinium (Fray and 
Park, 1986) or W- 7 (Shinyama et al., 1987) produced dose-dependent 
increases in renin release when added to the kidney. Trifluoperazine 
also increased the basal levels of renin secretion from isolated renal 
cortical cells (Fray et al., 1983). Infusion of W- 7 into the renal 
artery of rats did not alter mean arterial pressure, renal blood flow 
or urine flow. The control compound, W-5, which does not have 
calmodulin antagonist actions, also did not affect these parameters. 
W- 7 produced dose-related increases in PRA and renin secretion rate 
whereas W-5 did not produce these changes in renin release (Shinyama et 
al., 1987). These data suggest a role for calmodulin and intracellular 
calcium levels in the juxtaglomerular cells in modulating renin 
release. 
Some of the stimuli that inhibit renin secretion require the 
presence of extracellular calcium. Vanadate (Churchill and Churchill, 
1980), ouabain (Cruz-Soto et al., 1984), potassium (Park et al., 1986) 
and high renal perfusion pressure (Fray and Park, 1986) are dependent 
on calcium in order to mediate their effect. For example, ANG II 
suppressed renin release when added directly to the kidney via the 
renal artery (Bunag et al., 1967). Removal or lowering of the 
concentration of calcium in the perfusate medium prevented the effect 
of ANG II on renin release (May and Peart, 1986; Antonipillai and 
Horton, 1985). In addition, the ANG II-induced stimulation of 
aldosterone production from glomerulosa cells was enhanced after 
addition of BAY K 8644 (Hausdorff et al., 1986). These findings 
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suggest that calcium is necessary in order for ANG II to exert an 
action, and that inhibition of renin secretion by ANG II is dependent 
on a calcium mediated mechanism. Dietz (1986) demonstrated that 
verapamil, another calcium channel antagonist prevented the decrease in 
renin secretion produced by increasing perfusion pressure. This 
supported an earlier proposal by Fray (1980) stating that calcium 
influx is needed for elevated perfusion pressure to decrease renin 
release. Overall, the evidence implies that calcium suppresses renin 
release and may be the mechanism by which other factors {ANG II and 
increased perfusion pressure) inhibit renin release. 
2. Volume receptors 
The early study by Goldblatt et al. (1934) demonstrated that 
graded constriction of the renal arteries induced hypertension in dogs. 
This was believed to be due to the presence of a circulating 
vasopressor substance. In 1959, Tobian et al. observed that there was 
an inverse relationship between the granulation of juxtaglomerular 
cells and perfusion pressure. He therefore proposed the theory that 
the juxtaglomerular cells act as baroreceptors, changing the rate of 
renin release as determined by changes in arterial pressure. Imagawa 
~ al. (1984) showed that as arterial pressure is gradually increased 
by suprarenal aortic constriction, PRA decreases. These studies 
suggest that changes in perfusion pressure may be a stimulus for renin 
release. 
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2a. Intrarenal baroreceptor 
The role of an intrarenal baroreceptor has been studied using the 
non-filtering kidney model (Blaine et al., 1971). This model was 
developed to obstruct glomerular filtration and prevent changes in 
.sodium delivery to the macula densa from altering renin release (Blaine 
et al., 1970). Reduction of plasma volume by hemorrhage or reduction 
--
of renal blood flow by partial suprarenal aortic constriction produced 
significant increases in renin secretion (Blaine et al., 1970; 1971; 
Blaine and Davis, 1971). Renal denervation or adrenalectomy did not 
diminish the renin response to decreased blood flow. Since glomerular 
filtration ceased, the authors deduced that the change in renin release 
was not dependent on the macula densa and was likely due to the 
presence of an intrarenal baroreceptor. 
The role of an intrarenal baroreceptor has also been studied using 
an isolated perfused kidney (Fray, 1976). Increased perfusion pressure 
suppressed renin release from the isolated kidney. Alteration of the 
sodium concentration in the perfusion medium did not affect the renin 
response to increased perfusion pressure. These findings support the 
hypothesis of Blaine et al. (1971) that the macula densa may not be 
involved in mediating the changes in renin secretion produced by 
increased arterial pressure. Kaloyanides et al. (1973) demonstrated 
that the increase in renin secretion produced by ureteral occlusion was 
prevented by increasing renal arterial pressure. 
Results have also accumulated suggesting that the juxtaglomerular 
cells are sensitive to changes in arterial stretch. Vasodilation 
produced by papaverine decreased renin release from the isolated 
perfused kidney (Fray, 1976). 
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Perfusion of the kidney with either 
phenylephrine or methoxamine, two o agonists that produce 
vasoconstriction, increased renin activity. The increase in renin 
secretion produced by phenylephrine was blocked by co-administration of 
papaverine or by increased perfusion pressure. Since the 
juxtaglomerular cells are modified smooth muscle cells, it is likely 
that they may depolarize in response to stretch (similar to the 
response seen with increased plasma volume) or increased perfusion 
pressure. Depolarization may influence the membrane permeability to 
certain ions (Fray, 1976). Later, Fray (1980) demonstrated that the 
decrease in renin release produced by increased perfusion pressure was 
mediated by calcium. Intracellular recordings from renin-containing 
cells show that depolarization of the juxtaglomerular cells is produced 
by stimuli that inhibit renin release and may be mediated by an 
increase in calcium influx (Buhrle et al., 1985). 
2b. Cardiac mechanoreceptors 
In addition to the intrarenal baroreceptor, cardiac 
mechanoreceptors also are involved in the maintenance of renin 
secretion. Increased left and right atrial pressure produced by 
inflation of arterial balloons produces a decrease in plasma renin 
activity (Brennan et al., 1971). Kaufman (1987) on the otherhand, 
demonstrated that increased right atrial stretch did not alter plasma 
renin activity or the isoproterenol-induced increase in PRA in 
conscious rats. Other studies have supported the results of Brennan et 
al. (1971) indicating that the mechanoreceptors in the right atrium 
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influence renin release (Sanchez et al., 1987; Julius et .5!.l., 1983). 
In human studies, lower body compression produced by inflation of a 
cuff around the legs, caused a significant increase in right arterial 
pressure and a suppression of PRA (Sanchez et al., 1987; Julius~ .5!.l., 
1983). Tilting the subject upwards promoted gravitational pooling of 
blood and also increased PRA. The effect of tilting on renin was 
counteracted by lower body compression. Inversely, decreasing right 
atrial pressure by induced pooling of blood in the extremities, results 
in an increase in PRA (Julius et al., 1983). These findings suggest 
that the cardiopulmonary mechanoreceptors play an important role in the 
integration of postural changes and renin release. 
3. Autonomic nervous system 
3a. Role of the sympathetic nervous system 
The juxtaglomerular apparatus of the kidney was analyzed for the 
presence of adrenergic nerve terminals. Using electron microscopy, 
Barajas and Muller (1973) documented the presence of dense core 
varicosities in the vicinity of the JGA that are generally associated 
with adrenergic neurons. These nerve terminal regions synapsed on the 
cells of the afferent and efferent arteriole as well as on the 
glomerulus and the proximal and distal tubules (Buhrle et al., 1985; 
Barajas and Muller, 1973). Using horseradish peroxidase labelling 
techniques, the origin of the renal nerves has been identified in the 
celiac and nodose ganglion (Gattone et al., 1986) and there is 
innervation extending from the dorsal root ganglia in the spinal cord 
segments TlO-Ll (Ciriello and Calaresu, 1983; Kuo et al., 1982). 
35 
Typically, stimulation of the renal nerves results in a renal 
vasoconstriction, increased renin release and an increase in sodium 
reabsorption (DiBona, 1985). The increase in renin release occurs at 
stimulation frequencies that do not alter renal hemodynamics (Osborn et 
1 1981) . Renal denervation produces a decrease in basal renin L·• 
release (Grandjean et al., 1978) and a decrease in the amount of sodium 
reabsorbed from the tubules (Bello-Reuss et al., 1975; Fernandez-
Repollet et al., 1985). The antinatriuresis produced by renal nerve 
stimulation can be prevented by pretreatment with the Q antagonist 
phentolamine. The beta blockers, propranolol and atenolol reduce the 
renal nerve-induced increase in renin secretion (Osborn et al., 1983). 
It has been hypothesized that the increase in renin release 
resulting from sodium depletion is partially dependent on intact renal 
nerves. Denervation reduced the response of natriuresis to volume 
expansion in sodium-depleted rats. There was no difference in sodium 
excretion in rats that were maintained on a regular sodium diet. These 
results suggest that renal nerve stimulation plays a larger role in 
maintaining sodium excretion in sodium-deficient than in control states 
(DiBona and Sawin, 1985). 
Renal sympathetic nerve activity has been shown to influence the 
onset of hypertension by changing renal arterial pressure, sodium and 
water balance and renin release. Winternitz and Oparil (1982) 
demonstrated that renal denervation decreases blood pressure and 
increases the renal excretion of sodium in spontaneously hypertensive 
rats. Renal denervation delays the development of hypertension in 
renovascular hypertension (Vari et al., 1987) and in genetic forms of 
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hypertension (Kline et al., 1980; Dietz et al., 1978). 
3b. Beta receptors 
3b1. Renal beta receptors 
Infusion of either epinephrine or norepinephrine into dogs with 
maintained arterial pressure produces the same response with respect to 
renin release and renal function as renal nerve stimulation (Vander, 
1965). Renin release increases and the renal plasma flow and sodium 
excretion decreases. Vander (1965) proposed that stimulation of the 
renal nerves produced an increase in renin secretion that occurred 
secondarily to changes in sodium excretion. Studies using kidney 
slices have demonstrated that adminstration of the beta receptor 
agonist, isoproterenol, produces increases in renin release that are 
prevented by pretreatment with d, 1-propranolol ('Weinberger et al., 
1975; Vandongen et al., 1973). Addition of norepinephrine and 
epinephrine also produce increases in renin release that are prevented 
by addition of d,1-propranolol ('Weinberger et al., 1975). These 
effects are due to stimulation of beta receptors since pretreatment 
with either phenoxybenzamine, an alpha-antagonist or d-propranolol, a 
membrane stabilizing form of the beta antagonist propranolol, did not 
prevent the catecholamine-induced stimulation of renin secretion. 
Beta-adrenergic receptor subtypes were localized in rat kidney 
slices by autoradiography using the non-selective B antagonist, 
iodocyanopindolol, in the presence of the selective antagonists for the 
Bi (betaxolol) or B2 (zinterol) receptors (Healy et al., 1985). The 
results from this study identified the renal cortex as having the 
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highest concentration of renal beta-receptors. B1 binding occurs 
primarily on the afferent arterioles and on the glomeruli; B2 binding 
is predominantly on the renal tubules of the medulla. Functionally, 
the B1 adrenoceptor has been associated with renin release from the 
kidney. Himori et al. (1979) demonstrated that atenolol, a selective 
B1 antagonist, attenuates the increase in renin secretion produced by 
isoproterenol. A B2 antagonist, IPS-339, was not as effective in 
reducing the isoproterenol-induced increase in renin release. 
Stimulation of renal nerves at a low frequency (0. 5 Hz for 0. 5 ms) 
produces an increase in renin release without changing renal blood 
flow, sodium excretion or arterial pressure (Osborn et al. , 1985; 
1981). Pretreatment with atenolol blocked the renin response to renal 
nerve stimulation. In contrast, blockade of B2 receptors did not 
modify the increase in renin secretion. These studies suggest that the 
sympathetic nervous system increases renin release by stimulating B1 
receptors on the JG cells. 
3b2. Extrarenal beta receptors 
Recently, data have accumulated indicating that an extrarenal beta 
receptor regulates renin secretion independently of the renal beta 
receptors. In 1972, Reid et al. infused the beta adrenergic receptor 
agonist, isoproterenol, into the femoral vein of dogs and noticed 
increases in PRA and renin secretion rate in both innervated and 
denervated kidneys. Renal perfusion pressure was held constant by 
adjusting an aortic clamp so there was no influence of renal perfusion 
pressure on the renin response to isoproterenol. No changes in 
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glomerular filtration, renal plasma flow or electrolyte excretion in 
these animals were detected. In contrast, infusion of isoproterenol 
into the renal artery at similar doses produced no change in PRA or 
renin secretion rate. These results do not support the involvement of 
intrarenal beta receptors in the regulation of renin secretion, and 
indicate that beta adrenergic stimulation is mediated by an extrarenal 
mechanism. 
In 1979, Johnson et al. reproduced the findings of Reid et al. 
(1972) with isoproterenol and tested the effect of epinephrine on renin 
secretion infused both intravenously and intrarenally. Similarly, 
epinephrine produced increases in PRA when infused intravenously but 
not intrarenally. This increase in renin secretion was independent of 
renal nerves, changes in perfusion pressure and prostaglandins (Johnson 
et al. , 1979a). Propranolol blocked the effect of epinephrine. 
Further experiments were designed to identify the location of these 
extrarenal beta-receptors. Infusion of epinephrine into splanchnic 
circulation (Johnson, 1983) did not produce an increase in PRA as did 
intravenous infusion. Johnson (1982) also tested the possibility that 
the beta receptors were located in the cerebral vasculature by infusing 
epinephrine into the carotid arteries. At higher doses epinephrine 
produced an increase in PRA when infused into the carotid arteries and 
this dose also increased the circulating levels of epinephrine. At 
slightly lower doses there was no change in PRA. Epinephrine also 
produced increases in PRA in adrenalectomized animals, indicating that 
the extrarenal beta receptors are not located in the adrenal glands 
(Johnson, 1985). At this point Johnson established a role for 
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extrarenal beta receptors but did not address whether there was an 
interaction between renal and extrarenal receptors. A submaximal dose 
of epinephrine was infused intravenously and into the renal artery. 
The renin secretion rate was measured in both kidneys and the values 
were not different from one another (Johnson, 1984). It was concluded 
that there is no interaction between beta receptors and that renin 
secretion is regulated only by extrarenal beta receptors. Contrary to 
these findings by Johnson (1979; 1982; 1984; 1985) are the data that we 
have obtained in our laboratory (Urban and Van de Kar, 1986). We have 
demonstrated that addition of the beta agonist, isoproterenol, to rat 
kidney cortical slices produces significant increase in renin release 
from the kidney slices. The dose of isoproterenol that we used in the 
renin release bioassay, is more concentrated than that used by Johnson. 
Therefore, it may be likely that the beta receptors at the kidney level 
require a higher concentration of isoproterenol in order to produce an 
effect whereas extrarenal beta receptors may be more sensitive to lower 
doses. 
3c. Parasympathetic nervous system 
Cholinergic innervation of the kidney has been described by 
Barajas (1979). He observed that labelling for acetylcholinesterase 
followed the distribution pattern of catecholamine fluorescence. 
However, when the animals were treated with 6-hydroxydopamine (6-0HDA), 
a drug that destroys catecholaminergic nerve terminals, both 
norepinephrine and acetylcholine staining disappeared from the kidney. 
This suggested that the acetylcholinesterase and catecholamine-
containing neurons may in fact be the same neurons. 
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Addition of 
acetylcholine directly to kidney slices did not produce a significant 
change in renin release (De Vito et al., 1970). Schrier et al. (1975) 
studied the effects of vagotomy on renin secretion in dogs. Vagotomy 
produced a suppression of renin secretion. However, in 
hypophysectomized dogs the suppression of renin secretion after 
vagotomy was prevented. This result indicates that inhibition of renin 
secretion is due to release of a pituitary hormone and not to a direct 
innervation of the kidney by the parasympathetic fibers. The authors 
attributed this effect to an enhanced release of vasopressin after 
vagotomy. Therefore, it appears that cholinergic neurons do not 
contribute to the innervation of the kidney or to the regulation of 
renin release. 
4. Other factors that regulate renin secretion 
4a. Vasopressin 
Vasopressin (AVP) is a potent vasoconstrictor and antidiuretic 
hormone. In addition, vasopressin inhibits renin secretion. However, 
whether this inhibition occurs by direct action of AVP on the 
juxtaglomerular cells or secondarily due to AVP-induced changes in 
blood pressure has not been determined. 
Vander (1968) showed that infusion of AVP produced a decrease in 
basal renin release. However, Vander noted that the excretion of 
sodium was increased and proposed that AVP may inhibit renin by acting 
on the macula densa. Another study (Shade et al., 1973) using the non-
filtering kidney model, also demonstrated that AVP suppresses renin 
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release after intrarenal infusion. They reported that the doses of AVP 
used did not alter mean arterial pressure or renal blood flow. 
Furthermore, since this study was performed in a non-filtering kidney, 
the decrease in renin release occurred without a functioning macula 
densa, suggesting a direct effect of AVP on the juxtaglomerular cells. 
Addition of AVP to rat renal cortical slices produced a significant 
decrease in renin release (Park et al. , 1981). This is further 
indication that AVP acts directly on the juxtaglomerular cells. 
In addition to a direct effect on the kidney, AVP decreases renin 
release secondarily to changes in blood pressure (Schwartz and Reid, 
1986). The inhibitory effect of AVP on renin release has been studied 
using analogues for AVP that are selective for either antidiuresis (V2 
receptor) or vasoconstriction (V1 receptor). Infusion of the 
antidiuretic agonist, DDAVP (d-arg-vasopressin), does not modify PRA or 
arterial pressure. Pretreatment with a V1 receptor antagonist 
[(CH2)5Tyr(Me)AVP], prevented the AVP-induced increase in blood 
pressure and the decrease in PRA (Schwartz and Reid, 1986). These 
studies indicate that AVP reflexly inhibits renin secretion through 
increased blood pressure. However, whether AVP primarily suppresses 
renin release by this mechanism or by a direct action on the kidney has 
yet to be established. 
4b. Adenosine 
Adenosine has recently been shown to inhibit the release of renin 
from the kidney. Churchill and Churchill (1985) have described the 
presence of two adenosine receptors (A1 and A2) that differentially 
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regulate renin secretion. Both receptors are coupled to adenylate 
cyclase, but the Ai receptor inhibits while the A2 receptor stimulates 
adenylate cyclase. Stimulation of the Ai receptor produces suppression 
of renin release while activation of the A2 receptor increases renin 
release from kidney slices. These effects of adenosine on renin 
release are anatagonized by calcium channel inhibitors and are probably 
mediated by changes in intracellular calcium (Churchill and Churchill, 
1985). 
Adenosine produces vasoconstriction when injected into the renal 
artery (Osswald, 1984). Other studies have indicated that adenosine 
can also alter renal nerve activity. Stimulation of the renal 
sympathetic nerves at different frequencies produces vasoconstriction 
that is blocked, dose-dependently, by adenosine (Ekas et al., 1981). 
However, Arend et al. (1984) have demonstrated that the decrease in 
renin release produced by adenosine was not influenced by changes in 
renal blood flow or blood pressure. Administration of adenosine 
prevents the increase in renin release produced by prostacyclin (PGI2) 
and norepinephrine, suggesting that adenosine acts directly on the 
juxtaglomerular cell to inhibit renin release (Deray et al., 1987). 
4c. Prostaglandins 
Administration of the prostaglandin precursor, arachidonic acid, 
produces an increase in renin release from isolated glomeruli 
(Beierwaltes et al., 1982). Superfusion of the glomeruli with 
prostaglandins PGE1, PGE2 or thromboxane had no effect on renin release 
(Beierwaltes et al., 1982). However, if the rapid breakdown of PGI2 
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was prevented, thereby increasing the concentration of PGI2, or if the 
pH of the perfusate was increased which favors stability of the 
prostaglandins, renin release was stimulated. Inhibition of PGI2 
synthesis also prevented the arachidonic acid-induced increase of .renin 
release (Beierwaltes et al., 1982). The increase in renin release 
produced by PGI2 has also been described by Kirchner (1985) and Henrich 
and Campbell (1984). 
Prostaglandins have been shown to mediate the increase in renin 
release in response to sodium depletion. Indomethacin, a prostaglandin 
synthesis inhibitor, reduces renin release in the sodium depleted dog. 
However, when the animals are maintained on a regular sodium diet, 
indomethacin does not affect the basal levels of PRA (Deforrest et al., 
1980). The role of prostaglandins in mediating the response of PRA to 
changes in renal arterial pressure is more controversial. In dogs with 
either a denervated non-filtering kidney or an intact filtering kidney, 
suprarenal aortic constriction produces an increase in PRA. This 
increase in PRA is not blunted by treatment with indomethacin (Freeman 
et al., 1982) or meclofenamate (Villarreal et al., 1984). However, the 
decreases in renal perfusion pressure in these experiments were below 
the autoregulatory range (80 mmHg). Imagawa et al. (1985) produced an 
increase in renin release after suprarenal aortic constriction without 
going below the autoregulatory range. After treatment with 
indomethacin, the renin response to aortic constriction was abolished. 
It has been suggested that the difference in the prostaglandin response 
to suprarenal aortic constriction following reductions in perfusion 
pressure within the autoregulatory range may be dependent on renal 
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prostaglandins (Freeman et al., 1984). 
5. Feedback regulation of renin release 
As has been discussed, the renin-angiotensin system partially 
controls aldosterone secretion which maintains sodium and water 
balance. The mechanisms involved in renin secretion can also be 
described in terms of a feedback control system. The primary signals 
that stimulate the renin-angiotensin system are a decrease in plasma 
volume and blood pressure. The decrease in blood pressure not only 
activates the stretch receptor but also the macula densa by decreasing 
glomerular pressure and sodium delivery to the distal tubule. 
ANG II is the end product of the renin-angiotensin system and 
plays an important role in the feedback regulation of renin secretion. 
ANG II has been shown to inhibit renin release from the kidney (Vander 
and Geelhoed, 1965). This is referred to as the short feedback loop. 
Receptors for ANG II have been localized on the glomerulus (Bianchi et 
al., 1986). However, it is possible that stimulation of ANG II 
glomerular receptors would affect renin release as a result of changes 
that would occur as a consequence of alterations in the glomerular 
capillary pressure. Furthermore, ANG II constricts the efferent renal 
arterioles which increases the pressure in the capillaries, resulting 
in enhanced sodium and water reabsorption (Hall, 1986). The increased 
sodium and water reabsorption would lead to an increased plasma volume 
and concomitant decrease in renin release. ANG II stimulates the 
production of aldosterone from the adrenal gland (Aguilera et al. , 
1980; Davis and Freeman, 1976). Aldosterone acts at the renal distal 
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tubule to increase the reabsorption of sodium and water from the 
tubular lumen. This restores plasma volume and blood pressure, thus 
completing a long feedback loop . 
. F. Central nervous system regulation of renin secretion 
1. Role of the central nervous system 
There has been increasing evidence suggesting a role for central 
nervous system pathways in regulating renin secretion. The effect of 
electrical stimulation of several brain sites have been electrically 
stimulated on PRA have been studied. Richardson et al. (1974) compared 
the effects of ventrolateral medulla (VLM) stimulation on renin release 
from control and denervated kidneys. They observed that denervation 
prevented the increase in renin release following stimulation of the 
VML in cats. Propranolol also blocked this increase. These studies 
suggest that the renal sympathetic nerves are involved in mediating the 
increase in renin secretion after stimulation of the VLM. Passo et al. 
(1971) stimulated the dorsal medulla and similarly demonstrated that 
destruction of the renal nerves attenuated the PRA response to 
excitation of the dorsal medulla. In this study (Passo et al., 1971), 
plasma epinephrine levels were elevated, implicating the involvement of 
the sympathetic nervous system and adrenal catecholamines. 
Stimulation of the dorsal periaqueductal grey (PAG) in the 
mesencephalon produced a pressor response that was associated with an 
increase in renin activity. Renal denervation prevented the effect of 
electrical stimulation of the PAG on blood pressure and renin secretion 
(Ueda et al., 1967). 
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The fastigial nucleus of the cerebellum has been implicated in 
regulating autonomic functions, namely, elevating arterial pressure and 
heart rate. This has been referred to as the fastigial pressor 
response and requires an intact sympathetic nervous system (Del .Bo et 
.al., 1983). Koyama et al. (1980) stimulated the fastigial nucleus and 
observed a pressor response accompanied by a significant increase in 
PRA. This increase was reduced by transection of the superior 
cerebellar peduncles (SCP). The major output from the fastigial 
nucleus is to the pontine and medullary areas via the SCP. The authors 
therefore concluded that the pressor response to fastigial stimulation 
may be mediated by these cardioregulatory centers through the 
sympathetic nervous system. 
An increase in renin activity was observed after electrical 
stimulation of the lateral hypothalamus (Zanchetti and Stella, 1975). 
This was associated with a transient constriction of the renal artery. 
However, the elevation in PRA was maintained beyond the vascular 
response and was prevented by destruction of the renal nerves. These 
data are supported in part by Frankel et al. (1976) who also observed 
increases in PRA after stimulation of the lateral hypothalamus. On the 
other hand Zehr and Feigl (1973) observed a suppression of renin 
release in dogs after stimulation of a site in the lateral 
hypothalamus. This site was postulated to be a sympathetic inhibitory 
site since both blood pressure and renin levels decreased. No 
histology was presented to identify the sites of stimulation, so a 
comparison with those areas stimulated by Zanchetti and Stella (1975) 
could not be made. Stimulation of the posterior hypothalamus 
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(supramammillary region) produced an increase in PRA and blood pressure 
(Natcheff et al., 1977). This effect was also dependent on an intact 
sympathetic nervous system. Electrical stimulation of the 
paraventricular nucleus of the hypothalamus (PVN) produced dose-
dependent increases in renin release with increased stimulation 
frequency (Porter, 1986). Blood pressure was not affected by 
stimulation of the PVN. These data suggest a role for the PVN in 
increasing renin release independently of changes in blood pressure. 
The role of the renal nerves in mediating this effect has not yet been 
reported. 
2. Stress-induced renin secretion 
Stress is implicated in the pathogenesis of hypertension and 
cardiac disease. A variety of stress paradigms produce increases in 
blood pressure and the circulating levels of different hormones 
including corticosterone, prolactin and PRA. One of the first studies 
on the effect of stress on renin secretion was conducted by Leenen and 
Shapiro (1974), who subjected rats to different periods of intermittent 
foot shock. PRA was increased in rats 15 minutes after they received 
the shock. However, after the rats were exposed to this stimulus for 
over 2 hours, there was an apparent adjustment to the shock since there 
was no difference in PRA between the shock and control groups. Paris 
~ al. (1987) reported that intermittent foot shock for 2, 12 and 22 
minutes produced increases in PRA. In addition, PRA was increased by 
20 minutes of forced swimming in deep cold water, 20 minute 
immobilization and by both a 3 and 12 minute conditioned fear (CER) 
paradigm. 
that were 
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Jindra et al. (1980) also observed increases in PRA in rats 
immobilized for 20 minutes or received repeated 
immobilization of 150 minutes daily for 34 days. Exposure to a novel 
environment (open field) or to the presence of a hungry cat produced 
elevations in PRA (Clamage et al., 1976). The effect of novel 
environment on PRA could be attenuated by pretreatment with 
propranolol. Blair et al. (1976) reported that baboons that were 
subjected to an avoidance operant conditioning paradigm had elevated 
PRA values. The baboons were taught to sit in a chair and their task 
was to push a lever in order to avoid an electric shock. This study 
suggested that a psychological stimulus could evoke a stress response 
as measured by an increase in PRA. 
There are a variety of stress models that produce increases in 
PRA. The stress paradigm used in this laboratory consisted of a 3 or 
10 minute conditioned emotional or fear response paradigm. The rats 
are placed in a chamber on three consecutive days and after either a 3 
or 10 minute period, they receive a footshock. On the fourth day the 
rats are placed in the chamber and do not receive any shock. At this 
point they are anticipating the shock, which simulates anxiety or fear. 
The effect of CER on PRA can be attenuated, but not completely 
prevented by pretreatment with the beta receptor blocker propranolol 
(1.0 mg/kg i.p.; Van de Kar et al., 1984). Administration of the same 
dose of propranolol to rats that were subjected to restraint stress did 
not affect the increase in PRA (Sigg et al., 1978); however, the 
increase in PRA was diminished with higher doses of propranolol. 
Adrenal medullectomy combined with chemical sympathectomy (peripheral 
49 
injections of 6-0HDA) did not prevent the stress-induced increase in 
PRA (Richardson Morton et al., unpublished observations). With the 
restraint stress paradigm, demedullectomy did not alter the stress-
induced increase in PRA but renal denervation did reduce the observed 
.increase in PRA (Sigg et al., 1978). These conflicting results might 
suggest that different neural pathways are involved in mediating the 
stress-induced increase in PRA. 
Pharmacological studies have indicated that peripheral 
administration of the benzodiazepines, chlordiazepoxide and midazolam, 
which enhance GABA neurotransmission, did not alter the renin response 
to the GER paradigm (Van de Kar et al., 1984b). Naloxone, an opiate 
antagonist or diisopropyl fluorophosphate (DFP) an acetylcholinesterase 
inhibitor, also did not prevent the stress-induced rise in PRA or alter 
basal levels of renin release. Therefore, these results imply that 
neither the cholinergic, GABAergic or opiate systems are involved in 
regulating renin release in response to the GER (stress) paradigm. 
Electrolytic lesions in the dorsal raphe nucleus (DRN) prevented 
the stress-induced increase in renin secretion with both the 3 and 10 
minute GER paradigms (Van de Kar et al., 1984a; Richardson-Morton et 
al., 1986). However, this effect was not due to disruption of 
serotonergic fibers since 5,7-DHT injections into the DRN and 
pretreatment of rats with the S-HT2 antagonist, LY53857 did not prevent 
the effect of stress on renin secretion (Lorens et al., 1986). Gotoh 
~ al. (1987) and Richardson-Morton et al. (1986) showed that 
electrolytic lesions in the PVN prevented the increase in renin 
secretion in rats subjected to either immobilization or GER, 
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respectively. Selective destruction of the cell bodies in the PVN with 
ibotenic acid, also prevented the increase in PRA (Richardson-Morton et 
~·, 1986). In order to test the possible involvement of 
catecholamines in regulating the stress-induced release of renin, 6-
.0HDA was injected into the PVN and was found to attenuate the stress 
(GER) response on PRA (Richardson Morton et al., 1987). 
3. Role of serotonin (5-HT) on renin release 
3a. Effects of peripheral administration of 5-HT 
Administration of 5-HT, or the serotonin precursor, 5-
hydroxytryptophan (5-HTP) to rats produced increases in water intake 
(Kikta et al., 1981) that are mediated by the renin-angiotensin system 
(Meyer et al., 1974; Kikta et al., 1983). Pretreatment with the 
serotonin receptor antagonist, methysergide, prevented the dipsogenic 
effect of 5-HT and 5-HTP. In addition, rats that received either the 
beta blocker, propranolol (Meyer et S!l.., 1974; Kikta et al., 1983) or 
the angiotensin converting enzyme inhibitor captopril (Kikta et al., 
1983) had an attenuated drinking response to 5-HT. These results 
suggest that the renin-angiotensin system mediates the 5-HT-induced 
dipsogenesis. However, these studies did not examine whether this was 
a central effect of 5-HT nor did they postulate a mechanism for 5-HT 
stimulation of renin release. A study by Bunag et al. (1966b) showed 
that infusion of serotonin into the renal artery did not directly 
stimulate renin release from the kidney. Data presented in this study 
(Table 9) demonstrate that addition of 5-HT to kidney slices does not 
directly increase renin release. 
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Barney et al. (1981) and Meyer et al. (1974) demonstrated that 
injection of 5-HT either subcutaneously or intramuscularly to rats, 
produces increases in PRA. The effect of 5-HT on PRA is prevented by 
pretreatment with metergoline, a 5-HT antagonist. Treatment with 
propranolol or camphidonium, a ganglionic blocker, attenuated the 5-HT 
induced increase in PRA (Meyer et al., 1974) indicating that both 5-HT 
and the sympathetic nervous system are involved in regulating renin 
release. Zimmermann and Ganong (1980) administered two 5-HT 
precursors, 5-HTP and 1-tryptophan to anesthetized dogs and observed 
increases in PRA that were not due to changes in blood pressure. The 
elevation of PRA due to the 5-HT precursors was prevented by infusion 
of the central aromatic amino acid decarboxylase inhibitor, 
benserazide, but not by carbidopa, a decarboxylase inhibitor that does 
not cross the blood brain barrier. Pretreatment with metergoline or 
renal denervation also prevented the 5-HT-induced increase in PRA. 
Earlier studies by Epstein and Hamilton (1977) showed that in humans, 
the 5-HT antagonist, cyproheptadine, inhibited the furosemide-induced 
increase in PRA. Other studies by Modlinger et al. (1979) showed that 
oral administration of the 5-HT precursor 1-tryptophan to humans, 
produced an increase in renin secretion that was prevented by 
pretreatment with cyproheptadine. These were the first studies that 
suggested a role for brain 5-HT in stimulating renin release. 
3b. Role of brain 5-HT neurons 
Administration of the 5-HT releaser, p-chloroamphetamine (PCA) or 
the 5-HT agonist quipazine, produces dose-dependent increases in PRA 
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(Van de Kar et al. , 1981) . The effect of PCA is prevented by 
pretreatment with p-chlorophenylalanine (PCPA) a drug that inhibits 5-
HT synthesis. Fenfluramine, another 5-HT releaser, also produces dose 
-dependent increases in PRA that are prevented by pretreatment with 
PCPA or the 5-HT reuptake inhibitors, fluoxetine or indalpine (Van de 
Kar~ al., 1985b). The effect of a submaximal dose of fenfluramine on 
renin secretion was enhanced after pretreatment with 1-tryptophan. 
Administration of the 5-HT2 antagonist LY53857, prevents the increase 
in PRA and PRC produced by fenfluramine and the 5-HT agonist MK-212 
(Lorens and Van de Kar, 1987). LY53857 alone did not alter PRA or PRC. 
The 5-HT1a agonist 8-0H-DPAT (8-hydroxy-2- [ di-N-propylamino] tetralin) 
did not produce any change in either PRA or PRC. Ipsapirone, another 
5-HT1a agonist, produced increases in PRA and PRC only at higher doses 
(Lorens and Van de Kar, 1987). Administration of buspirone, a non-
benzodiazepine anxiolytic that also has 5-HT1a agonist activity 
produces a decrease in renin secretion at relatively low doses ( 1. 0 
mg/kg i. p.; Van de Kar et al., 1985c). These findings suggest that 
stimulation of 5-HT2 receptors enhances renin release whereas the 5-HT1 
receptors may not have a role in the control of renin secretion. 
Injection of the 5-HT neurotoxin 5,7-DHT (5,7-dihydroxytryptamine) 
into the dorsal raphe nucleus, a serotonergic cell group in the 
midbrain, prevented the PCA-induced increase in PRA. Injections of 
5, 7-DHT into the median raphe nucleus were without effect on renin 
secretion (Van de Kar et al., 1982b). Both of these lesion treatments 
significantly reduced brain 5-HT content. These were the first 
definitive findings for a role of brain serotonin neurons in the 
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regulation of renin secretion. Destruction of the mediobasal 
hypothalamus, either destroying or sparing the median eminence, 
prevents the increase in PRA produced by PCA (Karteszi et al., 1982). 
Posterolateral knife cuts through the mammillary bodies destroyed 
neuronal inputs to and from the hypothalamus, also blocked the increase 
in PRA produced by PCA. However, anterolateral deafferentation did not 
reduce the PRA response to PCA. Hypophysectomy did not prevent the 
PCA-induced increase in PRA 4 days after surgery (Karteszi et al., 
1982). Since the dorsal raphe nucleus is known to send projections to 
the hypothalamus it is likely that a serotonergic pathway stimulates 
renin secretion by some structure within the hypothalamus. Recently, 
Gotoh et al. (1987) reported that electrolytic lesions of the 
paraventricular nucleus (PVN) in the hypothalamus prevent the PCA-
induced increase in PRA. 
In the study by Zimmermann and Ganong (1980), renal denervation 
prevents the increase in PRA produced by 5-HTP or tryptophan. To 
investigate the role of the sympathetic nervous system in mediating the 
PCA-induced increase in PRA, beta blockers were administered before 
PCA. Alper and Ganong (1984) showed that pretreatment with the beta-
receptor antagonists propranolol and sotalol prevented the increase in 
PRA produced by PCA. These results were confirmed by Van de Kar and 
Richardson-Morton (1986). Both the selective beta1 receptor 
antagonist, atenolol, and the non-selective beta antagonist, sotalol, 
completely prevented the effect of PCA. However, more conclusive 
studies indicated that the sympathetic nervous system was not involved. 
Treatment of rats with the catecholamine blocker, bretylium tosylate, 
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or the cholinergic muscarinic antagonist, methyl atropine did not alter 
the PCA-induced increase in PRA (Van de Kar and Richardson-Morton, 
1986). Transection of the spinal cord proximal to the exit of the 
renal nerves, between the T1 or T2 vertebrae, did not modify the renin 
response to PCA. In addition, the effect of adrenal medullectomy 
combined with peripheral sympathectomy was also tested on renin 
secretion. The adrenal medulla was removed from rats and one week 
later they received weekly injections of 6-hydroxydopamine (6-0HDA) for 
4 weeks. This treatment decreased the renal content of norepinephrine 
to levels that were below the sensitivity limit of the assay (Van de 
Kar and Richardson-Morton, 1986). Administration of PCA produced 
significant increases in PRA in both the sham-operated rats and the 
rats that were sympathectomized. These results indicate that the 
sympathetic nervous system does not mediate the PCA-induced increase in 
renin release. These results appear to contradict the data obtained 
with the beta blockers. However, it should be considered that beta 
blockers have been shown to cross the blood brain barrier and compete 
with 5-HT for receptor sites. Propranolol, for example, is known to 
interact at the 5-HT receptor (Middlemiss et al., 1977) and has been 
shown to decrease the rate of 5-HT synthesis in the hypothalamus, 
midbrain and frontal cortex (Giarcovich and Enero, 1984). Therefore, 
it is possible that the beta blockers may be acting centrally to 
influence serotonergic transmission and that a central site of action 
for these beta blockers cannot be discounted. 
G. Role of humoral factor in regulating renin release 
The existence of an extrarenal humoral factor 
oeVito g,!;; al. in 1971. Plasma was collected 
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was presented by 
from bilaterally 
nephrectomized dogs that were made hypotensive by controlled 
hemorrhage. When the plasma from hypovolemic dogs was injected into 
unanesthetized control dogs, there was a significant increase in PRA. 
This elevation of PRA was not observed after injection of plasma from 
normotensive dogs. Polomski et al. (1974) could not reproduce these 
findings. No further studies on this factor were performed. 
Since the effect of PCA on renin secretion is not mediated by 
either the parasympathetic or the sympathetic nervous systems, another 
possibility is that the hypothalamus may release a factor into the 
circulation that can stimulate renin release from the kidney. A study 
by Van de Kar et 5!.l. (1982a) tested the hypothesis that PCA induces the 
release of a factor into the blood. A group of rats were 
nephrectomized and received either saline or PCA 24 hours after 
surgery. Their plasma was collected and administered at different 
times to recipient rats. Administration of the plasma from PCA-treated 
rats produced a significant increase in PRA at 30 minutes after 
injection. These results suggest that brain serotonin stimulates renin 
secretion by releasing a factor into the blood. Further transfusion 
experiments have indicated that the renin-releasing factor is heat 
stable and is present in the plasma of PCA-treated rats within the 
molecular weight range of 500-10,000. 
CHAPTER III 
MATERIALS AND METHODS 
A. Animals 
Male Sprague-Dawley rats (150-300 g) were purchased from Sasco-
King Animal Laboratories (Oregon, WI) and were housed, two per cage, in 
a temperature (22°C), light (12:12 light/dark cycle) and humidity (45% 
- 55%) controlled room. Rat chow (Wayne Lab Blox, Allied Mills Inc., 
Chicago,IL) and water were available ad libitum. 
B. Analytical methods 
1. In vitro renin release kidney slice bioassay for measurement of RRF 
activity 
A rat (150-200 g) was perfused under halothane anesthesia, with 
cold saline through the left cardiac ventricle. The abdomen was opened 
to expose the kidneys which were removed and immediately placed in cold 
saline (0.9% NaCl). The kidneys were palpated to remove excess blood 
and decapsulated. The poles (2-3 mm) were dissected and removed from 
the kidneys, and the kidney was cut in half through the papilla, glued 
to a 1-inch square piece of Plexiglas, and mounted on an Oxford Model G 
vibratome (10° angle, settings of 0 for vibration and speed). The 
kidney was always maintained in cold saline, and saline ice cubes were 
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added during the slicing to maintain the temperature at 4°c. Coronal 
slices (400 µm) were cut, and the first slice was discarded. Once the 
slice was cut, it was placed on ice in a petri dish containing cold 
saline, and the medullary tissue was excised from each slice w.ith a 
scalpel. The renal medulla does not contain renin and the highest 
density of renin secreting cells is in the outer cortex. Therefore, 
using coronal slices of cortical tissue ensures that the slices were 
homogenous with respect to renin content (Katz and Malvin, 1982a; Jones 
~al., 1979). Each slice was cut in half and randomly placed, two 
kidney slice halves per vial, in 10.0 ml vials that were siliconized 
(Prosil-28; Scientific Products, Specialty Chemicals, Gainesville, FL). 
Two ml of a Krebs-Ringer buffer were added to each vial. The Krebs-
Ringer solution has a composition of 118.0 mM NaCl, 1.22 mM KH2P04, 4.7 
mM KCl, 2.5 mM CaCl2, 1.2 mM MgS04, 10.0 mM glucose, and 25.0 mM NaHC03 
and was used throughout the experiments. The vials were placed in a 
water bath and the kidney slices were incubated at 37°C. Each vial 
received its own supply of a 95% 02-5% C02 gas mixture via a needle 
(20-gauge) that was attached to plastic tubing (Scientific Products, 
3/32 in. O.D., 1/32 in. I.D.) and inserted into plastic snap-on caps 
which fit snugly onto the vials. This allowed proper oxygenation of 
the vials without bubbling the medium. Cho and Malvin (1979) reported 
that bubbling of the incubation medium in which the kidney slices 
incubated inactivates renin at the air-water interface. This would 
result in low and variable values for renin release and the assay for 
renin would not indicate real changes in renin release over time. A 
few small holes in the caps relieved the pressure inside the vials. 
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The other end of the tubing was attached to a 12 place pipette manifold 
which was fitted to the hose that supplied the 95% 02-S% C02 gas. This 
system, when set up with 4-5 manifolds, could oxygenate a total of 48-
60 vials. 
The slices were placed in the vials with 2. 0 ml of Krebs-Ringer 
buffer for a 30 minute preincubation period. After 30 minutes, a 0.2 
ml sample was withdrawn from the vials for the determination of renin 
concentration. The vials were refilled with 2. 0 ml of Krebs-Ringer 
solution and test solutions (plasma fractions, plasma samples, drugs or 
brain and peripheral tissue extracts) were added to the vials. 
As a routine for each kidney slice bioassay, six vials received 
the vehicle (usually saline or Krebs-Ringer buffer) and another six 
vials received a dose of isoproterenol (10-6M - l0- 5M). This served as 
two controls for the bioassay: the vehicle was a control of basal 
levels of renin release and isoproterenol demonstrated maximal 
stimulus-induced renin release or the upper limit of the bioassay. 
The vials incubated for 1 hr; 0.2 ml was saved for renin assay, 
and the Krebs-Ringer solution was decanted and saved for measurement of 
pH and, on occasion, lactate dehydrogenase (LDH) activity. LDH is a 
cytosollic enzyme that is used as an indicator of cell lysis. The LDH 
assay were performed to ensure that the increases observed in renin 
release from the kidney slices were due to the applied stimulus and not 
due to lysis of the kidney cells. A final 2.0 ml was added for a 30 
minute postincubation period and a final 0. 2 ml sample was taken for 
determination of renin concentration. The slices in each vial were 
blotted dry and weighed. All samples were stored at -40°C until 
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determination of renin concentration. 
For each bioassay, in addition to the incubation values, samples 
were also measured for renin release during the 30 minute pre-
incubation and post-incubation periods. These were used as quality 
controls for each kidney slice vial. After each incubation, the post-
incubation value for renin release should have returned back to the 
levels seen in the pre-incubation. This indicated: (1) if the increase 
seen during the incubation period was truly due to the applied stimulus 
and (2) whether the kidney cells were dying. Using the comparisons of 
the pre-incubation and post-incubation periods along with the 
measurement of the pH and LDH enabled checks on the bioassay that would 
validate the viability of the kidney slices. 
2. Specificity of the bioassay for RRF 
2a. Test for non-specific activation of renin by plasma fractions 
Krebs-Ringer samples (2.0 ml) were preincubated with kidney slices 
for 1 hour. The kidney slices were removed and the Krebs-Ringer was 
pooled. Samples (0.2 ml) of either saline, saline-plasma (M.W. 
5,000-10,000) or PCA-plasma (M.W. - 5,000-10,000) fractions were added 
to 2. 0 ml of the Krebs -Ringer solution. These samples incubated at 
37°C for 1 hour and afterwards, 0. 2 ml aliquots were taken and saved 
for the determination of renin concentration (Method section B part 
3b). 
2b. Test for non-specific generation of angiotensin I from renin 
substrate by plasma fractions and brain extracts 
The samples that were used in the previous studies (plasma 
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fractions and brain extracts) were tested for possible renin-like 
activity that would result in the non-specific generation of 
angiotensin I in the incubation for the radioimmunoassay. A volume of 
2.0 µl of either rat hypothalamic, cerebellar, and pituitary extracts, 
or the saline-plasma and PCA-plasma fractions (M.W. - 5,000-10,000) 
were added to 0.2 ml of the Krebs-Ringer solution containing PMSF, 8-
HQ, phosphate buffer and nephrectomized plasma, which corresponded to 
the dilution of these test substances in the kidney slice bioassay. 
The samples incubated for 1 hour at 37°C, and the incubation was 
terminated by addition of 0. 2 ml of distilled water and immersion of 
the samples in a boiling water bath. The samples were then assayed for 
ANG I. 
3. Determination of renin concentration and plasma renin activity 
Renin activity of the kidney slices samples and plasma is measured 
by radioimmunoassay for generated ANG I according to the method of 
Haber et al. (1969) and Stockigt et al. (1971). 
3a. Preparation of renin substrate (angiotensinogen) 
Renin substrate (angiotensinogen) was obtained from the plasma of 
nephrectomized, male Sprague-Dawley rats (retired breeders, 450-500 g). 
Removal of the kidneys (the major source of renin) prevented the 
enzymatic reaction between renin and angiotensinogen in the plasma and 
allowed the plasma concentration of substrate to increase (Radziwill et 
al. , 1986). 
Approximately 40 animals were used for the preparation of renin 
substrate. The rats were anesthetized with halothane (Burns, Glenview, 
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IL) and care was taken to avoid any undue stress to the rats. The 
kidneys were palpated and a dorsal incision was made through the skin 
at the kidney level. The muscles of the back were teased apart by 
blunt dissection and the kidneys were removed through the openings in 
the body wall. The renal artery and vein were ligated and the kidneys 
were removed. The ligatures were placed back into the body cavity and 
the incision was sutured closed. Each rat then received an injection 
of dexamethasone (0.2 mg/rat, s.c.; Sigma, St. Louis, MO). 
Dexamethasone treatment increases the amount of angiotensinogen in the 
plasma (Reid, 1977). 
The rats were decapitated 24 hours after surgery. The trunk blood 
was collected in a beaker containing 0. 3 M ethylene diamine 
tetraacetate (EDTA, pH 7.4; approximately 0.5 ml per rat). The blood 
was centrifuged at 1500 x g, and the plasma was collected and stored at 
-40°c. 
3b. Determination of renin concentration in the Krebs-Ringer medium 
after incubation with kidney slices and in plasma. 
Renin concentration was measured by determining the amount of 
angiotensin I (ANG I) generated by incubating the sample (0.2 ml Krebs-
Ringer from kidney slices or plasma) for 1 hour with a saturating 
concentration of renin substrate. Renin substrate was 0.1 ml of plasma 
from nephrectomized rats that received an injection of dexamethasone 
(0.2 mg/rat, s.c.) 24 hours before sacrifice. 
The converting enzyme inhibitors 8-hydroxyquinoline (8-HQ, 10% 
suspension in 0.3 M EDTA; final concentration: 0.86 mM; Mallinckrodt, 
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St. Louis, MO) and phenylmethylsulfonyl fluoride (PMSF, 5 g in 150 ml 
ethanol; final concentration: 2.3 mM; Sigma, St. Louis, MO) were added 
(5 µl each) to the samples to prevent the degradation of ANG I to ANG 
II. PMSF inhibits the angiotensin converting enzyme by sulfonating the 
active site of the enzyme (Fahrney and Gold, 1962). 8-HQ prevents the 
action of converting enzyme by chelating divalent metals (Phillips, 
1956) which are necessary for its activity (Fitz, Boyd and Peart, 
1971). A volwne of 0.1 ml of sodiwn phosphate buffer (0.5 M, pH 6.0) 
was added to the samples to maintain the pH at 6. 0-6. 5 during the 
incubation. This pH range has been determined by us to be optimal for 
renin activity. The samples incubated at 37°C for 1 hour. The 
reaction was halted by addition of 1.6 ml cold distilled water to the 
Krebs-Ringer samples, or 0.2 ml of cold distilled water to the plasma 
samples, and subsequent immersion of the samples in a boiling water 
bath for 3 minutes. 
3c. Plasma renin activity 
Plasma renin activity was measured by radioimmunoassay of ANG I 
generated in the plasma sample after a 3 hour incubation. The 
converting enzyme inhibitors, 8-HQ and PMSF were added (25 µl and 20 
µ1) to 1.0 ml of plasma at the same final concentration (0.86 mM 8-HQ 
and 2.3 mM PMSF). Sodiwn phosphate buffer (0.5 ml; 0.5 M pH 6.0) was 
added to the plasma samples to reduce the pH of the samples to 6.0-6.5. 
The samples were incubated for 3 hours at 37°c to generate ANG I from 
endogenous angiotensinogen (renin substrate). The incubation was 
stopped by addition of 0. 5 ml distilled water and immersion of the 
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samples in a boiling water bath for 3 minutes. 
3d. Radioimmunoassay for generated angiotensin I (ANG I) 
After the incubation, the samples (renin concentration, plasma 
renin activity and plasma renin concentration) were centrifuged (13,000 
x g for 10 minutes; Fisher microcentrifuge Model M235A) and aliquots of 
the supernatant (20 µl and 50 µl) were diluted to a final volume of 0.5 
ml with Tris-HCl (pH 8. 0) and added to tubes (polystyrene, 12 x 75) 
with a 0.3 ml solution of an ANG I antibody in a Tris buffer (0.1 M pH 
8.0 containing 0.1% gelatin; Sigma, St.Louis, MO). The final volume is 
0.8 ml. The ANG I antisera (Reid #3 and Brownfield Tl351) were a gift 
from Dr. M. S. Brownfield, University of Wisconsin. These ANG I 
antis era were used at dilutions of 1: 100, 000 (Reid #3) or 1: 40, 000 
(T1351) with 35% binding and a sensitivity limit of 10 pg per tube. 
After a 24-48 hour incubation period at 4°c with the antiserum, an 1251 
labelled ANG I tracer was added to the tubes (10,000 counts per minute 
per tube) for an overnight incubation at 4°C. On the following day, 
0.5 ml of a charcoal-dextran (TSOO; Pharmacia, Piscataway, NJ) 
suspension and 1.5 ml of cold distilled water were added to the tubes. 
The tubes were then centrifuged at 2000 x g for 15 minutes. This 
separated the unbound 1251-ANG I from the antibody-bound tracer in the 
supernatant which was decanted. The charcoal pellets, containing the 
free 1251-ANG I, were counted on a Micromedic gamma counter. The data 
were reduced by RIA_AID computer program (Robert Maciel Associates, 
Inc., Arlington, MA). Intra-assay variability was 4.6% and interassay 
variability was 11. 9%. The values for renin release from the kidney 
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slices are reported as ng ANG I generated/hr. These values were then 
divided by the weight of the kidney slices to obtain ng ANG I/mg 
kidney/hr. PRA and PRC values were reported as ng ANG I/ml/3 hr and ng 
ANG I/ml/hr, respectively. 
ANG I (Beckman, Arlington Heights, IL) was radiolabelled with 125I 
(New England Nuclear, North Bellerica, MA) using the chloramine T 
(Sigma, St. Louis, MO) method of iodination (Greenwood, Hunter and 
Glover, 1963). Phosphate buffer (0.05 M; 0.02 ml), 12 µl ANG I (0.5 
µg/µl) and 20 µl chloramine T (3.5 mg/ml phosphate buffer) were added 
to the vial containing the 125I and mixed for 3 seconds. This was 
immediately followed by addition of 25 µl of sodium metabisulfite (4.5 
mg/ml phosphate buffer; J.T. Baker Chemical Co., Phillipsburg, NJ) to 
halt the reaction. Radiolabelled ANG I was first eluted with 0 .1 N 
acetic acid on a Bio-Rad AG l-X4 anion exchange resin (Bio-Rad 
Laboratories; Richmond, CA) column that was made from a siliconized 
disposable pasteur pipette (5 3/4"; Scientific Products) with a small 
amount of glass wool placed in the tip to support the anion exchange 
resin. Fractions (12 drops per tube) were collected from the column 
and the radioactivity in each tube was measured. The radioactive peak 
fractions eluted off this column (usually tube numbers 4-5) were then 
placed on a Sephadex Gl5 column (Kl5/90, 90 x 1.5 cm; Pharmacia, 
Piscataway, NJ) and eluted with 0. 05 N acetic acid containing 0 .1% 
bovine serum albumin (BSA; Sigma, St. Louis, MO). Fractions (2.0 ml) 
were collected off the Sephadex column and measured for radioactivity. 
The tubes that contained the radioactive ANG I (approximately five 
tubes, numbers 35-39) were pooled and stored at -10°C. 
c. 
1. 
65 
In vivo studies of the renin-releasing factor 
The effect of a serotonin releaser, PCA and serotonin agonists (MK-
212 and TFMPP) on PRA, PRC and plasma RRF concentration 
PCA is a drug that exerts its action by inducing the release of 
serotonin from the nerve endings (Sanders-Bush et al., 1975). 
Administration of PCA has been shown to increase the plasma 
concentration of RRF. To test if direct activation of serotonin 
receptors would induce the release of RRF into the blood, the serotonin 
agonists MK-212 [6-chloro-2-phenyl-(l-piperazinyl)-pyrazine] and TFMPP 
(m-trimethylphenyl piperazine) were administered to rats and their 
plasma was collected and assayed for RRF concentration, PRC and PRA. 
PCA (10 mg/kg, i.p.) was administered 1 hour before sacrifice. 
The serotonin agonists, MK-212 (Merck, Sharp and Dohme, Rahway, N.J.) 
and TFMPP (m-trifluoromethyl-phenylpiperazine; Aldrich Chemical CO. 
Inc.; Milwaukee, WI) were administered, at a dose of 10 mg/kg i.p, to 
rats 30 minutes before sacrifice. Saline and the drugs were 
administered at a volume of 2.0 ml/kg i.p. The rats were decapitated 
and their plasma was collected in chilled centrifuge tubes containing 
20 units of heparin. The samples were centrifuged at 1,500 x g for 30 
minutes. The plasma from each rat was divided into 3 aliquots. One 
aliquot of 1. 0 ml was saved for the determination of plasma renin 
activity and the second aliquot (0. 2 ml) was saved for the 
determination of plasma renin concentration (PRC). The third aliquot 
(2.0 ml), was saved for the determination of plasma RRF concentration. 
It was diluted with 2.0 ml distilled water, placed in a boiling water 
bath (to denature renin) for 20 minutes and centrifuged at 13,000 x g 
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for 20 minutes. The supernatant was lyophilized to dryness. The dry 
peptide residues were resuspended in 0.25 ml saline and 0.2 ml of the 
resuspended plasma was added to vials containing 2. 0 ml Krebs-Ringer 
and kidney slices to test for renin-releasing activity as desc;ribed 
above (section B part lb). 
2. Effect of a stressor on PRA and plasma RRF concentration 
2a. Description of the conditioned emotional response (stress) 
paradigm 
Rats were subjected to a conditioned emotional response (CER), or 
fear paradigm. The CER was performed in a rectangular chamber (49 cm 
long x 23 cm wide x 28 cm high) with a grid floor composed of stainless 
steel rods (7.6 mm diameter) spaced 1.3 cm apart. The front wall of the 
chamber was constructed from clear Plexiglas. The remaining walls and 
ceiling of the chamber were made of white Plexiglas. Illumination was 
provided by a fluorescent lamp (20 W) mounted on the outside of the 
rear wall. The chamber was located in a sound attenuated room 7. 5 
meters from the animal quarters. Scrambled constant current shock was 
delivered through the grid floor by a Grayson-Stadler shock generator. 
The rats were carried to the stress room in a plastic cage that was 
identical to their home cage. Three minutes following their placement 
in the chamber, the experimental animals received an inescapable foot 
shock (1. 0 mA DC for 10 seconds). Immediately thereafter, the rats 
were returned to their home cage. This procedure was repeated once a 
day for three consecutive days. Control rats were treated the same, 
except that shock was not administered at any time. By the third day, 
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it was quite apparent that the stressed rats had learned that placement 
in the chamber would be followed by a shock. In contrast to control 
animals, the stressed rats defecated, urinated and alternated between 
freezing and jumping behaviors. On the fourth day, the rats were 
placed in the chamber for three minutes. Instead of receiving the 
shock, they were removed and immediately sacrificed by decapitation in 
a room located 3.0 meters from the stress room. 
2b. Preparation of plasma from stressed and unstressed rats 
Blood from the decapitated rats was collected into centrifuge 
tubes containing 0.5 ml of a 0.3 M EDTA (ethylene diamine tetraacetate, 
pH 7.4; Sigma, St. Louis, MO) solution. The plasma was divided: 1.0 ml 
for determination of PRA and 0. 2 ml for determination of PRC. The 
third aliquot (2.0 ml), saved for determination of plasma RRF 
concentration, was diluted with 2. 0 ml distilled water, placed in a 
boiling water bath (to denature renin) for 20 minutes and centrifuged 
at 13,000 x g (Fisher microcentrifuge Model 235A) for 20 minutes. The 
supernatant was lyophilized to dryness. The dry peptide residues were 
resuspended in 0.25 ml saline and 0.2 ml of the resuspended plasma was 
added to vials containing 2.0 ml Krebs-Ringer and kidney slices to test 
for renin-releasing activity as described above. 
3. Role of disulfide bonds in RRF: In vivo study with cysteamine and 
PCA 
3a. In vivo study with PCA and cysteamine pretreatment 
It is possible that since the RRF is a peptide, it may be contain 
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disulfide bonds that stabilize the molecule and maintain its active 
conformation. Administration of cysteamine (2-aminoethanethiol) has 
been shown to destroy somatostatin (Palkovits, 1982) and prolactin 
(Sagar et al., 1985) immunoreactivity by reducing the disulfide .bonds 
present in these molecules. To determine if RRF contained disulfide 
bonds, cysteamine was administered 3 hours before PCA. The rationale 
behind this experiment was if RRF contained disulfide bonds, cysteamine 
would reduce the disulfide bonds and render RRF inactive and prevent 
the PCA-induced increase in plasma renin activity. 
Male rats were injected with cysteamine (300 mg/kg; Aldrich 
Chemical Co, Inc., Milwaukee, WI) or saline (2.0 ml/kg), subcutaneously 
(s.c.), 4 hours prior to sacrifice. This was followed 3 hours later, 
by injection of PCA (10 mg/kg) or saline at a volume of 2.0 ml/kg i.p. 
The rats were decapitated 1 hour after PCA injection, and trunk blood 
was collected in centrifuge tubes containing 0.5 ml of 0.3 M EDTA 
(pH 7 .4). The plasma was stored at -40°c until PRA and PRC were 
determined. 
3b. Lack of an effect of cysteamine in the renin assay 
The generation of ANG I from angiotensinogen has been found to be 
increased when the sulfhydryl reagents, cysteamine or dithiothreitol, 
were added during the incubation period (Poisner and Hong, 1977; 
Funae, Sasaki and Yamamoto, 1979). To ensure that the values for PRA 
in this experiment were not influenced by treatment with cysteamine, 
control plasma pools were incubated with and without cysteamine to test 
for interference in the assay. 
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Cysteamine was added to plasma samples for a final concentration 
of 3.8 x 10- 3 M. This value was calculated to be the hypothetical 
distribution of cysteamine per body weight (allowing 70% for body 
water) after mixing. High and normal PRA samples ( 1. 0 ml) were 
prepared with 8-HQ and PMSF (25 µl and 20 µl; final concentration 0.86 
mM 8-HQ and 2.3 mM PMSF) and sodium phosphate buffer (0.5 ml of a 0.5 M 
solution, pH 6. 0). In addition, 0.01 ml of cysteamine (0.38 M) was 
added to the samples for incubation for 3 hours at 37°C. The assay for 
generated ANG I was performed as previously described (Method section B 
part 3). 
4. Role of parathyroid hormone (PTH) as the mediator of the PCA-
induced increase in renin release (a possible RRF) 
Parathyroid hormone (PTH) was investigated as a possible renin-
releasing factor. It has been shown that PTH produces increases in 
plasma renin activity (Powell et al., 1978; Smith et al., 1979) and the 
molecular weight of PTH is approximately 9,000 which is similar to the 
molecular weight of RRF. To test the involvement of PTH in PCA-induced 
increase in PRA, parathyroidectomized rats were injected with PCA to 
test if removal of the parathyroid gland prevented the increase in PRA. 
Thyroparathyroidectomized and sham-operated rats were purchased 
from Kurt Johnson Laboratories (Bridgeview, IL). Rats were 
anesthetized with ether and a ventral incision was made on the ventral 
surface of the neck and the muscles were teased apart. The thyroid and 
parathyroid glands were removed and the wound was sutured. The 
thyroparathyroidectomized rats received daily injections of tri-
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iodothyronine (T3; 5 µg/kg s. c., dissolved in 1. 0 M NaOH and saline; 
calbiochem-Behring Corp., La Jolla, CA) after surgery and their water 
was supplemented with 2% calcium lactate and 10% glucose. Rat chow was 
available ad libitum. Sham operated animals underwent the same 
surgical procedure only without removal of the parathyroid and thyroid 
glands. They received daily vehicle injections. Rat chow and tap 
water were available ad libitum. On the fourth day after surgery, the 
rats received either an injection of PCA (10 mg/kg, i.p.) or saline 1 
hour before sacrifice. The rats were decapitated and trunk blood was 
collected into centrifuge tubes containing 0.3 M EDTA (pH 7.4). Plasma 
was stored at -40°C until determination of PRA. 
5. A dose-response study for possible renin-releasing activity of 
neurophysin II (NPII) 
Neurophysin II (NPII ; bovine) , the vasopressin associated 
neurophysin, was tested as a possible renin-releasing factor. Male 
Sprague-Dawley rats received intraperitoneal injections of neurophysin 
II (0.1, 0.5, 2.0, 10.0 or 20.0 µg/kg; Sigma, St. Louis, MO). The 
peptide was dissolved in 0. 9% saline and administered at a volume of 
2.0 ml/kg i.p., 20 minutes before sacrifice. The rats were sacrificed, 
and trunk blood was collected in centrifuge tubes containing 0.5 ml of 
0.3 M EDTA (pH 7.4). The plasma was stored at -40°c until PRA and PRC 
were determined. 
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In vitro characterization of RRF o. 
1. Preparation of PCA-plasma and saline-plasma fractions with 
molecular weights of 1,000-5,000; 5,000-10,000 and 10,000-20,000 
To determine the approximate molecular weight range of RRF, plasma 
from either PCA-treated or saline-treated rats was pooled and filtered 
to obtain plasma fractions of different molecular weights. These 
fractions were tested for renin-releasing activity in the renin release 
bioassay using kidney slices. 
In each of the following experiments, approximately 40 rats were 
nephrectomized under halothane (Burns; Glenview, IL) anesthesia 20 
hours before administration of p-chloroamphetamine (PCA; Regis, Morton 
Grove, IL) or saline. PCA (12 mg/kg, i.p.) and saline were 
administered at a volume of 2.0 ml/kg, 1 hour before decapitation. The 
blood was collected in centrifuge tubes containing 20 units of heparin 
(Upjohn; Kalamazoo, MI) and was centrifuged in a refrigerated 
centrifuge (1, 500 x g) for 30 minutes at 4°c. The plasma was pooled 
into either PCA-plasma (plasma from rats that were injected with PCA) 
or saline-plasma (plasma from rats treated with saline) pools (of 
approximately 150 ml each) depending on which treatment the animal 
received. Ultrafiltration of the plasma was performed in a low 
pressure stirred cell (Nuclepore, Pleasanton,CA) at 4°c. 
For this fractionation procedure, the PCA-plasma and saline-plasma 
pools were placed in a boiling water bath for 20 minutes, and 
centrifuged at 13, 000 x g for 20 minutes. Ultrafiltration of the 
supernatant of the plasma pools was performed at 4°C in a low pressure 
stirred cell first with a low adsorption membrane with a molecular 
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weight cut-off of 20, 000. The filtered fraction containing solutes 
with molecular weights below 20,000 was refiltered through a membrane 
with a molecular weight cutoff of 10,000. The latter fraction was then 
refiltered through a membrane with a molecular weight cutoff of 5,000. 
'l'he remaining fraction containing solutes with molecular weights below 
5,000 was refiltered through a membrane with a molecular weight cutoff 
of 1,000. The material that was retained on the respective membranes 
was resuspended in 3-4 ml saline. Thus, 3 separate fractions were 
obtained, one that contained solutes in the molecular weight range of 
1,000-5,000, one that contained solutes with a molecular weight range 
of 5,000-10,000 and the last fraction that contained solutes with 
molecular weights of 10,000-20,000. All the fractions were stored at 
-40°c. 
The PCA-plasma and saline-plasma fractions (M.W.-1,000-5,000; 
5,000-10,000 and 10,000-20,000) were added to the kidney slices (non-
bubbled method) at a volume of 0.2 ml for the 1 hour incubation period 
to test for renin-releasing activity. 
2. Evaluation of possible renin releasing activity of 5-HT and PCA in 
vitro 
Since PCA, a 5-HT releaser, was used to release RRF, it was also 
possible that the plasma that was tested for renin releasing activity 
contained some residual PCA molecules. In addition, since PCA releases 
5-HT, the 5-HT content in the plasma could also have been increased. 
PCA and 5-HT were added to the kidney slice bioassay to test if these 
drugs could have altered renin release. Fenfluramine (another 5-HT 
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releaser) and saline, were also added to kidney slices to test for 
renin-releasing activity. The drugs PCA (M.W. 206), 5-HT (M.W. 176; 
Sigma, St. Louis, MO) and fenfluramine (M.W. 249; A.H. Robins, 
Richmond, VA) were dissolved in saline for an initial concentration of 
10-4M. A volume of 0.02 ml of each drug was added to the kidney slices 
for the incubation period. The final dilution of the drug in the vials 
was l0- 6M; this corresponded to the calculated distribution of the drug 
in body water. This calculation was performed by estimating the 
concentration of the drug in body water (which was assumed to be 70% 
body weight). This value was then divided by the molecular weight of 
the drug to obtain the concentration of the substance within the 
animal. 
3. Incubation of the PCA-plasma and saline-plasma fractions with 
Pronase 
In order to test whether or not RRF is a peptide, a fraction of 
PCA-plasma and a fraction of saline-plasma (M.W. - 5,000-10,000) were 
incubated with pronase, a mixture of non-specific proteases (Narahashi, 
1970). If RRF were a peptide or a protein, then incubation with 
pronase should destroy its renin-releasing activity. 
Pronase E (a non-specific protease, type XIV, isolated from 
Streptomyces griseus that has an activity of 4 units per mg; Sigma, St. 
Louis, MO) was added to the PCA-plasma fraction that had renin-
releasing activity (the fraction containing solutes with molecular 
weights between 5,000-10,000) and to the equivalent fraction from 
saline-treated rats. Pronase was dissolved in a 0.1 M borate buffer pH 
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7.5 containing 5 mM CaCl2, at a concentration of 20 µg/200 µl and was 
added to a volume of 1.6 ml of PCA-plasma and saline-plasma fractions 
(M.W. 5,000-10,000). The borate buffer vehicle that was used to 
dissolve pronase was added at the same volume (0. 2 ml) to an equal 
aliquot (1.6 ml) of the PCA-plasma and saline-plasma fractions (M.W. -
5,000-10,000). All of the samples were incubated at 37°c for 4 hours. 
After incubation, all aliquots were placed in a boiling water bath for 
20 minutes (to denature the pronase) and centrifuged at 13,000 x g for 
30 minutes. The plasma fractions were added to the kidney slices at a 
volume of 0.2 ml per vial to test for renin-releasing activity. 
E. Studies of RRF in rat brain 
1. Dissection technique 
Rats were sacrificed by decapitation and the brains were removed 
immediately and placed on a cold glass plate kept on ice for 
dissection. The brains were dissected by the procedures outlined by 
Glowinski and Iversen (1966). The pituitary gland was removed from the 
sella turcica with the aid of a spatula. The cerebral cortices were 
gently dissected apart and removed from the rest of the brain. The 
hippocampus, caudate-putamen and amygdala were removed from the 
cortical tissue. The hippocampal formation was easily removed from the 
cortex by blunt dissection with a spatula. The amygdala was cut from 
the cortex at a site rostral to the hippocampus. The corpus callosum 
and lateral ventricle formed the boundaries for the caudate-putamen 
which was carefully dissected with a curved scissors. 
The hypothalamus was delineated rostrally by the optic chiasm and 
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caudally by the mammillary bodies. A transverse cut made at the level 
of the mammillary bodies separated the hypothalamus from the midbrain. 
The anterior commissure (located at the level of the optic chiasm) was 
the horizontal reference for the separation of the thalamus from the 
hypothalamus. 
The midbrain was separated from the pons by a diagonal knife cut 
just caudal to the inferior colliculi. The cerebellum was removed from 
the remaining brain tissue by blunt dissection and severing of the 
cerebellar peduncles. The pons was separated from the medulla by a cut 
caudal to the transverse fibers of the pons. After dissection, the 
brain parts were wrapped in aluminum foil and placed on dry ice. The 
samples were stored at -70°c. 
2. Extraction of the peptide from rat brain 
2a. Comparison of different extraction media from whole brain tissue 
Whole rat brains were cut sagittally and each half was homogenized 
(1 g/10 ml) with either: (1) cold 0.1 N hydrochloric acid, (2) hot 0.1 
N hydrochloric acid, (3) cold 0.1 N hydrochloric acid/absolute ethanol 
mixture (20:80 vol:vol), (4) cold 0.1 N perchloric acid, (5) hot 0.1 N 
perchloric acid or (6) boiling distilled water. The tissue was 
homogenized with a Potter-Elvehjem tissue grinder (Scientific Products, 
McGaw Park, IL), and centrifuged for 30 minutes at 18, 000 x g. The 
supernatant was transferred to polypropylene tubes, lyophilized and 
stored at - 70°c until they were tested for renin-releasing activity. 
The samples were reconstituted in 2.0 ml of Krebs-Ringer buffer and the 
pH of the samples was readjusted to 7. 0- 7. 4 with 1. 0 M NaOH before 
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addition to the kidney slices. The extract (0.20 ml) was added to the 
kidney slices for the 1 hour incubation period. 
2b. Comparison of extraction with cold 0.1 N perchloric acid and 
boiling distilled water from rat hypothalamus 
The extraction media that yielded the best results with whole 
brain tissue were the 0.1 N cold perchloric acid and boiling distilled 
water. Hypothalamic tissue was homogenized with either 0.1 N 
perchloric acid or boiling distilled water to test which medium was 
more effective in extracting RRF from hypothalamic tissue. Rat 
hypothalami (6 hypothalami, approximately 0.11 g) were homogenized in 
either cold 0 .1 N perchloric acid or boiling distilled water in a 1 
g/10 ml ratio with a pyrex glass tissue homogenizer. The homogenates 
were centrifuged for 30 minutes at 18,000 x g. The supernatants were 
transferred to polypropylene tubes, lyophilized and stored at - 70°c 
until they were tested for renin-releasing activity. These samples 
were resuspended in 0.1 ml of Krebs-Ringer buffer, the pH was 
readjusted (pH 7. 0- 7. 4 with 1. 0 M NaOH) and 0. 02 ml was added to the 
kidney slices during the incubation period. 
3. Preparation of hypothalamic, cerebellar and pituitary extracts 
Hypothalamic tissue was dissected from 10 rat brains immediately 
after decapitation and stored at -70°c. The brain was placed, dorsal 
surface down, and the hypothalamus was excised from the ventral surface 
with fine curved scissors. The rostral border was the decussation of 
the optic tracts and the decussation of the anterior commissure. The 
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caudal border was the mammillary bodies. The pituitary was removed 
from the sella turcica and the cerebellum was removed from the 
brainstem. A volume of 10 ml/g of boiling water was added to the 
hypothalamic (0.97 g), cerebellar (0.85 g) or pituitary (0.74 g) 
~issue. The tissue was homogenized with a glass tissue grinder, placed 
in a boiling water bath for 20 minutes and centrifuged at 13,000 x g 
for 30 minutes. An aliquot of 4. 5 ml of the supernatant from each 
tissue was lyophilized to dryness and resuspended in 0.2 ml of saline. 
A volume of 0.02 ml was added to the kidney slices to test for renin-
releasing activity. 
4. Dose response of hypothalamic tissue extracts 
Rat hypothalamic tissue (5.8 g, approximately 280 hypothalami) was 
homogenized in boiling distilled water (1 g/ml) with a pyrex tissue 
grinder. The homogenate was placed in a boiling water bath for 20 
minutes and centrifuged at 13,000 x g for 30 minutes. The supernatant 
was collected, 0.4 ml of the extract was saved for serial dilutions and 
1.6 ml of the supernatant was lyophilized (Savant Speed-Vac). The 
straight, non-lyophilized, hypothalamic extract was serially diluted 
with saline (1: 15, 1: 10, 1: 5, 1: 2 and 1: 1) to obtain the equivalent 
volume of the content of 0.07, 0.1, 0.2, 0.5 and 1 hypothalamus when 
added (0. 2 ml) to the kidney slices, respectively. The lyophilized 
pellet was resuspended in 0.4 ml of 0.9% saline and diluted (1:2 and 
1:1) to yield extracts that were equivalent to the content of 2 and 4 
hypothalami. Aliquots (0. 02 ml) of the hypothalamic extracts were 
added to the kidney slices for the 1 hour incubation. 
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5. Distribution of RRF in rat brain 
Rat brains were dissected as described in section E part 1. The 
brain areas that were analyzed for renin-releasing activity were the 
pituitary gland, pons, thalamus, caudate-putamen, hippocampus, 
midbrain, amygdala, hypothalamus, cerebral cortex, medulla oblongata 
and cerebellum. The brain tissues were homogenized in boiling 
distilled water (1 g/ml) with a glass tissue grinder. Afterwards, the 
homogenates were placed in a boiling water bath for 20 minutes and then 
centrifuged at 13,000 x g for 30 minutes. The extracts were added to 
the kidney slices at a volume of 0. 02 ml for the incubation period. 
This volume corresponded to the equivalent of 1 hypothalamus using the 
1 g/ml dilution. Standardizing the dilution and volume of the 
different extracts allowed direct comparison of the renin-releasing 
activity of the different brain areas. 
6. Distribution of RRF in colchicine-treated rat brains 
In order to identify the cell bodies of origin of RRF, rats were 
treated with colchicine, a drug that inhibits axonal transport of 
materials from the cell body, to prevent the movement of RRF from the 
cell body. The results from the renin release bioassay of the 
colchicine-treated brain parts would indicate where the cell bodies 
that contain RRF were located. After colchicine treatment, the areas 
that have high renin-releasing activity would indicate RRF contained in 
cell bodies. 
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6a. Animals 
Rats were prepared for stereotaxic surgery by anesthetizing them 
with pentobarbital (50 mg/kg i.p.; Butler Co., Columbus, OH) and 
pretreating them with methyl atropine bromide (0.4 mg/kg i.m.; Regis 
Chemical Co. , Morton Grove, IL) which minimized respiratory tract 
secretions. After surgery, the rats received an injection of 
ampicillin (50 mg/kg, i.m.; Sigma, St. Louis) to prevent infection. 
care was taken to avoid undue discomfort to the animals. 
6b. Intracerebroventricular injections of colchicine 
The rats were secured in a Kopf stereotaxic apparatus with the 
incisor bar 5. 0 mm below the intra-aural line. The injection needle 
was placed bilaterally, 1.4 mm lateral to the midsagittal suture, 0.5 
mm caudal from bregma and 4. 5 mm ventral from the skull surface. 
Colchicine (Sigma, St. Louis) was administered bilaterally (150 µg/20 
µl saline; 10 µl into each side over a 10 minute period) into the 
lateral cerebral ventricles. The needle was left in place for 5 
minutes to prevent dorsal diffusion of the drug. 
The rats were decapitated 48 hours after injection of colchicine 
and the brains were dissected as indicated in section E part 1. The 
brain parts were homogenized in boiling distilled water and 
centrifuged. The supernatant (0.02 ml) was added to the kidney slices 
to test for renin-releasing activity. 
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6c. Verification that colchicine does not interfere in the renin 
release bioassay 
In a test that preceded the determination of RRF in the brains of 
colchicine-treated rats, colchicine was added to the kidney slices to 
test whether colchicine would alter renin release. Saline or 
colchicine was added to three test substances saline, isoproterenol 
(10-SM) or cerebellar extract, (homogenized as 1 mg/ml in boiling 
distilled water) . The concentration of colchicine was calculated as 
the approximate dilution of colchicine in the treated rat brains (150 
µg colchicine into one brain (1. 80 g) homogenized in 1. 8 ml boiling 
distilled water, which corresponded to 0.083 mg colchicine/ml of 
sample]. This calculation did not take into account any diffusion of 
colchicine from the brain. The samples were added to the kidney slices 
at a volume of 0.02 ml for the incubation period. 
F. Distribution of RRF in peripheral tissues 
After decapitation, the adrenal gland, spleen, liver, kidney and 
skeletal muscle (from the abdomen) were dissected from normal rats. 
The tissues were homogenized (1 g/ml) with boiling distilled water in 
glass tissue homogenizers. The homogenates were placed in a boiling 
water bath for 20 minutes and centrifuged at 13,000 x g for 30 minutes. 
The supernatant of each extract (0. 02 ml) was added to the kidney 
slices for the incubation period. 
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G. Effect of nephrectomy on the hypothalamic content of RRF 
Rats were bilaterally nephrectomized as previously described in 
the Method section B part 3a. Another group of control or sham-
operated rats were treated identically except that their kidneys were 
.not removed. Twenty-four hours after surgery the rats were 
decapitated. The brains were quickly removed and the hypothalami were 
dissected and stored at - 70°C. On the day of the kidney slice 
bioassay, the hypothalami were individually homogenized 1 g/ml in 
boiling distilled water, placed in a boiling water bath and centrifuged 
(13, 000 x g) for 20 minutes. Each hypothalamic extract (20 µl) was 
tested individually in the RRF bioassay. 
H. Stimulation of RRF from hypothalamic neurons 
Superfusion of hypothalamic explants was performed to determine 
whether neurons in the hypothalamus could release RRF in response to 
depolarization. The method used for the superfusion of rat 
hypothalamus was adapted from that used by Gallardo and Ramirez (1977). 
1. Preparation of hypothalamic explants 
Rats (175-200 g) were decapitated and the hypothalami were quickly 
dissected and placed in a petri dish containing cold Krebs-Ringer 
buffer that was bubbled with 95% 02-5% C02. The Krebs-Ringer 
superfusion buffer used for this study had a composition of 117 mM 
NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 1.2 mM MgS04, 1.2 mM KH2P04, 11.5 mM 
glucose and 25 mM NaHC03 (final pH 7 .4). The rostral and caudal 
boundaries for the hypothalamus were the optic chiasm and the 
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mammillary bodies, respectively. The anterior commissure was used to 
define the dorsal limit of the hypothalamus. 
In some cases rat hypothalamo-hypophyseal explants were used, in 
others, the hypothalamic explants were used without the hypophysis. 
The brain was removed from the caudal approach and the pituitary was 
carefully removed away from the sella while still attached to the 
hypothalamus. The hypothalamus was then dissected from the rest of the 
brain and the hypothalamo-hypophyseal explant was placed in cold 
oxygenated Krebs-Ringer. A total of four explants were placed in each 
superfusion chamber. 
2. Superfusion of rat hypothalamic explants 
The superfusion chambers (0. 5 ml) were constructed from 3. 0 ml 
plastic disposable syringes that were cut in half. The hypothalamic 
tissue was placed at the bottom of the chamber and rested on a few 
strands of glass wool. Superfusion buffer entered the chamber from the 
bottom through a hypodermic needle (18 gauge) that was attached to the 
syringe (superfusion chamber; refer to Figure 2). The needle was 
inserted into rubber stoppers on a Plexiglas stand and the apparatus 
(stand with superfusion chambers) was placed in a water bath maintained 
at 37°C. The buffer was continuously delivered into the chamber by a 
Gilson peristaltic pump (Gilson Medical Electronics, Inc., Middleton, 
WI) at a flow rate of 0.08 ml/minute. A PE90 tubing (Becton Dickinson 
and Co., Parsippany, N.J.) led the buffer through a silastic manifold 
tubing (0. 065 inch I. D.) and another length of PE90 tubing connected 
the silastic tubing to the needle on the chamber. The Krebs-Ringer 
Inlet for 
Oz/COz 
Figure 2. Illustration of superfusion chamber. 
Sample 
outflow 
Plexiglas 
stand 
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buffer entered the chamber from the bottom and filled the chamber as it 
filtered up through the tissue. The chamber was closed with a rubber 
stopper containing two 20 gauge needles; one was fitted with PE90 
tubing that allowed the inflow of the 95% 02 - 5% C02 mixture and the 
other needle was fitted with tubing (PE90) that served as the outlet 
for the liquid (sample) and oxygen. As the gas entered the chamber, 
it formed bubbles that expelled the liquid sample through the tubing. 
This also kept the volume of the chamber constant at 0.5 ml. 
After a 30 minute equilibration period, samples were collected over 
a 30 minute control period into polypropylene tubes that were 
maintained on ice. To test for the potassium stimulated release of RRF 
from the hypothalamus, the Krebs-Ringer buffer was replaced with a high 
potassium Krebs-Ringer buffer containing 60 mM KCl. The composition of 
the high potassium Krebs-Ringer buffer was 61. 7 mM NaCl, 60 mM KCl, 
1.25 mM CaCl2, 1.2 mM MgS04, 1.2 mM KH2P04, 11.5 mM glucose and 25.0 mM 
NaHC03 (final pH 7 . 4) . The sodium concentration of the buffer was 
reduced to maintain the proper osmolarity. Samples were collected for 
30 minutes into polypropylene tubes that were kept on ice. For both 
the control and experimental (high potassium) periods, the pH of the 
buffer was monitored to confirm that the pH did not fluctuate over 
time. 
3. Preparation of superfusate samples 
After the samples were collected (approximately 3 ml), they were 
filtered and concentrated by ultrafiltration on a micropartition system 
(MPS I, Amicon, Danvers, MA) through a membrane that had a molecular 
weight cutoff of 500. 
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The samples that were collected with the high 
potassium buffer were further washed with 0. 9% saline to remove the 
excess potassium ions. The final volume for all the samples after 
concentration on the filter was 0.3 ml. This corresponded to 
approximately a 10 fold increase in concentration. A volume of 0.2 ml 
was added to the kidney slices to test for the renin-releasing activity 
of the hypothalamic superfusates. 
I. Statistical analysis of the data 
1. Representation of the data 
The data were represented as mean ± S.E.M. (standard error of the 
mean). The sample mean was the average of the numbers in the 
experimental group (n). The standard error of the mean (S.E.M.) was 
reported along with the mean to establish a confidence interval for the 
population mean. The S.E.M. was calculated from a formula relating the 
standard deviation and the number of samples in the test group (n). 
2. Statistical tests 
2a. Student's t-test 
The Student's t-test was used to compare two means either from the 
same sample population (paired t-test) or from different sample 
populations (unpaired t-test). As a rule for the analysis of these 
data, the significance levels used for the t-test and other tests 
(ANOVA and Duncan's new multiple range test) were 5% and 1%. The 
t-tests used were all two-tailed. Two-tailed t-tests are indicated 
when looking for a difference between the means (mean1 not equal to 
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mean2) rather than testing the probability that one mean is greater 
than the other (one-tailed t-test). 
2b. Analysis of variance 
The analysis of variance (ANOVA) was designed to compare several 
groups (means) after a treatment or to compare the same group using 
different treatments. The one way ANOVA was used to compare the effect 
of different treatments between relatively homogenous, random groups. 
The F value is calculated and defined as the ratio of two independent 
estimates of the variance (Steel and Torrie, 1960). The F value is 
compared to values in a table for the level of significance. A 
significant F value indicates that there is less than 5% or 1% that two 
or more means are not different between the treatment groups. However, 
the ANOVA does not show which means are significantly different from 
one another. 
The two way ANOVA is used when there are two or more ways of 
grouping the data (Steel and Torrie, 1960). The individuals in the 
experiment are grouped into blocks according to characteristics. For 
example, animals that are subject to surgery before receiving a drug 
treatment would comprise one block. The units within the block should 
be treated identically, minimizing any variations in techniques or 
conditions. This assures that the differences observed will be due to 
the effects of treatment. For a two way ANOVA, three F values are 
obtained: one indicates if there is a treatment effect; another 
indicates a difference between the blocks and the third indicates if 
there is an interaction between the treatment and block effects. 
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zc. Duncan's new multiple range test 
The Duncan's new multiple range test was applied in addition to 
the ANOVA to determine which means are statistically different (Duncan, 
1955). Generally, tests of comparison should be performed only when 
the F values are significant, however, a Duncan's multiple range test 
can be performed without a significant F value. The Duncan's also has 
a protection level within the computation of statistic that is 
determined by the degrees of freedom. The protection guards against 
the possibility of finding a false positive (Type I error; rejecting 
the Null hypothesis when it is true). Other multiple range or 
comparison tests have a protection level that is the same for all 
sample sizes. The data necessary to perform a multiple range test are 
the mean squared error obtained from the ANOVA, the number of samples 
in the group (n) and a value that is obtained from a table of 
significant ranges. The value obtained from the table is dependent on 
the degrees of freedom, the level of significance and the number of 
means being tested. The desired range is then multiplied by the 
standard error of the mean (obtained by taking the square root of the 
mean squared error divided by the number of samples) to make a shortest 
range of significance. If the distance between two means is greater 
than the shortest range of significance then the difference between the 
means is significant. 
CHAPTER IV 
RESULTS 
A. Development of a renin release bioassay 
Table 1 compares the values for renin release after a 30 minute 
incubation between the bubbled and unbubbled kidney slice methods. 
The unbubbled method yields renin values that were higher and more 
consistent (5.0 ± 0.6 to 7.5 ± 0.5 ng ANG I/mg kidney/hr) than those 
obtained with the bubbled method (0. 23 ± 0. 04 to 1. 90 ± 0. 30 ng ANG 
I/mg kidney/hr). 
The values for pH, kidney slices weight and renin release in one 
experiment are presented in Table 2. All these values were measured 
after a 30 minute incubation period. The kidney slice weights were 
within a small range of distribution with a mean of 18.3 ± 0.5 mg. The 
pH values of the incubation medium of the 24 vials ranged from 7.4 to 
7. 5 with a mean of 7. 45 ± 0. 01. Both the values for pH and kidney 
slice weight were within a close range indicating that the method of 
oxygenation and method of slicing the kidneys (vibratome) were 
reliable. The values for renin release from the slices ranged from 3.4 
to 11.1 ng ANG I/mg kidney tissue/hr with a mean value of 5.9 ± 0.37 ng 
ANG I/mg kidney/hr. This is a much smaller range than that observed 
with the bubbled kidney slice method. The small range of distribution 
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TABLE 1 Comparison of interexperimental variation of renin release (ng 
ANG I/mg kidney/hr) from kidney slices between the bubbled and improved 
unbubbled in vitro methods. 
Experiment Bubbled Method Experiment Unbubbled Method 
1 1. 90 ± 0. 30 (24) 5 7.2 ± 0.6 (24) 
2 1. 80 ± 0 .15 (24) 6 5.0 ± 0.6 (24) 
3 0.23 ± 0.04 (24) 7 7.5 ± 0.5 (24) 
4 0.53 ± 0.07 (24)* 8 6.4 ± 0.4 (24) 
9 6.7 ± 0.4 (24) 
10 5.9 ± 0.4 (24) 
11 7.1 ± 0.4 (36) 
* This value for renin release (experiment 4) was obtained from 
kidney slices that were cut on a vibratome, but were incubated in 
Krebs-Ringer that was bubbled with the 95% 02-5% C02 gas. The kidney 
slices used in experiments 1,2 and 3 were cut using a hand-held razor. 
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TABLE 2 lntraexperimental variability for renin release from kidney 
slices during incubation with Krebs-Ringer Bicarbonate solution for 30 
minutes. 
Weight of the slices Renin release 
Vial !!!! .L!W.. (ng ANG I/mg kidney/hr) 
1 7.4 17.9 4.9 
2 7.5 19.0 6.7 
3 7.6 16.0 6.2 
4 7.4 16.3 3.6 
5 7.4 20.1 5.0 
6 7.6 18.l 3.3 
7 7.5 19.8 3.4 
8 7.4 15.6 4.4 
9 7.5 19.6 6.5 
10 7.4 14.2 8.7 
11 7.5 17.2 5.1 
12 7.4 19.7 5.7 
13 7.4 17.2 5.2 
14 7.5 16.9 5.7 
15 7.5 16.6 7.0 
16 7.5 17.3 6.0 
17 7.5 22.0 6.1 
18 7.4 22.8 5.8 
19 7.5 22.0 6.6 
20 7.5 18.5 8.4 
21 7.4 15.3 3.4 
22 7.4 20.2 7.6 
23 7.4 14.1 11.1 
24 7.5 22.8 6.2 
Mean ± S.E.M 7.45 ± 0.01 18.3 ± 0.5 5.9 ± 0.4 
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of renin release, both intraexperimentally and interexperimentally, is 
is an indicator of the reliability of the new kidney slice method. 
Addition of isoproterenol produced a significant increase 
(Student's unpaired t-test, two-tailed, t=2.460, df-14, p < 0.05) in 
renin release from the kidney slices (Table 3). As can be seen in the 
following experiments, the values for renin release in the slices that 
received either saline or isoproterenol are reproducible between 
experiments. 
B. Check for specificity in the bioassay for RRF 
1. Test for non-specific activation of renin by plasma fractions 
(Table 4) 
This control experiment was performed to verify that the effect of 
the PCA-plasma fraction (M.W. 5,000-10,000) was not due to non-
specific activation of inactive renin that could have been released by 
the kidney slices. Kidney slices were removed from the Krebs-Ringer 
medium after a 1 hour incubation, and the Krebs-Ringer solutions were 
pooled and then divided into 2. 0 ml aliquots. Saline, saline-plasma 
(M.W. 5,000-10,000) or PCA-plasma (M.W. 5,000-10,000) samples were 
added to the Krebs-Ringer aliquots for a 1 hour incubation at 37°C. 
The concentration of renin was measured as the ability to generate ANG 
I from a saturating concentration of renin substrate. As can be seen 
from Table 4, there was no activation of renin by the plasma fractions. 
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TABLE 3 Effect of saline or isoproterenol (10- 7M) on renin release 
from kidney slices using the unbubbled method. 
Renin release 
(ng ANG I/mg kidney/hr) 
Saline (n-10) 10.6 ± 0.9 
Isoproterenol lo-7M (n-6) 19.7 ± 3.4* 
Data represent mean± S.E.M. 
* Significant difference from the saline group, p < 0. 05 (Student's 
unpaired t-test, two tailed: t=2.460, df=l4). 
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TABLE 4 Test for non-selective activation of renin in the incubation 
medium (Krebs-Ringer) by the fractions (M.W. 5,000-10,000) of plasma 
from saline-treated or PCA-treated rats. 
Renin activity 
Fraction added (ng ANG I/ml/hr) 
PCA-plasma fraction 
(M.W. 5,000-10,000) 231.2 ± 19.0 
Saline-plasma fraction 
(M.W. 5,000-10,000) 276.0 ± 8.8 
Saline 238.6 ± 22.8 
Each data point represent mean± S.E.M. of 6 determinations. 
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z. Test for non-specific generation of angiotensin I from renin 
substrate by plasma and brain fractions (Table 5) 
Another control experiment was performed to verify that the 
saline-plasma and PCA-plasma fractions (M.W. 5,000-10,000) and the 
different brain extracts did not have renin-like activity that would 
have resulted in the non-specific generation of ANG I. Rat 
hypothalamic, cerebellar, and pituitary extracts and the PCA-plasma and 
saline-plasma fractions (M.W. 5,000-10,000) were added to the Krebs-
Ringer buffer and incubated with renin substrate for 1 hour. As can be 
seen in Table 5, the values for the amount of generated ANG I were 
below the sensitivity limit of the assay indicating that the effect of 
the test substances on renin release from the kidney slices was not due 
to non-specific generation of ANG I in the bioassay. The normal rat 
plasma was tested at the same concentration as the other substances and 
produced detectable amounts of ANG I. 
C. In vivo studies of the renin-releasing factor 
1. The effect of the serotonin releaser, PCA and serotonin agonists 
(MK-212 and TFMPP) on PRA, PRC and plasma RRF concentration (Table 6) 
The 5-HT releaser PCA (10 mg/kg, i.p.) and two 5-HT agonists, MK-
212 (10 mg/kg, i.p.) and TFMPP (10 mg/kg, i.p.) were administered to 
rats to test if stimulation of serotonin receptors would increase PRA, 
PRC and the concentration of RRF in the blood. PCA, TFMPP and MK-212 
all significantly increased plasma renin ac ti vi ty [ANOVA: 
F(3,36)-22.741, p < 0.001; Duncan's multiple range test: shortest 
range of significance between means - 9.6, p < 0.01] and plasma renin 
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TABLE 5 Test for non-specific generation of angiotensin I from 
angiotensinogen (renin substrate) by hypothalamic, cerebellar, 
pituitary and plasma extracts and fractions. 
Substance added 
Rat hypothalamic extract 
Rat cerebellar extract 
Rat pituitary extract 
PCA-plasma fraction 
(M.W. 5,000-10,000) 
Saline-plasma fraction 
(M.W. 5,000-10,000) 
Unfractionated normal rat plasma 
ng ANG I generated/ml/hr 
N.D. 
N.D. 
N.D. 
N.D. 
N.D. 
3.75 ± 0.15 
Each point represents mean ± S. E .M. of 6 determinations. The 
extracts and fractions were incubated with renin substrate (20 µl/2.0 
ml) without renin in the medium to test if these extracts possessed 
renin-like activity. 
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TABLE 6 The effect of saline or PCA, MK-212 or TFMPP (10 mg/kg i.p.) 
on plasma renin activity (PRA), plasma renin concentration (PRC) and 
plasma concentration of renin-releasing factor (RRF) in conscious rats. 
PRA PRC RRF 
(ng ANG ILmlL3hr) (ng ANG ILml/hr) (ng ANG ILmg kidne:;x::/hr) 
Treatment 
saline 3.5 ± 0.4 5.1 ± 0.5 12.0 ± 0.8 
(n=l2) 
PCA 20.1 ± 2.2** 23.5 ± 3.4** 18.9 ± 1. 5* 
(n=ll) 
MK-212 40.7 ± 3.8**t 56.3 ± ll.7**t 19.3 ± 3.0* (n=ll) 
TFMPP 17.2 ± 2.5** 21.4 ± 3.4** 18.8 ± 2.8* (n=6) 
Data represent mean ± S.E.M. The number of rats (n) in each group is 
represented in parentheses. 
One way ANOVA for: PRA; F (3,36)-22.741, p < 0.001. 
PRC; F (3.36)-12.394, p < 0.001. 
RRF; F (3,36)- 3.147, p < 0.05. 
Duncan's new multiple range test: 
* Significant difference from saline group, p < 0.05. 
** Significant difference from saline group, p < 0.01. 
t Significant difference from all other groups, p < 0.01. 
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concentration [ANOVA: F(3,36)=12.394, p < 0.001; Duncan's multiple 
range test: shortest range of significance between means = 13.5, p < 
0.05; = 18.0, p < 0.01] when compared with the saline control group. 
The PRA and PRC values in the group that received MK-212 were 
significantly elevated over the other treatments (PCA and TFMPP) groups 
(Duncan's multiple range test: p < 0.01). The plasma concentration of 
RRF was significantly increased in the rats that received either PCA, 
MK-212 or TFMPP [ANOVA: F(3,36)=3.147, p < 0.05; Duncan's multiple 
range test: shortest range of significance between means - 6. 4, p < 
0.05]. There were no significant differences between any of the drug-
treated groups for RRF activity. These results indicate that 
stimulation of 5-HT receptors can increase PRA, PRC and the plasma 
concentration of RRF. 
2. Effect of stress on PRA and plasma RRF concentration (Table 7) 
It has been shown that rats that were stressed using a conditioned 
emotional response (CER) or fear paradigm had significantly elevated 
levels of PRA (Van de Kar et al, 1985; Richardson-Morton et al, 1987). 
Therefore, the plasma from stressed rats was tested in the kidney 
slices bioassay to determine whether stress could be a physiological 
stimulus that would increase the plasma concentration of RRF. Table 7 
shows the effect of stress on plasma renin activity (PRA) and on the 
plasma concentration of RRF. Rats that were subjected to the CER 
paradigm had significant increases in PRA (Student's t-test, two-
tailed; t-3.380, df=l9, p < 0.01) and also in the plasma concentration 
of RRF (Student's unpaired t-test, two-tailed; t-2.711, df-19, p < 
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TABLE 7 The effect of stress (conditioned emotional response or fear 
paradigm) on plasma renin activity (PRA) and the plasma concentration 
of renin-releasing factor (RRF). 
PRA RRF 
(ng ANG I/ml/3 hr) (ng ANG I/mg kidney/hr) 
control (n=9) 4.5 ± 0.8 12. 7 ± 1.1 
stress (n=12) 29.l ± 6.2** 16.0 ± 0.7* 
Data represent mean± S.E.M. 
** Significant difference from corresponding saline control group, 
p < 0.01, (Student unpaired t-test, two-tailed; t-3.380, df-19). 
* Significant difference from corresponding saline control, 
p < 0.02 (Student unpaired t-test, two-tailed; t-2.711, df-19). 
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0.02). These results indicate that stress can act as a physiological 
stimulus to induce the release of RRF into the blood. 
3. Presence of disulfide bonds in RRF: Study with cysteamine and PCA 
(Table Ba and Bb) 
Since RRF was characterized as a heat stable peptide, it is 
possible that this peptide contains disulfide bonds that stabilize the 
molecule and maintain the conformation for its renin-releasing 
activity. Therefore, destruction of these disulfide bonds with 
cysteamine, a drug that reduces disulfide bonds, might change the 
conformational change of RRF and destroy its renin-releasing activity. 
To test this hypothesis, rats were pretreated with cysteamine (300 
mg/kg, s.c.) before administration of PCA (10 mg/kg, i.p.). Tables Ba 
and Bb show the effect of cysteamine and PCA and cysteamine on plasma 
renin activity (PRA) and plasma renin concentration (PRC), 
respectively. Cysteamine did not increase in resting PRA values [Two 
way ANOVA: F(l,20)-3.345, p > 0.05]. Administration of PCA 
significantly increased PRA [Two way ANOVA: F(l,20)-17.016, p < 0.001; 
Duncan's multiple range test: shortest range of significance between 
means= 6.9, p < 0.05]. The two way ANOVA indicates that there was no 
interaction between cysteamine and PCA [Two way ANOVA: F(l,20)-0.0371, 
p > 0.1]. The cysteamine-PCA group was not different from the saline-
PCA group. PCA did not produce an increase in PRA after cysteamine 
when compared with its cysteamine-saline control group. 
The effects of cysteamine and PCA on plasma renin concentration 
(PRC) were very similar to the data obtained for PRA. Cysteamine 
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TABLE Ba Effect of pretreatment with cysteamine (300 mg/kg s. c.) on 
the p-chloroamphetamine (PCA; 10 mg/kg i.p.)-induced increase in plasma 
renin activity (PRA) 
Plasma renin activity (ng ANG I/ml/3 hr) 
saline cysteamine 
saline 6.0 ± 1.1 11.8 ± 2.6 
PCA 13. 5 ± 1. 8* 16.9 ± 3.0 
Data represent mean± S.E.M. n-8. 
Two way ANOVA: Factor A (cysteamine): F(l,20)-3.345, p > 0.05, N.S. 
Factor B (PCA): F(l,20)= 17.016, p < 0.001. 
Factor Ax B: F(l,20)= 0.0371, p > 0.10, N.S. 
Duncan's new multiple range test: 
Significant difference from saline-saline control group, 
* p < 0.05, shortest range of significance between means - 6.9. 
TABLE Sb Effect of pretreatment with cysteamine (300 mg/kg s.c.) on 
the p-chloroamphetamine (PCA) - induced increase in plasma renin 
concentration (PRC) 
saline 
PCA 
Plasma renin concentration 
(ng ANG I/ml/hr) 
saline cysteamine 
7.3±1.2 14.6 ± 4.5 
22.7 ± 3.8** 21.5 ± 3.5 
Data represent mean± S.E.M. n=8. 
Two way ANOVA: Factor A (cysteamine): F(l,20)= 0.585, p > 0.100, N.S. 
Factor B (PCA): F(l,20)= 19.811, p < 0.001. 
Factor Ax B: F(l,20)= 1.325, p > 0.100, N.S. 
Duncan's new multiple range test: 
Significant difference from saline-saline control group, 
** p < 0.01, shortest range of significance between means 11.9. 
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treatment did not increase PRC when compared with the saline-saline 
control [Two way ANOVA: F(l,20)-0.585, p > 0.100]. PCA produced a 
significant increase in PRC [Two way ANOVA: F(l,20)-19.811, p < 0.001]. 
Treatment with cysteamine did not block the effect of PCA [Two way 
ANOVA: F(l,20)-1.325, p > 0.100]. For both PRA and PRC, the values for 
the cysteamine-saline and cysteamine-PCA groups were not statistically 
different from each other. However, PCA did not produced a significant 
increase in the cysteamine-PCA group when compared with its 
corresponding control. There is no difference between the saline-PCA 
and cysteamine-PCA groups. 
The generation of ANG I from angiotensinogen was reported to be 
increased when disulfide reducing agents, such as cysteamine, were 
added to the incubation media (Poisner and Hong, 1977). To test for 
the possible interaction of cysteamine in the renin assay, control 
plasma pools were incubated with cysteamine, at a dose that was 
calculated as the theoretical distribution within body water. 
Cysteamine did not modify the amount of ANG I generated in either the 
normal [Student's t-test (unpaired), two-tailed: t-0.7612, df-10, p > 
0.05] or high [Student's t-test (unpaired), two-tailed: t=0.4155, 
df-10, p > 0.50] plasma renin activity pools (Table 9). 
These results indicate that cysteamine was not capable of 
preventing the PCA- induced increase in renin secretion. Furthermore, 
the concentration of cysteamine used in this experiment did not 
influence the generation of ANG I from the renin substrate and thus did 
not bias the results. 
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TABLE 9 Lack of cysteamine interference in the plasma renin activity 
assay. 
Plasma renin activity 
(ng ANG I/ml/3 hr) 
saline cysteamine 
normal 
plasma renin activity 9.3 ± 0.9 
high 
plasma renin activity 23.7 ± 1.6 
Data represent mean± S.E.M. n-5 in each group. 
Student's unpaired t-test (two-tailed): 
10.2 
23.0 
for normal PRA: t-0.7612, df-10, p > 0.50, N.S. 
for high PRA: t=0.4155, df=lO, p > 0.50, N.S. 
± 0.8 
± 0.7 
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4. Test for parathyroid hormone (PTH) as the mediator of the PCA-
induced increase in renin release (Table 10) 
Several laboratories have demonstrated that parathyroid hormone 
(PTH) increases PRA (Powell et al., 1978; Smith et al., 1979). 
Therefore, PTH was tested as a possible renin-releasing factor. PCA 
was administered to thyroparathyroidectomized rats to test if removal 
of the parathyroid gland would prevent the PCA- induced increase in 
plasma renin activity. 
Basal levels of plasma renin activity were unaffected by 
parathyroidectomy [Two way ANOVA: F(l,28)-2.154, p > 0.100]. 
Administration of PCA produced a significant increase in plasma renin 
activity in the sham-operated rats [Two way ANOVA: F(l,28)-22.774, p < 
0.001; Duncan's multiple range test: shortest range of significance 
between means - 33.2, p < 0.05]. Parathyroidectomy did not prevent the 
PCA-induced increase in plasma renin activity [Two way ANOVA: 
F(l,28)-1.736, p > 0.100; Duncan's multiple range test: shortest range 
of significance between means = 44. 9, p < 0. 01] . The sham- PCA and 
parathyroidectomy-PCA groups were not significantly different from each 
other. These results suggest that the parathyroid hormone is not the 
RRF. 
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TABLE 10 Effect of p-chloroamphetamine (PCA; 10 mg/kg i.p.) on plasma 
renin activity in sham and thyroparathyroidectomized rats. 
Plasma renin activity (ng ANG I/ml/3 hr) 
saline PCA 
Sham-operated 15.2 ± 2.6 52.3 ± 9.5* 
Parathyroidectomized 16. 8 ± 1. 7 82.2 ± 19.0** 
Data represent mean± S.E.M. n = 8. 
Two way ANOVA: 
Factor A (PCA): F(l,28)=22.774, p < 0.001. 
Factor B (parathyroidectomy): F(l,28)=2.154, p > 0.1, N.S. 
Factor Ax B: F(l,28)-1.736, p > 0.1, N.S. 
Duncan's new multiple range test: 
Significant difference from corresponding saline group, 
* p < 0.05, shortest range of significance between means 
** p < 0.01, shortest range of significance between means 
33.2. 
44.9. 
5, Test for possible renin-releasing activity of neurophysin II 
(Table 11) 
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Lesions in the paraventricular nucleus (PVN) prevent both the PCA-
induced (Gotoh et al., 1987) and the stress-induced increases 
(Richardson Morton et al., 1986; Gotoh il al., 1987) in plasma renin 
activity. Neurophysin II (NPII), is synthesized in the PVN, released 
from the neural lobe, and has a molecular weight of approximately 
10,000. There is no known physiological action for the neurophysins 
and therefore, NPII was tested as a possible renin-releasing factor. 
Intraperitoneal injection of increasing doses of neurophysin II did not 
alter PRA [One way ANOVA: F(5,39)=0.2291, p > 0.100] or PRC [One way 
ANOVA: F(5,39)-0.4959, p > 0.100] levels indicating that neurophysin II 
does not have any renin-releasing activity and is probably not the RRF. 
D. Summary of data using unbubbled kidney slice method 
1. Effect of saline-plasma or PCA-plasma fractions (M.W. 1,000-5,000; 
5, 000-10, 000 and 10, 000-20, 000) on renin release from kidney slices 
(Table 12) 
Table 12 shows the effect of the PCA-plasma and saline-plasma 
fractions (M.W. 1,000-5,000; 5,000-10,000 and 10,000-20,000) on renin 
release from the kidney slices. All of the fractions exhibited some 
renin-releasing activity. The PCA-plasma fraction containing 
substances with molecular weights 5,000-10,000 produced a three-fold 
increase in renin release when compared with any of the other plasma 
fractions; this increase was significant [ANOVA: F(6,55)-10.48, p < 
0.001; Duncan's multiple range test: shortest range of significance 
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TABLE 11 Failure of increasing doses of neurophysin II (bovine) to 
alter plasma renin activity (PRA) and plasma renin concentration (PRC) 
in conscious rats. 
Dose of Neurophysin II PRA PRC 
(ug/kg. i.p.) (ng ANG I/ml/3 hr) (ng ANG I/ml/hr) 
saline 7.9 ± 0.9 10.2 ± 0.6 
0.1 9.0 ± 1.0 11.9 ± 1.6 
0.5 9.1 ± 1.1 11.0 ± 1.2 
2.0 9.1 ± 1.0 12.4 ± 1.2 
10.0 8.9 ± 0.7 11.0 ± 1.0 
20.0 8.2 ± 1.2 10.2 ± 1.6 
Data represent mean± S.E.M. n-8 per group. 
One way ANOVA: PRA; F(5,39)- 0.229, p > 0.1, N.S. 
PRC; F(5,39)- 0.495, p > 0.1, N.S. 
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TABLE 12 The effect of saline or plasma fractions from saline-treated 
or PCA-treated (10 mg/kg i.p) nephrectomized rats on renin release from 
kidney slices. 
PCA-plasma fractions 
M.W. 1,000-5,000 (10) 
M.W. - 5,000-10,000 (17) 
M.W. = 10,000-20,000 (6) 
Saline-plasma fractions 
M.W. = 1,000-5,000 (5) 
M.W. = 5,000-10,000 (10) 
M.W. 10,000-20,000 (5) 
Saline (9) 
Renin Release 
(ng ANG I/mg kidney/hr) 
12. 0 ± 1. 8 
32.0 ± 4.1* 
12. 3 ± 1. 6 
11.3 ± 1.5 
9.5 ± 1.3 
10.9 ± 1. 9 
6.2 ± 1.0 
Data represent mean± S.E.M., n is represented in parentheses. 
One way ANOVA F(6,55)-10.48, p < 0.001. 
Duncan's new multiple range test: 
* Significant difference from all other groups, p < 0.01; shortest 
range of significance between means = 18.0. 
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between means - 18.0, p < 0.01]. Lactate dehydrogenase was also 
measured in the incubation medium and was determined to be 0. 034 ± 
O. 006 µmol pyruvate/ml/min for the saline-plasma group (M. W. 5, 000-
10, 000) and 0.032 ± 0.006 µmol pyruvate/ml/min for the PCA-plasma group 
(M.W. 5,000-10,000). The LDH values were lower than those reported in 
the literature for kidney slices (Fray et al., 1983), and indicate that 
the increase in renin release from the group that received the PCA-
plasma fraction (M.W. 5,000-10,000) was not due to cell lysis. 
2. Test for possible renin-releasing activity of 5-HT or PCA (Table 13) 
Since the PCA-plasma produced increases in renin release from the 
kidney slices it could be suggested that either 5-HT or PCA molecules 
in the plasma fractions could increase renin release from the slices. 
Therefore, 5-HT, PCA and fenfluramine, another 5-HT releaser were 
tested for renin-releasing activity. None of these drugs were 
effective in stimulating renin release from the kidney slices [ANOVA: 
F(3,11)=0.18, p > 0.1]. These results suggest that the increase in 
renin release seen with PCA-plasma was not due to either PCA or 5-HT 
molecules. 
3. Incubation of the saline-plasma and PCA-plasma fraction (M.W. 5,000-
10,000) with pronase (Table 14) 
To determine if RRF is a peptide, the PCA-plasma and saline-
plasma fractions that contained renin-releasing activity (M.W. 5,000-
10,000) were incubated with pronase and the samples were added to the 
kidney slices. Incubation of the PCA-plasma fraction (M.W. 5,000-
109 
TABLE 13 Inability of 5-HT (10-6M), p-chloroamphetamine (10-6M) and 
fenfluramine (10-6M) to increase renin release from kidney slices. 
Renin release 
Test substance (ng ANG I/mg kidney/hr) 
Saline (4) 
10-6M 5-HT (4) 
10-6M PCA (3) 
10-6M Fenfluramine (4) 
9.4 
8.8 
8.6 
9.5 
± 1.0 
± 1.2 
± 1.1 
± 0.4 
Data represent mean± S.E.M .. n is represented in parentheses. 
One way ANOVA F(3,ll)-0.18, p > 0.100, N.S. 
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TABLE 14 Ability of pronase to destroy the renin-releasing activity 
of the PCA-plasma fraction (M.W. 5,000-10,000). 
Renin release 
Fraction added n (ng ANG I/mg kidney/hr) 
Vehicle-treated 
PCA-plasma fraction 9 15.7 ± 1.2* 
Pronase-treated 
PCA-plasma fraction 10 5.6 ± 0.4 
Vehicle-treated 
Saline-plasma fraction 6 10.6 ± 1. 3 
Pronase-treated 
Saline-plasma fraction 6 11. 7 ± 0.9 
Saline 9 6.4 ± 0.5 
Isoproterenol (10-6M) 6 19.6 ± 1.9* 
Data represent mean± S.E.M., n represents number of determinations. 
One way ANOVA F(5,39)= 29.84, p < 0.001. 
Duncan's new multiple range test: 
* Significant difference from saline or the corresponding pronase-
treated group, p < 0.01; shortest range of significance between means -
4.2. 
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10,000) with pr-0nase completely eliminated its renin-releasing activity 
[ANOVA: F(S,39)-29.84, p < 0.001; Duncan's multiple range test: 
shortest range of significance between means - 4.2, p < 0.01]. The low 
renin-releasing activity of the saline-plasma fraction (M. W. 5, 000-
10, 000) was not affected by treatment with pronase. These data suggest 
that RRF present in the PCA-plasma is a peptide and that the increase 
in renin release seen with the saline-plasma is not due to a peptide 
factor. Saline and isoproterenol were tested in the bioassay as 
representative values for the low and high (stimulus induced) renin 
release. 
The proteolytic activity of pronase was verified using a casein 
agar plate. Casein is one of the substrates for pronase. The pronase 
was mixed with the plasma fractions and a sample was added to a casein 
agar plate. The proteolytic activity showed up on the agar as a clear 
ring, indicating that pronase had digested the casein. After 
incubation of the pronase with the plasma fraction, the samples were 
boiled. Boiling inactivated the pronase and prevented any further 
proteolysis; this was also verified using the casein agar plate. 
E. Studies of the renin-releasing factor in rat brain 
1. Extraction of RRF from rat brain tissue 
la. Test of different extraction media on the recovery of renin-
releasing activity from whole brain (Table 15) 
One of the preliminary studies for the distribution of RRF in rat 
brain included the testing of different extraction media on the 
recovery of renin-releasing activity from whole rat brain. Whole rat 
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brains were extracted as described in Method section E part 1 in 
different extraction media, and added to the kidney slices. The hrains 
that were extracted with cold perchloric acid (0.1 N) had the highest 
renin-releasing activity (One way ANOVA: F(6,59)-4.428, p < 0.001]. 
This increase was statistically significant from the saline control and 
the hot and cold hydrochloric acid extract groups (Duncan's multiple 
range test: shortest range of significance between means 5.9, p < 
0.01). 
(20:80) 
Brains that were extracted with either cold 0.1 N HCl/ethanol 
or with hot distilled water also had a significant 
concentration of renin-releasing activity when compared with the saline 
group (Duncan's multiple range test: shortest range of significance 
between means = 4.5, p < 0.05). Hot perchloric acid (0.1 N) extract 
and hot and cold hydrochloric acid (0.1 N) extracts had renin-releasing 
activity that did not differ from the saline control values. From 
these results it appears that cold perchloric acid, cold 0.1 N 
HCl/ethanol and boiling distilled water were the most effective in 
recovering renin-releasing substances from whole rat brain. 
lb. Comparison of extraction with cold 0 .1 N perchloric acid and 
boiling distilled water on the recovery of RRF from rat hypothalamus 
(Table 16) 
Rat hypothalamic tissue was tested for the recovery of renin-
releasing substances using cold 0.1 N perchloric acid or boiling 
distilled water as the extraction media. The extracts were added to 
the kidney slices and the renin-releasing activity of the two extracts 
were compared. The hypothalamic tissue that was homogenized in the 
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TABLE 15 Comparison of different extraction media on renin-releasing 
activity from whole rat brains. 
Extraction media !l 
Cold hydrochloric acid (0.1 N) 9 
Hot hydrochloric acid (0.1 N) 9 
Cold 0.1 N HCl/ethanol (20:80) 9 
Cold perchloric acid (0.1 N) 10 
Hot perchloric acid (0.1 N) 10 
Hot distilled water 8 
saline 12 
Data represent mean± S.E.M. 
One way ANOVA: F(6,59)- 4.428, p < 0.001. 
Duncan's new multiple range test: 
Renin release 
(ng ANG I/mg kidney/hr) 
7.9 ± 0.3 
7.2 ± 0.3 
11.9 ± 2.2* 
13.8 ± 2.1** 
10.4 ± 1.6 
11.0 ± 0.6* 
6.2 ± 0.6 
Significant difference from saline control group, 
* p < 0.05, shortest range of significance between means - 4.5. 
** p < 0.01, shortest range of significance between means 5.9. 
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TABLE 16 Comparison of 0.1 N perchloric acid and distilled water on 
the recovery of renin-releasing factor (RRF) from rat hypothalamus. 
Renin release 
(ng ANG I/mg kidney/hr) 
cold 0.1 N perchloric acid 11.1±1.7 
hot distilled water 22.4 ± 4.2* 
Data represent mean± S.E.M. n-4. 
* Significant difference from cold perchloric acid extract group, p < 
0.05 (Student's unpaired t-test, two-tailed, t-2.516, df-6). 
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boiling distilled water had significantly more renin-releasing activity 
than the hypothalamic tissue extracted with perchloric acid extract 
[Student's t-test (unpaired), two-tailed: t-2.516, df-6, p < 0.05]. 
These data differ from the data obtained in the previous study that 
indicated that perchloric acid was more effective in recovering renin-
releasing activity from whole rat brain. This suggests that the renin-
releasing substance in the hypothalamus and that (those) in whole rat 
brain may be different. One advantage in using boiling distilled water 
for the extraction medium is that the hypothalamic homogenates do not 
need the pH readjusted before addition to the kidney slices. For the 
following studies on RRF the tissues were homogenized in boiling 
distilled water. 
2. Renin-releasing activity of hypothalamic, cerebellar and pituitary 
extracts (Table 17) 
The hypothalamus, cerebellum and pituitary tissues were 
homogenized in boiling distilled water (see Method section E part 3) 
and the extracts were added to the kidney slices to test for renin-
releasing activity. The hypothalamic extract produced a significant 
increase in renin release from the kidney slices [One way ANOVA: 
F(4,46)-ll.474, p < 0.001] when compared with either the saline control 
(Duncan's multiple range test: shortest range of significance between 
means - 8. 5, p < 0. 05) or the pituitary extract values (Duncan's 
multiple range test: shortest range of significance between means -
10.9, p < 0.01). The cerebellar extract significantly increased renin 
release from the kidney slices when compared with the pituitary extract 
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TABLE 17 Effect of rat hypothalamic, cerebellar and pituitary extracts 
on renin release from kidney slices. 
Renin Release 
Substance added (ng ANG I/mg kidney/hr) 
Saline (13) 9.7 ± 0.6 
Hypothalamic Extract (16) 19.1 ± 2.l**t 
Cerebellar Extract (10) 15.3 ± 2.1* 
Pituitary Extract (8) 5.7 ± 0.6 
Isoproterenol 10-6M (5) 19.7 ± 2.6**t 
Each data point represents mean± S.E.M. The number of determinations 
(n) is represented in parentheses. 
One way ANOVA: F(4,46)- 11.474, p < 0.001. 
Duncan's new multiple range test: 
t Significant difference from the saline group, p < 0. 05, shortest 
range of significance between means 8.5. 
Significant difference from pituitary extract 
* p < 0.05, shortest range of significance between means 
** p < 0.01, shortest range of significance between means 
8.5. 
10.9. 
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(Duncan's multiple range test; p < 0.05) but the effect was not 
significant when compared with the saline group. Pituitary extract 
produced a small, but statistically insignificant, decrease in renin 
release when compared with the saline values. Saline and isoproterenol 
(10-6 M) were added to the kidney slices to demonstrate the high and 
low values of renin release for the bioassay. These results suggest 
that the hypothalamus and cerebellum contain renin-releasing 
substances. The pituitary may contain substances that inhibit renin 
release in vitro. 
3. Dose-response effect of the renin-releasing activity of hypothalamic 
tissue (Figure 3) 
The hypothalamus has been shown in the previous study to contain 
renin-releasing substances. Rat hypothalami were prepared (Method 
section E part 4) and added to the kidney slices in dilutions that 
corresponded to the content of 0.07, 0.1, 0.2, 0.5, 1.0, 2.0 and 4.0 
hypothalami. Addition of hypothalamic extract to the kidney slices 
produced a dose-dependent increase in renin release. The content of 
0.5 hypothalamus produced a significant increase in renin release that 
was also significantly different from the equivalent of 0. 2 
hypothalamus (Duncan's multiple range test: shortest range of 
significnce between means - 6.3, p < 0.05). There was a significant, 
and maximal, increase in renin release when the equivalent of the 
content of one hypothalamus was added to the kidney slices (One way 
ANOVA: F(B,50)-10.520, p < 0.001; Duncan's multiple range test: 
shortest range of significance between means - 8.2, p < 0.01]. The 
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FIGURE 3 Dose-response effect of rat hypothalamic tissue extract on 
renin-releasing activity. 
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maximal response was also obtained when the equivalents of 2 and 4 
hypothalami were added to the slices. These values were also 
significantly different from the equivalent of 0.5 hypothalamus. 
Saline and isoproterenol were added as low and high (stimulus-induced) 
controls for the bioassay. These results indicate that the kidney 
slices can respond with a maximal stimulation of renin release when the 
equivalent of the content of one hypothalamus is added to the kidney 
slices. For subsequent studies, tissue extracts were added to the 
kidney slices in the volume that corresponded to the equivalent of the 
content of one hypothalamus (0. 02 ml of tissue extract in a 1 g/ml 
dilution with boiling distilled water). 
4. Distribution of RRF in rat brain (Figure 4) 
Rat brains were dissected and the individual parts were prepared as 
indicated in Method section E part 5. The extracts were added to the 
kidney slices to test for renin-releasing activity. Figure 4 shows the 
distribution of renin-releasing activity in different brain regions. 
The data are arranged in order of increasing renin-releasing activity 
[ANOVA: F(l4,110)-4.693, p < 0.005]. Saline and isoproterenol (lo-5 M) 
were tested along with the samples to control for the low and high 
levels of the bioassay. The following brain regions had RRF activity 
that was statistically different from the saline control or the 
pituitary extract groups: the hypothalamus, cerebral cortex (Duncan's 
multiple range test: shortest range of significance between means -
6.2, p < 0.05), medulla oblongata and cerebellum (Duncan's multiple 
range test: shortest range of significance between means - 7.0, 
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FIGURE 4 Distribution of renin-releasing activity in different regions 
of the rat brain. 
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p < 0. 01). There were no significant differences in the renin-
releasing activity between these groups. The pituitary had the least 
amount of renin-releasing activity followed by, in increasing order, 
the pons, thalamus, caudate, hippocampus, midbrain, and amygQ.ala. 
These values were not significantly different from the saline control 
value. These data demonstrate that there is an unequal distribution of 
renin-releasing activity in the rat brain. The areas that contain the 
highest amounts of renin-releasing activity are the cerebellum followed 
by the medulla, cerebral cortex and hypothalamus. 
5. Distribution of RRF in brains of colchicine-treated rats (Figure 5) 
Sa. Test of colchicine-treated brain extracts 
The results from Figure 4, cannot distinguish RRF in cell bodies 
from RRF in nerve terminals. In order to identify RRF in the cell 
bodies, a group of rats were treated with colchicine (48 hours), a drug 
that inhibits axonal transport of cell products toward the nerve 
terminals. Therefore, treatment of rats with colchicine would prevent 
the movement of peptides, such as RRF, from the cell body to the nerve 
terminals. The brains from colchicine-treated rats were dissected, 
homogenized and added to the kidney slices to test for renin-releasing 
activity as was performed with the control brains. 
Figure 5 shows the distribution of renin-releasing activity in 
colchicine-treated rat brains. When compared with Figure 4, there was 
a redistribution of renin-releasing activity. The most visible 
difference after colchicine-treatment was that the hypothalamus was the 
only brain region that exhibited significant renin-releasing activity 
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FIGURE 5 Distribution of renin-releasing activity in brains of 
colchicine-treated rats. 
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[One way ANOVA: F(l3,78)-2.997, p < 0.005]. This activity was 
significantly different from saline, caudate-putamen, midbrain, muscle 
and cerebellar extracts (Duncan's multiple range test: shortest range 
of significance between means - 10.8, p < 0.01) and from the pituitary, 
hippocampus, amygdala, cortex and medulla extracts (Duncan's multiple 
range test: shortest range of significance between means - 8. 3, p < 
0.05). The renin-releasing activity of the hypothalamus was also 
slightly, but not significantly, increased above the value for 
isoproterenol-stimulated renin release. In addition to the 
hypothalamus, the renin-releasing activity of the pituitary, pons and 
thalamus in colchicine-treated rats was slightly but not significantly 
increased when compared with the corresponding areas from the brains of 
non-treated rats (Figure 4). The renin-releasing activity previously 
observed in the cerebral cortex, medulla and cerebellum was reduced, 
and the value for renin-releasing activity in the cerebellum was at the 
level of saline control values. The renin-releasing activity of the 
caudate-putamen, hippocampus, midbrain and amygdala was also decreased 
slightly after colchicine treatment in comparison with the non-treated 
controls. Saline and isoproterenol (lo-5 M) were run as controls for 
the bioassay. Skeletal muscle extract was also tested in the bioassay 
as a tissue control. These results suggest that RRF cell bodies are 
located in the hypothalamus and that the renin-releasing activity that 
was observed in the cerebral cortex, medulla and cerebellum was 
probably due to the presence of RRF in nerve terminals. 
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Sb. Test for colchicine interference in the renin release bioassay 
(Table 18) 
Before the actual bioassay was performed with the colchicine-
treated brain parts, a preliminary kidney slice assay was performed to 
test for the possible interference of colchicine in the release of 
renin from the kidney slices. Colchicine (0. 083 mg/ml extract) was 
added to either saline, isoproterenol (lo- 5 M) or cerebellar extract to 
test if colchicine would interfere in either basal or stimulus-induced 
renin release from the kidney slices. lsoproterenol (Duncan's multiple 
range test: shortest range of significance between means - 6. 2, p < 
0.05) and cerebellar (Duncan's multiple range test: shortest range of 
significance between 
significant increases 
means 8.4, p 
in renin release 
< 0.01) extract produced 
from the kidney slices when 
compared with the saline control group [One way ANOVA: F(S,23)-7.330, p 
< 0. 001). There were no significant differences in renin-releasing 
activity between the colchicine and saline groups for each test 
substance. This dose of colchicine (0.083 mg/ml) was calculated as the 
theoretical dilution of drug in the brain. This theoretical value 
maybe larger than the actual distribution since this calculation did 
not take into account the leakage of the drug from the CSF 
(cerebrospinal fluid) to the periphery. Therefore, the data 
demonstrate that the dose of colchicine used in the brain scan 
experiment would not have interfered with renin release from the kidney 
slices in the RRF bioassay. 
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TABLE 18 Failure of colchicine to alter renin release from the kidney 
slices. 
Renin release Cng ANG I/mg kidney/hr) 
saline colchicine 
saline 13.5 ± 1.6 13.4 ± 1.4 
isoproterenol 10-5M 21. 7 ± 2.4* 19.7 ± 1.1* 
cerebellum extract 25.5 ± 2.0** 24.4 ± 2.6** 
Data represent mean± S.E.M. n-5. 
One way ANOVA: F(5,23)-7.330, p < 0.001 
Significant difference from saline-saline or colchicine-saline control 
groups Duncan's new multiple range test: 
* p < 0.05, shortest range of significance between means 
** p < 0.01, shortest range of significance between means 
6.2. 
8.4. 
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F. Distribution of renin-releasing activity in peripheral tissues 
{Figure 6) 
Since a number of peptides are distributed in the central nervous 
system and in peripheral tissues, some peripheral tissues were tested 
for renin-releasing activity. The adrenal gland, skeletal muscle, 
spleen, liver and kidney were homogenized in boiling water and the 
extracts were added to the kidney slices. Figure 6 shows the renin-
releasing activity of different peripheral tissues. The skeletal 
muscle, spleen and liver extracts did not exhibit any significant 
renin-releasing activity. The adrenal gland extract produced a 
significant decrease in renin release from the kidney slices (ANOVA: 
F(5,28)-6.318, p < 0.005; Duncan's multiple range test: shortest range 
of significance between means - 4. 5, p < 0. 05] . The kidney extract 
produced a significant increase in the amount of ANG I detected. 
It was possible that not all the renin in the kidney extract was 
inactivated by the boiling procedure. Therefore addition of kidney 
extract to the kidney slices may have increased the amount of renin in 
the sample. To test this possibility, kidney extract, at a 
concentration that equalled the dilution of the kidney extract in the 
Krebs-Ringer buffer during the kidney slice bioassay (0.02 ml 
sample/2.0 ml), was incubated with renin substrate (0.1 ml 
nephrectomized plasma). The kidney extract was able to generate 73.1 
ng ANG I/ml. When this value was divided by the average weight of the 
kidney slices for that bioassay (15.7 mg), this resulted in an addition 
of approximately 4.6 ng ANG I/mg kidney/hr. Subtracting this number 
from the value for renin release with kidney extract (14.6 ng ANG I/mg 
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FIGURE 6 
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kidney/hr) would have yielded a final value of 10 ng ANG I/mg 
kidney/hr, and this value would not have been statistically different 
from the saline control group. Therefore it is likely that the 
increase in ANG I with the kidney extract was due to the presence of 
renin in the extract. 
G. Effect of nephrectomy on the hypothalamic content of RRF (Figure 7) 
The colchicine experiment indicated that the hypothalamus contains 
RRF cell bodies. If there were a feedback loop involved in the 
regulation of RRF release, then removal of the kidneys should result in 
a change of hypothalamic RRF. The hypothalami from nephrectomized 
(NEPHX) and sham-operated rats were homogenized in boiling water and 
the extracts were added to the kidney slices for the incubation period. 
The hypothalamic extract from nephrectomized rats produced a 
significant increase in renin release from the kidney slices [ANOVA: 
F(3,22)-8.09, p < 0.005) when compared with either the saline control 
(Duncan's multiple range test: shortest range of significance between 
means = 8.7, p < 0.01) or the hypothalamic extract from sham-operated 
rats (Duncan's multiple range test: shortest range of significance 
between means 6.5, p < 0.05) groups. The hypothalamic extract from 
sham-operated rats produced a small increase in renin release, however, 
this increase was not statistically significant when compared with the 
saline control. Saline and isoproterenol (lo-6 M) were also added as 
controls for the bioassay. The data show that removal of the kidneys 
from rats results in an increase in the hypothalamic content of RRF. 
These findings may suggest that the kidney may be involved in a 
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FIGURE 7 Effect of bilateral nephrectomy (24 hours) on the 
hypothalamic content of renin-releasing factor (RRF). 
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feedback loop that regulates the production and release of RRF from the 
hypothalamus. 
H. Test for the neuronal release of RRF: Study with superfused 
hypothalami (Figure 8) 
The study with the colchicine-treated rats suggest that RRF cell 
bodies are localized in the hypothalamus. If this is a true 
neuroendocrine system, then the neurons containing the peptide (RRF) 
should be able to be stimulated to release the factor. This 
possibility was tested by using hypothalamic explants. Hypothalami or 
rat hypothalamic-pituitary explants were superfused for a 30 minute 
control period followed by a 30 minute test period with a high-
potassium Krebs-Ringer solution to stimulate the release of the 
peptide. The samples were collected, concentrated by ultrafiltration 
and the fraction that was retained on the filter (molecular weights 
greater than 500) were added to the kidney slices to assay for renin-
releasing activity. 
The samples from the hypothalamic explants that were superfused 
for the 30 minute control period with regular (control) buffer had a 
value for renin release that was slightly increased, but not 
significantly different from the saline control value. The 
superfusates from the hypothalamic explants that were superfused with 
the high potassium Krebs-Ringer solution had a significantly higher 
renin-releasing activity than when they were superfused with the 
control buffer [One way ANOVA: F(3,26)-9.894, p < 0.001; Duncan's 
multiple range test: shortest range of significance between means -
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FIGURE 8 Secretion of renin-releasing factor (RRF) from superfused 
hypothalamus: Effect of high potassium (60 mM). 
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4.7, p < 0.05]. The value for renin-releasing activity of the 
potassium stimulated hypothalamic explant was not statistically 
different from the isoproterenol group. Both of these groups had renin 
release values that were significantly increased over the saline and 
control buffer superfused groups (Duncan's multiple range test: 
shortest range of significance between means - 6.4, p < 0.01). As a 
routine saline and isoproterenol were added to kidney slices as 
controls. This result indicates that the hypothalamus can be 
stimulated to secrete renin-releasing substances. 
CHAPTER V 
DISCUSSION 
A. Summary 
The results of this dissertation support the hypothesis for the 
existence of a renin-releasing factor (RRF) that is released from the 
brain into the circulation. Using an improved and reliable method for 
measuring renin release from kidney slices, these studies indicate that 
RRF is a heat stable peptide having a molecular weight between 5,000-
10,000. These data support previous in vivo studies indicating that a 
factor in the plasma (M.W. 500-10,000) of PCA-treated rats is capable 
of increasing plasma renin activity (PRA) in recipient rats (Van de Kar 
et al. , 1982a). Stimulation of serotonergic receptors and stress 
triggers the release of RRF into the blood. These studies suggest that 
the hypothalamus contains RRF which produces a dose-dependent increase 
in renin release from kidney slices. Further investigation revealed 
that RRF is unevenly distributed within the brain with the cerebellum, 
medulla oblongata, cerebral cortex and the hypothalamus exhibiting the 
highest concentration of RRF. Studies using brains from colchicine-
treated rats suggest that RRF cell bodies are localized in the 
hypothalamus. It is also noted that the renin-releasing activity 
previously observed in the cerebellum, medulla and cerebral cortex was 
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reduced which suggests that RRF in these brain regions is present in 
nerve terminals. Superfusion of rat hypothalamus explants with high 
potassium medium demonstrated that RRF neurons in the hypothalamus can 
be stimulated to release RRF. The hypothalamic content of RRF was 
significantly increased after bilateral nephrectomy suggesting the 
possible presence of a feedback loop from the kidneys to the 
hypothalamus which is responsible for the maintenance of RRF at a 
homeostatic level. 
Bioassay of several peripheral tissues indicated that the spleen, 
liver, skeletal muscle and kidney do not contain RRF. Adrenal extract 
produced a decrease in renin release from kidney slices which may be 
due to the presence of inhibitory peptides or transmitters in the 
adrenal gland. The study further determined that parathyroid hormone 
(PTH) and neurophysin II (NPII) are not RRF. 
B. Renin release bioassay 
1. In vivo bioassay 
The first investigations on RRF were performed in conscious rats 
in a series of cross - transfusion experiments (Van de Kar et al. , 
1982a). The plasma from PCA-treated rats was concentrated and injected 
into conscious recipient rats. Plasma renin activity (PRA) was 
measured in the recipient rats to determine whether there was a factor 
in the blood from PCA-treated rats that increased renin secretion. The 
results from these experiments indicated the presence of a blood-borne 
factor with a molecular weight between 500-10,000. Injecting plasma 
fractions into conscious rats could have altered either sodium balance, 
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plasma osmolarity or even blood pressure which, in turn, would have 
altered plasma renin activity. Therefore, it was possible that 
physiological changes in the recipient rats could have interfered with 
the effect of RRF. To eliminate these influences, an in vitro renin 
release bioassay was developed so that the effect of RRF could be 
observed directly on the kidney. 
2. In vitro kidney slice bioassay 
In vitro kidney slice methods have been used to study the direct 
effects of various stimuli on renin release (Henrich and Campbell, 
1984; O'Dea et al., 1984; Fray and Laurens, 1981; Katz and Malvin, 
1982a). The kidney slice method used in these studies was based on the 
method used by Katz and Malvin (1982a). After experimenting with the 
methods of slicing and oxygenation, the resulting method of measuring 
renin release in vitro was an improvement over the other methods. 
Cutting the tissue by hand (Churchill and Churchill, 1982; Henrich and 
Campbell, 1984) or with a Stadie-Riggs microtome (Katz and Malvin, 
1982a) could cause variation in slice thickness and deformation of the 
kidney due to changes in the amount of pressure that is put on the 
kidney during slicing. Using a vibratome to slice the kidney tissue 
ensured that each slice was of uniform thickness, primarily because the 
vibratome cuts the kidney without applying pressure to the kidney 
tissue or deforming it. The uniformity in slice size could be 
correlated with the kidney slice weight (Table 2). 
Another modification of the method involved coronal sectioning of 
the kidney. By cutting the kidney coronally instead of sagittally each 
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slice contained equal amounts of cortical tissue (both outer and inner 
cortex) and medullary tissue. The highest content of renin secreting 
cells is located in the outer cortex (Katz and Malvin, 1982b; Jones et 
_ru.., 1979). The renal medulla however, has virtually no renin activity 
(Katz and Malvin, 1982b) and thus, was removed. The kidney slices then 
contained primarily inner and outer cortical tissue. Medullary 
dissection ensured that the slices were homogenous with respect to 
renin content. Using this coronal method of slicing more than 30 
slices per kidney could be obtained which was far more than the 2-4 
slices which were previously obtained using sagittal cuts (Katz and 
Malvin, 1982a; Churchill and Churchill, 1982; Cho and Malvin, 1979). 
Proper oxygenation of the vials is important to the viability of 
the slices. Cho and Malvin (1979) demonstrated that direct bubbling of 
the Krebs-Ringer buffer surrounding the kidney slices decreased the 
amount or activity of renin present in the medium and also prevented 
the accumulation of renin activity over time. The decrease in renin 
was due to inactivation of the enzyme at the air-liquid interface. The 
values for renin release using the bubbled kidney slice method were 
lower and less consistent than those presented using the modified 
(unbubbled) method (Table 1). By changing to the unbubbled method the 
values for renin release became more consistent and reproducible. 
Histological and immunocytochemical studies were performed to 
verify the viability of the kidney slices both before and after the 
incubation periods (Van de Kar et al., 1987). Histological analysis 
revealed that the glomerulus and adjacent juxtaglomerular apparatus 
appeared healthy both before and after incubation. Immunocytochemical 
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staining for immunoreactive renin was localized to segments of the 
afferent arterioles. Again, there were no differences between the 
staining in the slices either prior to, or after, 2.5 hours of 
incubation. These findings suggest that the content of renin was not 
depleted during the incubation period. Other reports indicate that the 
renal content of renin is not depleted by a similar incubation period 
(De Vito et al., 1970). These analyses of the kidney slices indicate 
that the juxtaglomerular cells in the kidneys remain healthy during the 
RRF bioassay. 
An indicator for a viable kidney slice method is the determination 
of lactate dehydrogenase (LDH) in the medium surrounding the kidney 
slices. LDH is a cytoplasmic enzyme that is commonly used as a 
indicator for the leakage of cell contents into the medium. Reports by 
Churchill (1979) and Lyons (1980) showed that LDH activity in the 
medium did not parallel the release of renin from the slices. LDH did 
accumulate during the incubation, however, the rate of accumulation was 
not affected by factors that increased renin release. The values for 
LDH reported for the unbubbled kidney slice method discussed above were 
lower than reported in the literature (Fray~ J!.l., 1983) and were not 
different between the treatment groups that received the PCA-plasma or 
saline-plasma fraction (M.W. 5,000-10,000). Even though the kidney 
slices that received the PCA-plasma fraction released more than two 
times as much renin as the vials that received the saline-plasma 
fraction, the LDH values were the same. 
An additional precaution taken with the kidney slice bioassay was 
to use young rat kidneys for the slices. The kidneys used for the 
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bioassay were taken from rats that weigh less than 250 g. It has been 
noted in our laboratory that as the rats age their kidney slices often 
hypersecrete renin into the Krebs-Ringer medium which masks any 
treatment effect during the incubation. Using rats between 150-250 g 
increases the probability that the kidneys will be responsive to a 
stimulus. Corman ~ al. (1985) saw that as the rats grew older their 
kidneys increased in weight. They noticed that the increase in kidney 
size is due to enlargement of the glomerulus and proximal tubules. 
Furthermore, the filtering capabilities of the kidney is decreased in 
older rats. Fray (1978) noted that the kidneys from sodium-depleted 
rats had higher basal levels of renin release than kidneys from 
controls rats. It is possible that there are alterations in the 
handling of sodium that causes the kidneys to release more renin. The 
aging of the kidney may not be related to a change in one function but 
may be the result of changes in several processes. It is possible that 
the alterations in renin release, in Yi..t!:,Q, from older kidneys are due 
not only to changes in the renin-angiotensin system but to age related 
nephropathies. 
To test the reliability of the kidney slice bioassay isoproterenol 
was added to the kidney slices. Addition of isoproterenol (10-5-10-6 
M) is known to cause renin release from the kidney (Henrich and 
Campbell, 1984; O'Dea et al., 1984; Katz and Malvin, 1982a; Churchill 
and Churchill, 1982) by stimulating beta receptors (Capponi and 
Vallotton, 1976; Weinberger et al., 1975). An increase in renin 
release was observed using the unbubbled kidney slice method (Table 3) 
after a 1 hour incubation with isoproterenol. Using the new method, a 
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10-7M dose of isoproterenol was able to produce a significant increase 
in renin release whereas, with the bubbled kidney slice method, a 10-5 
M dose did not produce a statistically significant increase. The 
literature generally cites increases of 1.3-2.2 times the control 
values for isoproterenol-induced renin release after 1-2 hours of 
incubation. Addition of 10- 7 M isoproterenol produced more than a 
three - fold increase in renin release over a period of 3 hours in the 
unbubbled renin release bioassay (Urban and Van de Kar, 1986). When 
compared with the values in the literature, this is a larger increase 
in renin release produced with a smaller dose of isoproterenol; this 
illustrates that the bioassay is sensitive and responds to a stimulus. 
One limitation to this bioassay is the narrow dynamic range for 
assessing renin release. It is not often that values for renin release 
are larger than 25 ng ANG I/mg kidney/hr. It is likely that there is 
more renin being released than can be detected by this bioassay. One 
possibility is that renin may be degraded in each of the kidney slice 
vials during the incubation period, since we have not measured the rate 
of accumulation and degradation of renin in these vials. 
C. In vivo studies on plasma RRF 
1. Effect of 5-HT agonists on PRA, PRC and plasma RRF concentration 
Since PCA stimulates the release of RRF, the serotonin agonists 
MK-212 and TFMPP were administered, in addition to PCA, to conscious 
rats to test if these 5-HT agonists could stimulate the release of RRF. 
PCA, MK-212 and TFMPP increased PRA, PRC and plasma RRF levels. For 
both PRA and PRC, the levels produced by MK-212 were higher than the 
PCA- and TFMPP-treated groups (Table 6). 
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Both MK-212 and TFMPP are 
known to bind to 5-HT receptors. However, their relative potency at 
the receptor subtypes differ. MK-212 is a serotonin agonist 
(Clineschmidt, 1979) that also has been shown to increase 
phosphoinositol turnover in cortical slices (Conn and Sanders-Bush, 
1985). The serotonin-induced increase in phosphoinositol turnover is 
coupled to 5-HT2 receptors whereas stimulation of 5-HT1 receptors 
results in an increase of adenylate cyclase activity (Sanders-Bush and 
Conn, 1985). The selective 5-HT2 antagonist LY53857 prevented the 
increase in PRA after either treatment with MK-212 or fenfluramine 
supporting the hypothe~is that 5-HT2 receptors regulate renin secretion 
(Lorens and Van de Kar, 1987). Studies by Clineschmidt et Al. (1978) 
showed that MK-212 can inhibit the serotonin uptake system at the dose 
that was used in this study (10 mg/kg, i.p.). They demonstrated that 
pretreatment of rats with MK-212 prevents the depletion of serotonin 
observed 72 hours after treatment with PCA. PCA gains access to the 
neuron via the reuptake pump. Pretreatment with an uptake inhibitor 
prevents PCA from entering the nerve terminal and thus inhibits its 
action. It is possible that by blocking the serotonin uptake pump, MK-
212 increases the amount of serotonin available at the synapse (Wong ~ 
al., 1985). Assuming that the renin response, seen with the 10 mg/kg 
dose of MK-212 is not due to maximal occupation of the receptors, it is 
likely that by a combination of both stimulating 5-HT2 receptors and 
increasing the synaptic availability of serotonin, MK-212 could produce 
a potentiation of the renin response. 
Administration of the 5-HT1B receptor agonist, TFMPP, produces 
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significant increases in PRA and PRC, although the increase in PRC is 
not as elevated as that produced by either MK-212 or PCA. A number of 
studies have demonstrated that TFMPP binds preferentially to 5-HT1B 
receptors (McKenney and Glennon, 1986; Asarch et al. , 1985). This 
result is in disagreement with the theory that only 5-HT2 receptors are 
involved in the regulation of renin secretion. However, administration 
of RU24969, a non-selective 5-HTlA&B agonist, produces dose-dependent 
increases in PRA and PRC that are inhibited by pretreatment with 
LY53857 (Van de Kar et al., 1987). This indicates that the putative 5-
HT1 agonist, RU24969 also has affinity and activity at the 5-HT2 
receptor or that LY53857 also blocks the 5-HT1B receptor. In a study 
by Pettibone and Williams (1984), TFMPP and similar piperazine-
containing compounds, were found to act as serotonin releasers and 
displace endogenous stores of serotonin. Fuller~ al. (1981), have 
reported that TFMPP can act as an uptake inhibitor since it prevented 
the depletion of brain serotonin by PCA. Furthermore , Conn and 
Sanders-Bush (1985) have indicated that TFMPP can produce an increase 
in phosphoinositol hydrolysis, an effect that is associated with 5-HT2 
receptors. It is possible that TFMPP produces an increase in PRA, PRC 
and RRF levels by an action that is not attributable to its 5-HT1 
activity. TFMPP could release enough serotonin to increase renin 
secretion, or it is even possible that TFMPP may have activity at the 
5-HT2 receptor site in addition to its 5-HT1B activity. 
Administration of the serotonin agonists MK-212 and TFMPP and the 
serotonin releaser, PCA, all increased the plasma concentration of RRF. 
The difference in the mechanism of action of the drugs can be noticed 
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in the PRA and PRC values, however, the values for plasma RRF 
concentration are equally elevated, indicating that each drug released 
about the same amount of RRF. It is difficult to explain why the RRF 
values do not reflect the difference PRA and PRC values. It is evident 
that serotonin receptors were stimulated to release RRF into the 
plasma. One reason for the consistent values for RRF concentration is 
that the kidneys may have been stimulated maximally with the addition 
of the plasma samples so that any difference in RRF concentration 
between the drug treatments (measured as renin release from the kidney 
slices) was not detectable by the bioassay. Isoproterenol was not 
added in this bioassay so it is difficult to define the dynamic range 
of this bioassay. It is not likely that the activity of RRF was 
digested by proteases since the plasma samples were boiled for 20 
minutes and the larger proteolytic enzymes would not have survived the 
boiling process. Another possibility is that some RRF was inactivated 
by brush border enzymes present in the proximal tubule of the renal 
cortex. A study by Ward and Johnson (1978) showed that kidney extracts 
inactivated substance P faster than the extracts of either liver or 
lung. The highest activity of substance P degradation occurred in the 
brush border of the proximal tubules. The bioassay is performed on 
renal cortical slices that contain a high concentration of proximal 
tubules (Van de Kar et al., 1987). Therefore, it is likely that some 
RRF could have been catabolized during the bioassay since no 
precautions were taken to inactivated these enzymes. 
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2. Role of stress on plasma RRF concentration 
Rats that are subjected to a variety of stress paradigms have 
increased levels of corticosterone, prolactin and renin (Paris il !ll., 
1987; Richardson-Morton et al., 1986; Van de Kar et al., 1984; 1985; 
Eljarmak et al., 1982). The effect of a stressor such as conditioned 
emotional response (Richardson-Morton et al., 1986) and immobilization 
(Gotoh et al., 1987) on renin secretion can be prevented by 
electrolytic lesions in the hypothalamic paraventricular nucleus (PVN). 
This result does not appear to be due to decreased levels of renin 
substrate that would occur as a result of interrupting the 
adrenocortical axis since the corresponding PRC values, measured with a 
saturating concentration of exogenous renin substrate, are also 
decreased (Richardson-Morton et al., 1986). Further studies have 
indicated that cell bodies in the PVN are responsible for mediating the 
stress-induced increase in PRA and PRC (Richardson-Morton et !ll., 
1987). Furthermore, electrolytic lesions in the PVN also prevented the 
increase in PRA after administration of PCA (Gotoh il !ll., 1987). 
Since the PVN contains neurons that can release peptides into the 
circulation, it is likely that the release of RRF may be stimulated by 
stressful conditions. Stress produces an increase in PRA and plasma 
RRF concentration when compared with the renin-releasing activity of 
plasma from control (non-stressed) rats (Table 7). That the increase 
in PRA was about four times greater than the change observed with the 
RRF concentration. There are many factors that can influence the PRA 
values in stressed rats. PRA is a measurement that reflects changes in 
central and peripheral sympathetic nerve activity, changes in sodium 
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levels and blood pressure, in addition to increases due to RRF. When 
measuring the plasma concentration of RRF, only the direct effect of 
the factor is being detected at the kidney level which is evaluated by 
incubating the plasma fraction with renal cortical slices. 
Furthermore, the renal cortical slice is only a fraction of the total 
renin-releasing ability of the kidney. If more kidney tissue were 
added to the bioassay, the increase in renin-releasing activity could 
have been greater. 
D. Characterization of plasma RRF in vitro 
Administration of PCA to rats produced an increase in plasma renin 
activity that was due to the presence of a blood-borne renin-releasing 
factor (RRF; Van de Kar, et al., 1982a). RRF was identified to be 
present in the plasma fraction with molecular weights of 500-10,000. 
The PCA-plasma fraction (M.W. 500-10,000) was also tested in the renin 
release bioassay and produced dose-dependent increases in renin 
release. Further studies using the PCA-plasma fraction with smaller 
molecular weight ranges indicated that RRF is within the 5,000-10,000 
molecular weight range. RRF is also heat stable. These studies were 
performed using the bubbled kidney slice method (Urban et al., 1985). 
Although there were fairly large increases in renin release among the 
treatment groups (0.1 ± 0.06 and 0.66 ± 0.38 ng ANG I/mg kidney/hr), 
these differences were not significant. This was due in part to the 
fact that there was a low number of samples in each group (n-3), and 
there was also a large variation among the values for renin release 
within each group. This was reflected in the relatively large standard 
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error of the mean (S.E.M.). The large S.E.M. values indicated the need 
for a more reliable method for measuring renin release. Therefore, the 
unbubbled method, that proved to be reliable and reproducible was 
developed and used for the rest of the experiments. 
The studies using the plasma fractions were repeated using the new 
unbubbled method. The results indicate that the 5,000-10,000 molecular 
weight PCA-plasma fraction had the highest amount of renin-releasing 
activity. This replicates the results found using the previous bubbled 
bioassay method. Thus, we obtained similar results using both the 
bubbled and unbubbled in vitro renin release bioassays and an in ~ 
renin release bioassay (Van de Kar et .5!.l., 1982a). This suggests that 
even though the bubbled method was not very reliable for measuring 
renin release, it showed a response to an applied stimulus. More 
importantly, replication of the results using different methods, 
reinforces the validity of the observation. 
Nephrectomy is known to increase plasma angiotensinogen (renin 
substrate) levels (Carretero and Gross, 1967). Therefore plasma from 
nephrectomized rats would be expected to contain increased amounts of 
angiotensinogen. It is not likely that angiotensinogen would influence 
renin release from the kidney slices since the molecular weight of 
angiotensinogen is approximately 60,000 (Tewksbury, 1983) and the 
plasma fraction that increased renin release contained solutes with 
molecular weights from 5, 000-10, 000. Furthermore, angiotensinogen is 
denatured by heat and would not have survived the boiling process prior 
to fractionation of the plasma. For the same reasons, renin would not 
be present in the plasma fractions: renin is heat labile and also has a 
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larger molecular weight (40,000). Moreover, the plasma renin activity 
values in rats that are anephric are at the sensitivity limit of the 
assay indicating that there is little, if any, renin present in the 
plasma. In addition, if renin or angiotensinogen were responsible for 
the renin-releasing activity, these substances would be expected to be 
present in the saline-plasma fraction and would have produced a similar 
increase in renin release. 
Serotonin (5-HT) and PCA were not capable of directly producing an 
increase in renin release from the kidney slices indicating that these 
drugs are not renin-releasing factors. Furthermore, these molecules 
are small (PCA: M.W.-206; 5-HT: M.W.-179) and would have been filtered 
through the lower molecular weight membrane (M.W. cutoff 5,000). 
Circulating catecholamines which are known to alter renin release are 
also not likely to be the renin-releasing factor since they also have 
low molecular weights and are heat labile. 
The renin-releasing activity of the PCA-plasma fraction (M.W. 
5,000-10,000) is destroyed by incubation with pronase; in addition with 
the heat stability of RRF these studies suggest that RRF is a peptide. 
Pronase non-selectively digests peptide bonds (Narahashi, 1970). The 
renin-releasing activity of this PCA-plasma fraction (M.W. 5,000-
10,000) is lower than in the previous experiment (Table 12 versus Table 
14). This difference in potency may be partially due to the presence 
of calcium chloride (5 mM) that was present in the pronase vehicle 
(borate buffer). The final concentration of the calcium chloride that 
was added to the kidney slice buffer was approximately 5.5 x lo-5 M. 
The presence of calcium at this dose has been shown to inhibit renin 
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secretion (Park et al., 1986; Antonipillai and Horton, 1985). 
Therefore, this increase in the calcium content of the kidney slice 
buffer may have altered the response of the kidneys to the PCA-plasma 
fraction. The renin-releasing activity of the corresponding saline-
plasma fraction (M.W. 5,000-10,000) was not affected by treatment with 
pronase, suggesting that the substance in this fraction that increases 
renin release is not a peptide. The substance present in the saline-
plasma fraction might therefore be different from the factor present in 
the PCA-plasma fraction. Furthermore, the other plasma fractions (M.W. 
1,000-5,000 and 10,000-20,000) also exhibited some renin-releasing 
activity. It is possible that the increase in renin release seen with 
these other plasma fractions may be due to incomplete fractionation of 
RRF or due to a change in the osmolali ty of the buffer bathing the 
kidney slices. The ultrafiltration method employed is not an absolute 
method for determining molecular weight but is primarily used to 
concentrate solutes within different molecular weight ranges. Some of 
RRF may have been retained in the large molecular weight fraction and, 
if the molecular weight of RRF is closer to 5,000, it could have been 
filtered through into the lower (1,000-5,000) molecular weight 
fraction. This explanation may account for some of the activity 
present in the other PCA-plasma fractions (M.W. 1,000-5,000 and 10,000-
20,000). However, in the saline-plasma fractions there is also some 
renin-releasing activity. Administration of PCA stimulates release of 
RRF, but it is also likely that there may be a small basal release of 
the peptide that would be detected in the plasma of the saline-treated 
rats. However, this possibility is not supported by the data obtained 
from the pronase experiment. 
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If the saline-plasma fraction (M. W. 
5,000-10,000) contained the same substance as the PCA-plasma then 
pronase should have destroyed the renin-releasing activity present in 
the saline-plasma fraction. 
Since these fractions contain solutes with different molecular 
weights it is difficult to conceive that one substance produces these 
increases. One possibility may be that these fractions change the 
osmolality of the Krebs-Ringer buffer when they are added to the kidney 
slices which would affect renin release. Studies have indicated that 
decreases in osmolality stimulate the release of renin in vitro 
suggesting that the release of renin may be regulated by the cell 
volume of the juxtaglomerular cells (Skott, 1986; Frederikson et~ .• 
1975). If the plasma fractions do alter the osmolality of the Krebs-
Ringer buffer, it would most likely result in a relative increase in 
osmolality since these fractions are concentrated plasma and contain 
high concentrations of protein. According to the hypothesis of 
Frederikson et al. (1975) and Skott (1986) these concentrated plasma 
fractions should decrease renin release from the kidney slices. Hall 
and Guyton (1976) reported that infusions of hypertonic dextran or 
albumin increased renin secretion rate in anesthetized dogs. 
Similarly, Fray and Laurens (1981) reported that addition of albumin to 
juxtaglomerular cells increases renin release from the cells probably 
by sequestering, and lowering, the extracellular calcium concentration. 
It could be possible that there may be substances in the PCA-plasma and 
saline-plasma fractions that could lower the amount of extracellular 
calcium thereby increasing renin release over the saline control 
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values. 
Recent evidence has indicated that in addition to active renin, an 
inactive form of renin is present in the plasma (Bouhnik ~ Sl].., 1985; 
Inagarni et al., 1983). Inactive renin, or prorenin, is primarily 
produced in the kidney (Taugner et Sl].., 1987; Bouhnik ~ Sl].., 1985) and 
circulates in the plasma where it is activated. There are a variety of 
conditions that can activate prorenin, such as cold activation 
(Wilczynski and Osmond, 1983), proteolysis with trypsin (Takada ~al., 
1986; Wilczynski and Osmond, 1986), and acidification (Wilczynski and 
Osmond, 1983). The actual stimulus for activation of prorenin in the 
plasma in vivo has not been identified. One possibility for the 
increased amount of renin activity seen with the addition of the PCA-
plasma (M.W. 5,000-10,000) could have been that the plasma fraction 
contained an activator that would convert prorenin in the medium 
surrounding the kidney slices to active renin. PCA-plasma and saline-
plasma fractions (M.W. 5,000-10,000), when added to the pooled Krebs-
Ringer buffer that was previously incubated with kidney slices, did not 
produce an increase in renin activity above the saline control group 
(Table 4). This indicates that the increased amount of renin release 
from the kidney slices was not due to activation of prorenin by the 
plasma fractions. 
The plasma fractions were also tested for possible renin-like 
activity that would have resulted in higher values for ANG I generated 
in the renin assay. The PCA-plasma and saline-plasma (M. W. 5, 000-
10, 000) fractions were incubated with renin substrate to test if they 
could generate ANG I. The plasma fractions were not capable of 
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producing any measurable amounts of ANG I, which demonstrates that 
there was no renin-like enzyme activity present in these plasma 
fractions. These two tests verify that the increase in the amount of 
ANG I generated from the samples was due to the release of renin from 
the kidney slices and not to activation of prorenin or the presence of 
renin-like enzymes in the plasma fractions. This conclusion is logical 
since the molecular weights of renin and cathepsin D, a renin- like 
enzyme, have molecular weights around 40,000. 
E. Studies of RRF in rat brain 
1. Extraction media 
Rat hypothalami that are homogenized with boiling distilled water 
yield a higher amount of renin-releasing activity than hypothalami that 
are homogenized with cold perchloric acid (0.1 N). Since RRF is a heat 
stable peptide, the brain tissue could be homogenized in boiling water 
to denature other larger proteins, leaving the renin-releasing activity 
of RRF unaffected. It would be expected that the whole brain extracts 
and hypothalamic extracts would exhibit similar values for renin-
releasing activity with the different extraction media. The comparison 
of extraction media with whole brain homogenates indicate that the cold 
perchloric acid (0 .1 N) is the better solution for extracting renin-
releasing activity. Boiling distilled water and cold 0 .1 N 
hydrochloric acid/ethanol (20:80) were equally effective in recovering 
renin-releasing substances from whole brain tissue. The results from 
the whole brain versus hypothalamic tissue homogenates are not in total 
agreement. These data imply that extraction of whole brain with cold 
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perchloric acid may extract or activate other renin-releasing 
substances not located in the hypothalamus. 
2. Central nervous system (CNS) distribution of RRF 
Rat hypothalamic extract produces dose-dependent increases in 
renin-release from the kidney slices (Figure 3). The equivalent of the 
content of one hypothalamus, when added to the kidney slices, produces 
a maximal stimulation of renin release. This indicates that there are 
receptors on the kidney that can respond to different concentrations of 
RRF. This also is an important finding because it made it possible to 
standardized the amount of tissue extract that was added to the kidney 
slices so that the relative concentration in renin-releasing activity 
of different brain regions could be compared. The renin-releasing 
activity of other brain regions were compared to the renin-releasing 
activity present in one hypothalamus. 
Bioassay of rat brain regions showed a differential distribution 
of renin-releasing activity (Figure 4). In addition to the 
hypothalamus and cerebellum which have been shown previously to contain 
renin-releasing substances (Van de Kar il 1!l,., 1987b), the cerebral 
cortex and medulla oblongata also have significant amounts of renin-
releasing substances. Other brain regions (pons, thalamus, caudate, 
hippocampus, midbrain and amygdala) do not contain significant 
concentrations of RRF although there is some renin-releasing activity 
present in these regions. 
Addition of pituitary extract produced a small decrease in renin 
release from the kidney slices. Since the whole pituitary (both neural 
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and anterior lobes) was homogenized, the decrease in renin release may 
be due to the presence of vasopressin in the neural lobe. Vasopressin 
is known to inhibit renin secretion (Schwartz and Reid, 1985; Vander, 
1968). The high vasopressin content in the pituitary may have masked 
any renin-releasing activity. The hypothalamic PVN and SON (supraoptic 
nucleus) contain vasopressin cell bodies, however, an increase in renin 
release is still observed when the hypothalamic extract is added to the 
kidney slices. Within the PVN and SON neurons, vasopressin is 
synthesized and processed along with neurophysin and a smaller 
glycoprotein. Vasopressin is separated from the neurophysin as they 
are transported down the axon to the nerve terminals where they are 
released (Gamier et al., 1985; Masse et al., 1982; Russell et al., 
1982). It can be hypothesized that when vasopressin is bound to the 
carrier protein (neurophysin) it may not interact at the kidney 
receptor and thus will not suppress renin release. Therefore, based on 
this conjecture, the renin-releasing activity of the hypothalamus would 
not be masked by the inhibitory action of vasopressin. 
Colchicine is known to inhibit microtubule transport (Andreu and 
Timasheff, 1986). Treatment with colchicine has been used to prevent 
the axonal transport of peptides from the cell body in order to 
concentrate the peptide within the cell body (Emanuele tl ll·, 1985; 
Kawata et al., 1985). Therefore brain areas that have increased renin-
releasing activity should indicate the presence of RRF in cell bodies. 
The brain areas that have a decrease in activity would indicate the 
presence of RRF in nerve terminals. After intracerebroventricular 
injections of colchicine, the renin-releasing activity in the rat brain 
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was redistributed. The hypothalamus was the only brain region that had 
renin-releasing activity that was significantly increased over all 
other brain regions except the pons and thalamus. These results 
suggest that the cell bodies containing RRF are located in the 
hypothalamus. 
Using an HPLC (high performance liquid chromatography, GPC-100 
column) system and a G50 Sephadex gel chromatography column, rat 
hypothalamic extract was separated into different molecular weight 
fractions and the renin-releasing activity of the fractions was 
determined. There was a significant concentration of renin-releasing 
activity in three peaks within the molecular weight range of 
approximately 4,800-6,000 
unpublished observations). 
(Van de Kar, Brownfield and Urban, 
These fractions have not been tested for 
susceptibility to pronase digestion. 
In addition to the presence of RRF in the rat CNS, bovine 
hypothalamus also contains renin-releasing substances (Van de Kar il 
al., 1987b). Bovine hypothalamic extract was filtered to obtain 
different molecular weight fractions which were tested in the renin 
release bioassay for the presence of RRF. These fractions were treated 
with pronase to test whether there were similar renin-releasing 
substances in the hypothalamus. We determined that the bovine 
hypothalamus contains renin-releasing peptides within the molecular 
weight ranges of approximately 1,000-5,000 and 5,000-10,000 (Van de Kar 
et al., 1987b). Discovering the presence of renin-releasing peptides 
in bovine hypothalamus with a similar molecular weight range as the rat 
plasma fractions, suggests that the rat may not be the only species to 
have RRF. 
154 
The bovine hypothalamic fraction (M.W. 5,000-10,000) may 
contain the same or similar renin-releasing peptides as the rat plasma 
fraction. One dissimilarity between the rat plasma and bovine 
hypothalamus fractions is that the bovine hypothalamus contains renin-
releas ing activity in a fraction with a molecular weight range of 
1,000-5,000. Renin-releasing activity was only present in the rat 
plasma fraction within the 5,000-10,000 molecular weight range. It is 
possible that in the bovine hypothalamus, the smaller peptide may be a 
metabolite of the larger peptide that does not reach the bloodstream, 
or it may even be a different substance altogether. 
F. Distribution of RRF in peripheral tissues 
Many neuropeptides are not only localized to the brain but also 
exist in peripheral tissues. For example, vasoactive intestinal 
polypeptide (VIP), neurotensin, substance P, neuropeptide Y (NPY) and 
atrial natriuretic factor (ANF) are peptides that can be identified in 
neurons in the brain and also are distributed in different peripheral 
tissues. The test for renin-releasing activity in various peripheral 
tissues indicated that only the kidney extract produced an increase in 
the amount of ANG I detected in the RRF bioassay. This effect was 
likely due to excess ANG I that was generated by renin in the kidney 
extract which escaped denaturation before it was added to the kidney 
slices. 
Addition of adrenal extract to the kidney slices inhibited renin 
release. The adrenal medulla contains a high content of 
catecholamines. These are not likely to be involved in the decrease in 
155 
renin release since catecholamines are not heat stable and are likely 
to be destroyed by addition of water and heating at lOOoc for 20 
minutes. However, if the catecholamines did survive the treatment it 
• 
could be likely that they would decrease renin release by stimulating 
alpha receptors. 
Glucocorticoids and mineralocorticoids are localized in the 
adrenal cortex. These hormones play a role in the maintenance of 
glucose and sodium balance and plasma volume. Administration of 
steroids decreases the elevated levels of plasma renin activity that 
occurs after adrenalectomy (Nasjletti and Masson, 1969). Infusion of 
prednisolone, a glucocorticoid with some mineralocorticoid activity, 
also decreases plasma renin activity in normal subjects. The 
suppression of renin after administration of glucocorticoids in 
conscious animals probably occurs secondarily to the increase in plasma 
volume. Receptors for corticosterone (Lee et ~ .• 1983) and 
aldosterone (Scholer et al., 1979) have been identified by binding 
studies to be localized along the nephron and on distal segments of the 
cortical tubules, respectively. De Vito et al. (1970) reported that 
addition of aldosterone to kidney slices produces about a 30% decrease 
in renin release from the slices whereas addition of 
deoxycorticosterone has no effect on renin release. 
In addition to catecholamines and steroids, immunocytochemical 
methods have identified other transmitters and peptides in the adrenal 
medulla. Serotonin (Holzwarth and Brownfield, 1985), VIP (Hokfelt et 
al., 1981; Holzwarth, 1984), neurotensin (Lundberg tl al., 1982), 
substance P (Hokfelt et al., 1977), neuropeptide Y (NPY; Varndell fil 
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al., 1984; Majane et al., 1985), somatostatin and enkephalin (Lundberg 
gt al., 1982) were identified in the adrenal medulla. In the case of 
VIP, some fibers were also found in the adrenal cortex. In our 
studies, 5-HT has been demonstrated not to alter the release of renin 
from the kidney slices, therefore 5-HT would not produce the decrease 
in renin release produced by the adrenal extract. VIP stimulates the 
secretion of renin both in yivo (Porter et §1., 1985) and in vitro 
(Porter et al. , 1983) . Therefore any VIP that is present in the 
adrenal homogenate would not be responsible for decreasing renin 
release from the kidney slices. On the otherhand, NPY (Hackenthal and 
Taugner, 1986), substance P (Gullner and Bartter, 1979; Gullner §.!:al., 
1979) and somatostatin (Izumi et al., 1979) have been shown to decrease 
renin release .in vitro. Substance P, even though it is a potent 
vasodilator which would reflexly increase PRA, produced a decrease in 
PRA at doses that do not alter blood pressure (Izumi et §1., 1979). 
NPY slightly decreases plasma renin activity in conscious animals 
(Pfister et al., 1986) at doses that do not influence mean arterial 
pressure or heart rate. Neurotensin also produces hypotension like 
substance P, but may not affect renin release (Gullner and Bartter, 
1979). Based on these findings it is probable that the decrease in 
renin release from the kidney slices produced by adrenal extract may be 
due to the presence of NPY, substance P or somatostatin which are known 
to suppress renin release. 
G. Evidence for a RRF neuroendocrine system 
1. Superfusion of rat hypothalamus 
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Since the main grouping of RRF cell bodies have been localized to 
the hypothalamus, hypothalamic explants were stimulated to test for the 
release RRF. Superfusion of the hypothalamic explants with a high 
potassium solution (60 mM), which depolarizes the neurons, results in 
increased release of RRF. This observation indicates that RRF neurons 
can respond to a stimulus and that the nerve terminal regions are 
likely to be present in the hypothalamus. For a neuropeptide to be 
released from the hypothalamus there are essentially three pathways: 
1.) The neuron may send a projection down the pituitary stalk to the 
posterior pituitary lobe, 2.) the neuron may terminate in the region 
of the median eminence where the peptide is released into the portal 
blood and 3.) the peptide may be released into the third ventricle 
where it will enter the cerebrospinal fluid (CSF). Based on the 
earlier in vivo studies of the PCA-induced increase in renin secretion, 
the role of the pituitary in the release of the peptide still needs to 
be resolved. Hypophysectomy prevented the PCA-induced increase in PRA 
after 22 days but did not affect PRA 4 days after surgery (Karteszi et 
al., 1982; Van de Kar et .5!.l., 1982). Both hypothalamic explants and 
hypothalamic-hypophyseal explants that had the pituitary and 
infundibulum attached, were used for the superfusion study. The 
results suggest that there was no need for the hypothalamus to have an 
intact pituitary stalk in order to release RRF. This suggests that the 
terminals involved in the release of RRF were intact and may terminate 
in the median eminence which would not have been destroyed in the 
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dissection procedure. These results do not rule out the involvement of 
the pituitary gland in the release of RRF. However, they do lend 
credibility to the hypothesis that RRF is part of a neuroendocrine 
system. 
2. Effect of bilateral nephrectomy on hypothalamic content of RRF 
Another characteristic of a neuroendocrine system is that the 
release of the factor may be regulated by the end product or hormone. 
The release of corticotropin releasing factor (CRF) is regulated by 
circulating levels of corticosterone. High levels of corticosteroids 
will inhibit the release of ACTH and CRF from the hypothalamus to 
control the plasma levels of CRF (Keller-Wood and Dallman, 1984). When 
the adrenal gland is removed, thereby removing corticosterone feedback, 
the hypothalamic content of CRF is increased (Plotsky and Sawchenko, 
1987; Piekut and Joseph, 1986; Sawchenko and Swanson, 1985). The 
studies by Piekut and Joseph (1986) and Sawchenko and Swanson (1985) 
were performed in rats that were adrenalectomized for at least seven 
days. However, the recent study by Plotsky and Sawchenko (1987) 
indicate that 24 hours after adrenalectomy there is a significant 
increase in CRF, as determined by radioimmunoassay, and in CRF staining 
in the PVN. This study suggests that nephrectomy performed 24 hours 
before sacrifice may also be a long enough time to observe an increase 
in the hypothalamic concentration of RRF. 
The data suggest that removal of the kidneys eliminates an 
inhibitory input for RRF secretion and production. By removing the 
kidneys, there is a reduced capacity to inhibit the synthesis and 
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possibly, the release of RRF from the hypothalamus. Therefore, RRF 
cells will continue to synthesize and secrete RRF as long as there is 
no feedback stimulus from the kidney to reduce their activity. This 
feedback factor may be a product of the renin-angiotensin system, 
possibly ANG II or aldosterone. Based on these results we could 
speculate that ANG II may be the mediator of the feedback loop from the 
kidney to the brain. The subfornical organ (SFO) is a 
circumventricular organ that is located in the third ventricle and is 
responsive to changes in the circulating levels of ANG II (Gross et 
al., 1985). The SFO has been documented to send projections to the PVN 
(Tanaka et al., 1986) that are implicated in the control of blood 
pressure (Gutman et al., 1985). In an earlier study, Tanaka et Sll. 
(1985) demonstrated that stimulation of the neurons in the SFO produced 
an inhibition in the activity of 50% of the PVN neurons tested. This 
suggests that the SFO sends projections to the PVN that can regulate 
the firing rate of neurons in the PVN. More studies need to be 
performed to characterize this RRF feedback loop. However, it is 
probable that elevated levels of ANG II produce by increased renin 
release, may stimulate neurons in the SFO which project to the PVN to 
maintain the release of RRF at a homeostatic level. 
It is important to note that in the bilateral nephrectomy and the 
colchicine studies, the levels of renin-releasing activity in the 
hypothalamus is elevated over the isoproterenol control values. Even 
though these increases are not significantly different, this may give 
an indication as to whether or not RRF stimulates a renal beta 
receptor. It is probable that isoproterenol is maximally stimulating 
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the renal beta receptors since different doses of isoproterenol c10-5_ 
10-7 M) produce similar increases in renin secretion. This indicates 
that the beta receptors may be saturated since the more concentrated 
dose (lo- 5 M) does not produce a further increase in renin release from 
the slices when compared with the 10- 7 M dose of isoproterenol. The 
elevations observed with isoproterenol usually produce increases in 
renin release around 20-23 ng ANG I/mg kidney/hr. However, with the 
PCA-plasma fraction (M.W. 5,000-10,000; Table 8) and the hypothalamic 
extracts, increases in renin release from the kidney slices range from 
23-32 ng ANG I/mg kidney/hr. These results are not sufficient evidence 
for the existence of separate RRF receptors, but may give hint on the 
possibility of selective RRF receptors in the kidney. 
When the beta antagonist, d,1-propranolol, is added to the kidney 
slices prior to addition of the PCA-plasma fraction or plasma from 
stressed rats, there is a slight inhibition of both basal and RRF-
stimulated renin release which may be due to the membrane stabilizing 
effects of d-propranolol. However, there still is a significant 
increase in renin release when the PCA-plasma fraction is added to the 
kidney slices. Other beta blockers have been tested. Nadolol and 
atenolol, on the otherhand, prevented the renin-releasing activity of 
the PCA-plasma fraction (Urban and Van de Kar, unpublished results). 
These data are conflicting and do not conclusively state whether or not 
RRF stimulates renal beta receptors. Clearly, the receptor that 
mediates the effect of RRF on renin release from the kidney needs to be 
studied further. 
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H. Possible renin-releasing peptides 
There are a number of peptides that stimulate renin release. A 
few of them are within the 5,000-10,000 molecular weight range. At the 
time that these studies were performed, the molecular weight of RRF was 
identified to be in the range of 5,000-10,000. It was not until after 
these studies were performed that the molecular weight of RRF was 
identified to be within the 4,800-6,000 molecular weight range. 
Insulin (M.W. 6000) and parathyroid hormone (PTH, M.W. 9000) are two 
hormones that are within the molecular weight range of 5,000-10,000 and 
are known to increase renin release. 
Insulin is primarily synthesized in the pancreas, however, recent 
evidence has accumulated indicating the presence of insulin-like 
immunoreactivity and binding sites in the brain and, of particular 
interest for this study, in the hypothalamus (Baskin et.§].., 1983; Van 
Houten et al. , 1980) . Induction of diabetes by alloxan injection 
produces a decrease in PRA that is restored to normal when the diabetic 
rats are supplemented with insulin (Pratt~~ .• 1985). The levels of 
sodium remain normal. However, potassium levels are increased in the 
diabetic rats and it is likely that the decreased PRA values were 
produced by the increased plasma concentration of potassium (Vander, 
1970). Infusion of insulin produces increases in plasma renin activity 
(Otsuka et al., 1970) that is prevented by either pretreatment with 
propranolol (Assaykeen et al., 1970) or by the prostaglandin synthesis 
inhibitor, indomethacin (Campbell and Zimmer, 1980). The distribution 
of insulin in the rat CNS appears to be concentrated around the 
periventricular area (Baskin et ~ .• 1983; Dorn et al., 1981). 
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Considerable staining for immunoreactive insulin has been identified in 
the ependymal cells lining the wall of the third ventricle and in the 
hypothalamus (Dorn et !!l., 1981). The cerebellum and brainstem contain 
small, almost nondetectable concentrations of insulin as determined by 
radioimmunoassay. Before insulin is ruled out as a putative RRF, 
insulin should be tested in an in vitro renin release bioassay to test 
its renin-releasing activity without the effects of potassium and 
increases in circulating catecholamines that can occur in vivo. 
Parathyroid hormone (PTH) produces increases in PRA (Smith et !!l., 
1979; Powell et al., 1978; Broulik et al., 1986). PTH infusion did not 
alter plasma calcium levels or blood pressure but pretreatment with a 
beta blocker (metipranol) attenuated the renin response to PTH in 
humans (Broulik et al., 1986). The PCA-induced increase in PRA was not 
affected by removal of the parathyroid gland indicating that PTH is not 
the RRF. If PTH were the RRF then removal of the parathyroid gland 
would have blocked the effect of PCA on renin secretion. 
There are other peptides that are known to regulate renin 
secretion. Even though some of the peptides are not within the 
molecular weight range of the PCA-plasma fraction that has renin-
releasing activity, recent evidence with the sephadex G-50 and HPLC gel 
filtration (GPC-100 column) indicated that there may be hypothalamic 
substances with molecular weights below 5,000 that are capable of 
inducing renin release from the kidney slices (Van de Kar, Brownfield 
and Urban, unpublished observations). Glucagon (M.W. 3350), has been 
shown to increase renin secretion from the kidney (Ueda et al., 1978; 
Vandongen et al., 1973). When infused into the renal artery at a 
163 
relatively low dose, glucagon produced increased heart rate, renal 
blood flow and glomerular filtration rate. At a higher dose, glucagon 
produced similar changes in the renal hemodynamic parameters and in 
addition produced a significant increase in renin release (Ueda et al., 
1978). Pretreatment with propranolol did not prevent the increase in 
renin release produced by glucagon (Ueda tl al. , · 1978; Vandongen et 
al., 1973). Glucagon and isoproterenol stimulate adenylate cyclase in 
the renal medulla (Mulvehill et al., 1976). However, the effect of 
glucagon on adenylate cyclase activity is not inhibited by propranolol, 
indicating a glucagon specific adenylate cyclase. Therefore it is 
likely that glucagon may stimulate renin secretion by activating 
adenylate cyclase in the renal cortex. 
Vasoactive intestinal peptide (VIP; M.'W. 3326) increases renin 
release both in vivo (Porter et al., 1983; 1985) and in vitro (Porter 
et al., 1983). There is a high density of VIP-immunoreactive neurons 
in the hypothalamus, specifically, the suprachiasmatic nucleus (SCN) of 
the rat (Loren et al., 1979; Sims tl l!.l., 1980; Samson tl al., 1979). 
The SCN is known to receive serotonergic inputs from the midbrain raphe 
nuclei (Azmitia and Segal, 1978; Bobillier tl .f!l., 1976; Van de Kar and 
Lorens, 1979). Reduction of serotonergic inputs into the SCN, by 
injection with 5,6-dihydroxytryptamine (5,6-DHT), produced a decrease 
in the amount of VIP but not of vasopressin in the SCN (Kawakami et 
al., 1985). These results from this study (Kawakami et ill., 1985) are 
suspect because the neurotoxin 5,6-DHT produces non-specific damage to 
neurons (non-serotonergic) surrounding the injection site (Baumgarten 
et al., 1973). Shimatsu et al. (1982) have shown that intraventricular 
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( icv) injection of serotonin stimulates the release of VIP into the 
portal blood. The plasma concentration of VIP was also increased after 
icv injection of serotonin. It is possible that VIP could be the RRF, 
based on the hypothalamic localization of the cell bodies and fibers, 
and the fact that serotonin can stimulate VIP release from the 
hypothalamus. 
However, when comparing the distribution of RRF with that of VIP 
in the CNS, there is a discrepancy between the distribution of VIP and 
that of RRF. One of the primary differences is that the cerebellum 
dose not contain any VIP-immunoreactivity (Loren et il., 1979; Samson 
et al., 1979). The cerebellum, in control rats, had significant renin-
releasing activity that was reduced in colchicine-treated rats. 
Furthermore, the cerebral cortex contains a high concentration of VIP 
cell bodies (Loren et al., 1979; Sims et .ill., 1980) but the RRF 
concentration in the cerebral cortex was significantly reduced after 
colchicine-treatment when compared with the hypothalamic extract. This 
decrease in renin-releasing activity suggests the presence of RRF in 
nerve terminals, not in cell bodies. From the current data, it is 
noticeable that the patterns of distribution for RRf and VIP are not 
similar, since the molecular weights of these peptides differ also, it 
seems unlikely that VIP and RRF are the same peptide. 
Hauger-Klevene et al. (1970) have shown that adrenocorticotropic 
hormone (ACTH) produces an increase in PRA, that is inhibited by 
blockade of the sympathetic nervous system with pentolinium, a 
ganglionic blocker. The release of ACTH from the pituitary has been 
shown to be influenced by serotonergic neurotransmission (Fuller, 1981; 
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Szafarczyk et al., 1980). However, it is not likely that ACTH is the 
RRF, since hypophysectomy does not prevent the PCA-induced increase in 
PRA (Karteszi et al. , 1982). Lesions of the dorsal raphe nucleus 
prevent the PCA-induced increase in PRA, but do not alter the increase 
in corticosterone levels (Van de Kar il gl., 1982b). Posterolateral 
deafferentation of the hypothalamus also blocked the effect of PCA on 
PRA but not on corticosterone (Van de Karil al., 1985a; Karteszi il 
al., 1982). This indicates that the PCA-induced release of renin and 
ACTH may be mediated by different pathways. 
Atrial natriuretic factor (ANF) plays a role in regulating blood 
pressure and sodium balance. In 1981, De Bold et al. reported that 
peptides in the cardiac atria contain a natriuretic factor. ANF 
produces an increase in sodium excretion accompanied by a decrease in 
plasma volume and a decrease in blood pressure. ANF is, therefore, the 
antithesis of the renin-angiotensin-aldosterone system. Infusion of 
ANF to conscious animals results in an increase in sodium excretion 
(Murray et al. , 1985) and a decrease in blood pressure and renin 
release (Burnett et al. , 1984; Sosa et al. , 1986; Seymour il Al., 
1985). Studies by Deray et al. (1987) show that infusion of ANF into 
nonfiltering canine kidneys does not alter the increase in renin 
release produced by addition of either norepinephrine or prostacyclin, 
whereas adenosine did attenuate the renin response to these agents. 
Based on these studies the authors conclude that ANF does not have a 
direct action on the juxtaglomerular cells. 
Autoradiographic studies using kidney tissue localized ANF 
receptors to the renal outer cortex with concentrations of binding 
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sites over the glomerulus (Healy and Fanestil, 1986; Murphy tl al., 
1985). There is also a light distribution of binding sites in the 
renal medulla. In vitro studies have not clearly determined to what 
extent ANF regulates renin secretion directly from the kidney. Using a 
juxtaglomerular cell culture and renal cortical slices, Kurtz tl al. 
(1986) and Henrich et al. (1986) showed that addition of ANF decreases 
renin secretion. This effect is independent of calcium, since 
pretreatment with verapamil did not alter the ANF-induced decrease in 
renin secretion .. Other studies using similar doses of ANF indicate no 
change in renin release (Rodriguez-Puyol et al., 1986). However ANF 
further potentiated the ANG II-induced inhibition of renin release 
(Antonipillai et al., 1986). Stimulation of renin release by 
isoproterenol was unaffected by ANF. Contrary to these findings are 
the results obtained by Hackenthal et al. (1985) and Hiruma et ll· 
(1986) who reported that ANF stimulates renin release. It is not 
likely that ANF is the RRF since its physiological actions are directly 
opposed to renin. So far, the stimuli that increase the plasma 
concentration of RRF also increase PRA and PRC. If ANF were the RRF, 
it would most likely result in an initial decrease in PRA since the 
natriuresis would reflexly inhibit renin secretion by increasing the 
delivery of sodium chloride to the macula densa. 
The existence of a hypertension-producing, aldosterone-secreting 
factor (ASF) has been reviewed by Carey and Sen (1986). ASF is a 
glycoprotein with a molecular weight of approximately 26, 000 with a 
smaller active fragment of 4,000 (Sen et al., 1981). Sen et il. (1986) 
report that ASF does not alter PRA, ANG II or angiotensinogen 
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concentration in the rat. Therefore, it does not seem likely that RRF 
is ASF. Furthermore, immunofluorescence studies have localized ASF to 
the anterior pituitary with no significant binding in the hypothalamus, 
cerebral cortex, cerebellum, brainstem or peripheral tissues (kidney, 
spleen, nerves, adrenal gland, thyroid, gastrointestinal tract; Sen et 
al., 1977). This distribution pattern in the CNS does not parallel 
that of RRF and therefore, it can be concluded that ASF and RRF are 
different factors. 
For some peptides, such as prolactin and somatostatin, the 
presence of a disulfide bonds are necessary for these hormones to exert 
their physiological effect (Wehrenburg et al., 1983; Palkovits et al., 
1982). In an attempt to determine if RRF contains disulfide bonds, 
cysteamine was administered before PCA. Reduction of possible 
disulfide bonds in the RRF could change the configuration of the 
molecule and thus destroy its renin-releasing activity. The results 
indicate that cysteamine did not alter the PCA-induced increase in PRA 
or PRC. However, PCA did not produce a significant increase in renin 
levels after cysteamine treatment when compared with either the 
corresponding cysteamine control group or the saline-PCA group. In 
these same animals, cysteamine reduced prolactin immunoreactivity. 
Therefore, there may be another action of cysteamine that alters 
resting renin levels. We have shown, that at the dose used in this 
experiment, cysteamine does not alter the renin-angiotensinogen 
interaction as described previously (Poisner and Hong, 1977). It could 
be possible that the increase in renin secretion may be due to a stress 
effect. At the time that the animals received the second injection, 
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lesions were observed at the injection site in some of the animals that 
received cysteamine. By reviewing the data again, it is seen that 
there is more variability among the values for PRA and PRC in the 
cysteamine groups. This is reflected in the S.E.M. However, the only 
information this data provides is that cysteamine was not able to 
inhibit thee renin-releasing activity of RRF that might be necessary 
for its renin-releasing activity. 
Cysteamine is capable of 
prolactin (Sagar et al., 1985; 
reducing the 
Wehrenberg 
immunoreactivity of 
et al., 1983) and 
somatostatin (Palkovits et al., 1982; Webb et al., 1986; Cameron and 
Fernstrom, 1986) but not that of vasopressin or oxytocin (Palkovits et 
al., 1982; Cameron and Fernstrom, 1986) which also contain disulfide 
bonds. Therefore it appears that the ability of cysteamine to reduce 
disulfide bonds in a molecule may depend, in part, on the position of 
the disulfide bond in the molecule and in part, on the importance of 
the disulfide bond in maintaining a functional conformation. A study 
by Cameron and Fernstrom (1986) demonstrated that cysteamine treatment 
can affect the in vivo incorporation of [ 35s] cysteine into 
somatostatin, oxytocin and vasopressin. This indicates that cysteamine 
might also interfere with the synthesis of proteins which may result in 
a reduction of activity. Treatment with cysteamine did not alter the 
renin-releasing activity of RRF. Therefore it can be concluded that 
either RRF does not contain disulfide bonds or that the bonds are not 
necessary for RRF to maintain its activity. Further studies should be 
done to establish the presence of disulfide bonds in RRF. 
169 
I. Role of RRF as a neurotransmitter 
It is possible that in addition to its renin-releasing activity, 
RRF may also function as a neurotransmitter in the central nervous 
system. This is supported in part by the fact that there are RRF nerve 
terminals in the cerebral cortex, cerebellum and medulla. Since these 
brain regions are not known to be involved in releasing peptides into 
the blood, it is reasonable to think that RRF may be acting as a 
neurotransmitter. Werman (1966) has established eight criteria that 
need to be fulfilled in order to classify a substance as a 
neurotransmitter: 
1. The substance must be present in neuronal tissue with an 
uneven distribution in the CNS. 
2. Stimulation of identified neurons should cause release of this 
putative neurotransmitter. 
3. Direct application of the substance should produce responses 
that are similar to those produced by stimulating the neurons. 
4. & 5. Receptors should be identified that interact with the 
substance and stimulation of these receptors should produce a 
postsynaptic effect. 
6. Precursors and synthetic enzymes must be demonstrated in the 
neuronal element. 
7. Inactivating mechanisms should exist that terminate the action 
of the neurotransmitter. 
8. A substance (agonist) should be able to mimic the natural 
transmitter. 
Using these criteria and applying them to the results that we have 
observed for RRF, it becomes evident that RRF fulfills some of the 
criteria. First, we have demonstrated that RRF is differentially 
distributed within the brain. Release of RRF has been demonstrated 
from hypothalamic explants in vitro and stimulation of serotonergic 
neurons in vivo has increased the plasma concentration of RRF. Both 
the PCA-plasma fraction (M.W. 5,000-10,000) and the hypothalamic 
extract produced dose-dependent increases in renin release from the 
170 
kidney slices suggesting a direct action on renal receptors. The dose-
response effect agrees with the occupancy assumption theory that 
presumes that as more receptors on the kidney are filled there is a 
larger increase in the effect of the neurotransmitter. These results 
satisfy requirements 3, and 4 & 5 (to a lesser degree), identifying 
receptors that respond to application of RRF. ALthough the kidney is 
not a post-synaptic element, there are receptors on the kidney that 
respond to application of RRF. The other criteria have not been 
addressed in this dissertation and have not, as of yet, been studied in 
this, or any other, laboratory. As the work continues with RRF, future 
studies may address these other issues and confirm the role of RRF as a 
neurotransmitter. However, with the data that we have collected so far 
it is conceivable that RRF may be part of a neuroendocrine system and 
may in fact be a neurotransmitter. 
1. Possible role of RRF in the CNS 
The renin-releasing activity of the pons, pituitary and thalamus 
was slightly elevated after colchicine treatment. The renin-releasing 
activity that was present in the cerebral cortex, medulla oblongata and 
the cerebellum was decreased suggesting that RRF in these areas is 
present in nerve terminals. These data may give some indication for 
possible RRF pathways outside the hypothalamus. The studies by Gotoh 
et al. (1987) and Richardson-Morton ~ al. (1986) have indicated that 
lesions in the PVN prevent the PCA-induced and stress-induced increases 
in renin secretion. Since RRF cells bodies are localized in the 
hypothalamus it is possible that RRF may be contained in hypothalamic 
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PVN neurons and that some projections of RRF neurons may parallel those 
of already identified PVN pathways. 
Recent studies have focussed on the PVN as an integrator of 
neuroendocrine and autonomic responses (Sawchenko and Swanson, 1981). 
It is conceivable that if RRF is contained in the PVN, it too, may act 
as a regulator. The presence of RRF in the medulla, and in the pons, 
suggest that RRF may be involved in the regulation of blood pressure 
since these areas of the brain also monitor blood pressure (Nakai et 
al., 1982). We have demonstrated that RRF releases renin both in vivo 
and in vitro. However, its importance in regulating blood pressure 
remains to be determined since we have not observed any increases in 
blood pressure in rats that have received doses of concentrated PCA-
plasma fractions (Van de Kar and Urban, unpublished results). It is 
equally likely that RRF may exert an action that is independent of 
cardiovascular regulation. The brainstem also is the site of 
integration of tracts and nuclei of the cranial nerves, primarily the 
hypoglossal, glossopharyngeal, vagus and accessory nerves. Therefore, 
the RRF could also integrate messages from the cranial nerves that may 
be involved with olfaction, taste, muscle movements or even 
respiration. 
The role of the cerebellum in mediating autonomic functions has 
been studied in other laboratories. Stimulation of the fastigial 
nucleus of the cerebellum results in increased levels of plasma renin 
activity (Koyama et al., 1980) and increases in heart rate and blood 
pressure (Del Bo et al., 1983). Renal sympathetic nerve discharge, 
heart rate and blood pressure, in the decerebrate rabbit, are all 
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increased when the cerebellum (uvula) is electrically stimulated 
(Bradley et fil., 1987). The uvula receives auditory, somato-sensory 
and proprioceptive inputs, the authors speculate that the cerebellum 
may be involved in a startle response resulting in cardiovascular 
changes. Our results suggest that RRF terminals are present in the 
cerebellum and release of plasma RRF is increased during stress. It 
can be speculated that in addition to sending a projection to the 
pituitary or median eminence, that there is a collateral RRF projection 
to the cerebellum. This pathway may be activated during either a 
startle or stress response which might have some influence on the 
cerebellar neurons that regulate cardiovascular function in addition to 
releasing RRF into the circulation. 
2. Role of RRF in stress 
The role that RRF plays in stress-induced renin secretion needs to 
be further defined. It appears that the effect of stress on renin 
secretion is not regulated by a serotonergic mechanism, since 
injections of the serotonin-selective neurotoxin, 5,7-DHT into the 
dorsal raphe nucleus did not affect the stress-induced increase in PRA 
nor did pretreatment with the S-HT2 antagonist LY53857 (Lorens et al., 
1986). Stress is a stimulus that increases sympathetic nerve activity 
resulting in an increase in PRA (Jindra il Jll., 1984; 1980) and 
hypertension (Dobrakovova et al., 1984). Privitera et al. (1979) found 
that administration of propranolol intracisternally to rats suppresses 
renin secretion and produces hypotension. Identical doses of 
propranolol intravenously do not produce the same effects. Renal 
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denervation selectively attenuates the decrease in renin secretion but 
not the hypotensive effect of propranolol. Contrary to these results 
is the finding that injections of the catecholamine neurotoxin 6-
, hydroxydopamine (6-0HDA), combined with adrenal medullectomy did not 
prevent the stress-induced increase in PRA (Richardson-Morton et al., 
unpublished observations). This study indicates that the peripheral 
sympathetic nervous system is not the sole mediator of the stress-
induced increase 'in PRA. However, intraperitoneal administration of 
propranolol greatly attenuates the renin response to stress (Van de Kar 
et al., 1985). Propranolol crosses the blood-brain barrier. 
Therefore, this study does not differentiate between central and 
peripheral beta blockade. Further studies by Richardson-Morton et 1l].. 
(1987) have shown that injections of 6-0HDA into the PVN attenuates the 
stress-induced increase in PRA, suggesting that a central 
catecholaminer~ic mechanism of action is involved. The PVN appears to 
play a pivotal role in the regulation of the stress-induced increase in 
PRA (Richardson-Morton et al., 1987; 1986; Gotoh et 1l].., 1987) and may 
also be invol~ed in the regulation of the release of RRF since lesions 
of this nucleus prevent the PCA-induced increase in PRA (Gotoh et al., 
1987). Therefore I would speculate that the serotonergic and 
catecholaminergic systems converge on the PVN to differentially 
regulate the release of RRF from the hypothalamus. It is also likely 
that catecholamine receptors on cell bodies in the PVN are activated 
' during stress and trigger the release of RRF. 
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J. CONCLUSION 
These studies provide evidence for a blood-borne renin-releasing 
factor. RRF cell bodies are localized in the hypothalamus and RRF is 
released from the hypothalamus when these neurons are depolarized. The 
present studies have shown that the release of RRF is stimulated by 
activation of serotonergic receptors and stressful stimuli. Further 
studies to identify other physiological factors, such as changes in 
sodium balance or blood pressure, that may increase the release of RRF 
need to be performed. 
We postulate a neural circuit for the regulation of the release of 
RRF. This circuit is represented in Figure 8. From the studies 
performed by Van de Kar et al. (1982) and Karteszi et al. (1982) it has 
been demonstrated that the dorsal raphe nucleus sends a serotonergic 
projection -to the mediobasal hypothalamus which stimulates renin 
secretion. Data presented by Richardson-Morton et al. (1987) and Gotoh 
et al. (1987) suggest that neurons in the PVN mediate both the stress-
induced and PCA-induced increases in renin secretion. Since the PVN 
receives very little serotonergic innervation, we have considered the 
possibility that the projection from the dorsal raphe may synapse on an 
/ 
interneuron in the arcuate nucleus. The arcuate nucleus receives 
considerable serotonergic innervation from the dorsal raphe nucleus and 
is known to project to neurons in the PVN. We propose that stimulation 
of neurons in the PVN results in the release of RRF into the 
circulation. RRF then circulates in the blood to the kidney and causes 
the release of renin. An increase in PRA increases the circulating 
levels of ANG II. ANG II would then feedback on the CNS system that 
Figure 9. 
release. 
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Postulated neuronal circuit for the regulation of RRF 
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regulates renin secretion by stimulating neurons in the SFO. Tanaka et 
al. (1986) have indicated that there are projections from the SFO to 
the PVN that can regulate the firing of PVN neurons. As the work 
continues in this area, it is possible that this neuronal circuit may 
change with future results. 
/ 
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